OA21055A - Azalactam compounds as HPK1 inhibitors. - Google Patents
Azalactam compounds as HPK1 inhibitors. Download PDFInfo
- Publication number
- OA21055A OA21055A OA1202200449 OA21055A OA 21055 A OA21055 A OA 21055A OA 1202200449 OA1202200449 OA 1202200449 OA 21055 A OA21055 A OA 21055A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- dihydro
- pyrrolo
- compound
- pyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 416
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title description 87
- 239000003112 inhibitor Substances 0.000 title description 12
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 119
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 201000011510 cancer Diseases 0.000 claims abstract description 54
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 230000002159 abnormal effect Effects 0.000 claims abstract description 30
- 230000010261 cell growth Effects 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 177
- 125000001424 substituent group Chemical group 0.000 claims description 127
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 113
- 229910052739 hydrogen Inorganic materials 0.000 claims description 106
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 103
- 239000001257 hydrogen Substances 0.000 claims description 103
- -1 (Ci-Csjalkoxy Chemical group 0.000 claims description 82
- 125000005843 halogen group Chemical group 0.000 claims description 74
- 125000003545 alkoxy group Chemical group 0.000 claims description 69
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 64
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 41
- 150000002431 hydrogen Chemical class 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- BRBMDFAROPPCNO-IKGGRYGDSA-N CC[C@@H]1N2C(C3=CC=CC(N(CC4=C5C=C(N6[C@H](C)CCC6)N=C4[C@H](C)N)C5=O)=N3)=NN=C2CC1 Chemical compound CC[C@@H]1N2C(C3=CC=CC(N(CC4=C5C=C(N6[C@H](C)CCC6)N=C4[C@H](C)N)C5=O)=N3)=NN=C2CC1 BRBMDFAROPPCNO-IKGGRYGDSA-N 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- BRBMDFAROPPCNO-ZACQAIPSSA-N CC[C@@H]1N2C(C3=CC=CC(N(CC4=C5C=C(N6[C@H](C)CCC6)N=C4[C@@H](C)N)C5=O)=N3)=NN=C2CC1 Chemical compound CC[C@@H]1N2C(C3=CC=CC(N(CC4=C5C=C(N6[C@H](C)CCC6)N=C4[C@@H](C)N)C5=O)=N3)=NN=C2CC1 BRBMDFAROPPCNO-ZACQAIPSSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- HFTWWDARPWZARK-UHFFFAOYSA-N CC1N2C(C3=CC=CC(N(CC4=C5C=C(C6(C)CC6)N=C4C(COC)N)C5=O)=N3)=NN=C2CC1 Chemical compound CC1N2C(C3=CC=CC(N(CC4=C5C=C(C6(C)CC6)N=C4C(COC)N)C5=O)=N3)=NN=C2CC1 HFTWWDARPWZARK-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 200
- 150000003839 salts Chemical class 0.000 abstract description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 212
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 174
- 239000000243 solution Substances 0.000 description 115
- 239000007787 solid Substances 0.000 description 107
- 235000019439 ethyl acetate Nutrition 0.000 description 105
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 104
- 238000005481 NMR spectroscopy Methods 0.000 description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 89
- 239000000543 intermediate Substances 0.000 description 85
- 238000006243 chemical reaction Methods 0.000 description 82
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 48
- 229910052681 coesite Inorganic materials 0.000 description 46
- 229910052906 cristobalite Inorganic materials 0.000 description 46
- 229910052682 stishovite Inorganic materials 0.000 description 46
- 229910052905 tridymite Inorganic materials 0.000 description 46
- 238000003818 flash chromatography Methods 0.000 description 45
- 239000007858 starting material Substances 0.000 description 45
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 42
- 239000000377 silicon dioxide Substances 0.000 description 42
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
- 210000001744 T-lymphocyte Anatomy 0.000 description 38
- 239000012044 organic layer Substances 0.000 description 38
- 239000010410 layer Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 34
- 239000012267 brine Substances 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 32
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 31
- 239000007832 Na2SO4 Substances 0.000 description 31
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- 238000009472 formulation Methods 0.000 description 31
- 229910052938 sodium sulfate Inorganic materials 0.000 description 31
- 125000006239 protecting group Chemical group 0.000 description 30
- 239000012065 filter cake Substances 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 27
- 239000002253 acid Substances 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000012467 final product Substances 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 239000013078 crystal Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 23
- 208000035475 disorder Diseases 0.000 description 22
- 239000002585 base Substances 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 20
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 20
- 230000004913 activation Effects 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 19
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 19
- XALRJSQWGGSJJU-UHFFFAOYSA-N pyrrolo[3,4-c]pyridin-1-one Chemical compound N1=CC=C2C(=O)N=CC2=C1 XALRJSQWGGSJJU-UHFFFAOYSA-N 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 230000002708 enhancing effect Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 239000010949 copper Substances 0.000 description 16
- 239000000651 prodrug Substances 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 16
- LFILDSDQMSCNBV-LURJTMIESA-N propane-2-sulfinamide Chemical compound CC(C)[S@@](N)=O LFILDSDQMSCNBV-LURJTMIESA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 229910052717 sulfur Chemical group 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000003776 cleavage reaction Methods 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 229910052763 palladium Inorganic materials 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 229910052802 copper Inorganic materials 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 239000012047 saturated solution Substances 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- 101000944921 Homo sapiens Ribosomal protein S6 kinase alpha-2 Proteins 0.000 description 13
- 108010003506 Protein Kinase D2 Proteins 0.000 description 13
- 102100033534 Ribosomal protein S6 kinase alpha-2 Human genes 0.000 description 13
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Natural products O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 108091008874 T cell receptors Proteins 0.000 description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
- 238000006555 catalytic reaction Methods 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- ITPRZAYYCJNBLF-UHFFFAOYSA-O pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=[N+]=C[CH]1 ITPRZAYYCJNBLF-UHFFFAOYSA-O 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 10
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000013480 data collection Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 238000004293 19F NMR spectroscopy Methods 0.000 description 6
- SRXJXELVJLGVFV-GFCCVEGCSA-N 2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridine-3-carbaldehyde Chemical compound ClC1=NC(=CC(=C1C=O)C(=O)N1CCCCC1)N1[C@@H](CCC1)C SRXJXELVJLGVFV-GFCCVEGCSA-N 0.000 description 6
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 6
- XXYYWWRRXWGJJC-MRVPVSSYSA-N 6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydropyrrolo[3,4-c]pyridine-4-carbonitrile Chemical compound C[C@H](CCC1)N1C1=CC(C(NC2)=O)=C2C(C#N)=N1 XXYYWWRRXWGJJC-MRVPVSSYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- YZHQYQHUBBBKOJ-UHFFFAOYSA-N N1N=NC=C1.BrC1=NC=CC=C1 Chemical compound N1N=NC=C1.BrC1=NC=CC=C1 YZHQYQHUBBBKOJ-UHFFFAOYSA-N 0.000 description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006880 cross-coupling reaction Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- NWWBTHVRHUCSND-QMMMGPOBSA-N (4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC[C@@H](CCC(O)=O)NC(=O)OC(C)(C)C NWWBTHVRHUCSND-QMMMGPOBSA-N 0.000 description 5
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 5
- CUDQTPCGOPBJEO-UHFFFAOYSA-N 6-bromopyridine-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CC(Br)=N1 CUDQTPCGOPBJEO-UHFFFAOYSA-N 0.000 description 5
- IMJCXCLFKAAQGS-SNVBAGLBSA-N CC(C)(C)OC(N[C@H](CCC(NNC(C1=NC(Br)=CC=C1)=O)=O)CF)=O Chemical compound CC(C)(C)OC(N[C@H](CCC(NNC(C1=NC(Br)=CC=C1)=O)=O)CF)=O IMJCXCLFKAAQGS-SNVBAGLBSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 5
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- BUSZBFLICYKHPQ-JTQLQIEISA-N ethyl (4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound CC[C@@H](CCC(OCC)=O)NC(OC(C)(C)C)=O BUSZBFLICYKHPQ-JTQLQIEISA-N 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- RQNWGNHIVICCGQ-SSDOTTSWSA-N tert-butyl (2r)-2-(fluoromethyl)-5-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1[C@@H](CF)CCC1=O RQNWGNHIVICCGQ-SSDOTTSWSA-N 0.000 description 5
- KBZXHGVMYKPGJC-SNVBAGLBSA-N tert-butyl N-[(2R)-4-[5-(6-bromopyridin-2-yl)-1,3,4-oxadiazol-2-yl]-1-fluorobutan-2-yl]carbamate Chemical compound CC(C)(C)OC(N[C@H](CCC1=NN=C(C2=NC(Br)=CC=C2)O1)CF)=O KBZXHGVMYKPGJC-SNVBAGLBSA-N 0.000 description 5
- AFDHROQLEWPFTN-JTQLQIEISA-N tert-butyl N-[(2S)-4-[5-(6-bromopyridin-2-yl)-1,3,4-oxadiazol-2-yl]butan-2-yl]carbamate Chemical compound C[C@@H](CCC1=NN=C(C2=NC(Br)=CC=C2)O1)NC(OC(C)(C)C)=O AFDHROQLEWPFTN-JTQLQIEISA-N 0.000 description 5
- ARSNJASYTHIDAO-JTQLQIEISA-N tert-butyl N-[(2S)-5-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-5-oxopentan-2-yl]carbamate Chemical compound C[C@@H](CCC(NNC(C1=NC(Br)=CC=C1)=O)=O)NC(OC(C)(C)C)=O ARSNJASYTHIDAO-JTQLQIEISA-N 0.000 description 5
- GHUOBGHYIOUIJY-NSHDSACASA-N tert-butyl N-[(3S)-6-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-6-oxohexan-3-yl]carbamate Chemical compound CC[C@@H](CCC(NNC(C1=NC(Br)=CC=C1)=O)=O)NC(OC(C)(C)C)=O GHUOBGHYIOUIJY-NSHDSACASA-N 0.000 description 5
- GXBCPVBIHSWEPK-UHFFFAOYSA-N tert-butyl N-[[6-(dimethylamino)-4-(dimethylcarbamoyl)-3-formylpyridin-2-yl]methyl]-N-methylcarbamate Chemical compound CC(OC(=O)N(CC1=NC(N(C)C)=CC(=C1C=O)C(=O)N(C)C)C)(C)C GXBCPVBIHSWEPK-UHFFFAOYSA-N 0.000 description 5
- UETSWVCUPQBUGT-QMMMGPOBSA-N tert-butyl n-[(2s)-1-[methoxy(methyl)amino]-1-oxobutan-2-yl]carbamate Chemical compound CON(C)C(=O)[C@H](CC)NC(=O)OC(C)(C)C UETSWVCUPQBUGT-QMMMGPOBSA-N 0.000 description 5
- WQNMHLGUIXQTED-SCSAIBSYSA-N (5r)-5-(fluoromethyl)pyrrolidin-2-one Chemical compound FC[C@H]1CCC(=O)N1 WQNMHLGUIXQTED-SCSAIBSYSA-N 0.000 description 4
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 4
- SDNVUDAIVIGPOZ-UHFFFAOYSA-N 4-chloro-6-(1-methylcyclopropyl)-2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical compound N1=C(C2=C(C=C1C1(C)CC1)C(=O)NC2)Cl SDNVUDAIVIGPOZ-UHFFFAOYSA-N 0.000 description 4
- BJCVQRHKEMFVSJ-SSDOTTSWSA-N CC(C)(C)OC(N[C@H](CCC(NN)=O)CF)=O Chemical compound CC(C)(C)OC(N[C@H](CCC(NN)=O)CF)=O BJCVQRHKEMFVSJ-SSDOTTSWSA-N 0.000 description 4
- PCLQNKMTRCBENP-QMMMGPOBSA-N CC[C@@H]1N2C(C3=NC(Br)=CC=C3)=NN=C2CC1 Chemical compound CC[C@@H]1N2C(C3=NC(Br)=CC=C3)=NN=C2CC1 PCLQNKMTRCBENP-QMMMGPOBSA-N 0.000 description 4
- GKEBUBKXPZISTE-UHFFFAOYSA-N CN(C(C)C)C1=NC=CC(=C1)C(=O)N Chemical compound CN(C(C)C)C1=NC=CC(=C1)C(=O)N GKEBUBKXPZISTE-UHFFFAOYSA-N 0.000 description 4
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 4
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 4
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000012448 Lithium borohydride Substances 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- DHGKJOLQMNWRQY-GFCCVEGCSA-N [2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-4-yl]-piperidin-1-ylmethanone Chemical compound ClC1=NC(=CC(=C1)C(=O)N1CCCCC1)N1[C@@H](CCC1)C DHGKJOLQMNWRQY-GFCCVEGCSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- QTXXUBIPVJYLMS-DDXVTDLHSA-N ethyl (E,4S)-4-[(2-methylpropan-2-yl)oxycarbonylamino]hex-2-enoate Chemical compound CCOC(=O)\C=C\[C@H](CC)NC(=O)OC(C)(C)C QTXXUBIPVJYLMS-DDXVTDLHSA-N 0.000 description 4
- JVIOXWIVRANHCX-UHFFFAOYSA-N ethyl 2-chloro-3-cyano-6-(1-methylcyclopropyl)pyridine-4-carboxylate Chemical compound ClC1=NC(=CC(=C1C#N)C(=O)OCC)C1(CC1)C JVIOXWIVRANHCX-UHFFFAOYSA-N 0.000 description 4
- DJEHGYLWORVESK-UHFFFAOYSA-N ethyl 3-cyano-6-(1-methylcyclopropyl)-2-oxo-1H-pyridine-4-carboxylate Chemical compound C(#N)C=1C(=NC(=CC=1C(=O)OCC)C1(CC1)C)O DJEHGYLWORVESK-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- KZJXDIRVJWRYMY-UHFFFAOYSA-N methyl 6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydropyrrolo[3,4-c]pyridine-4-carboxylate Chemical compound O(C)C(=O)C1=NC(N(C(C)C)C)=CC2=C1CNC2=O KZJXDIRVJWRYMY-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- QVQXGBGLXBZVJT-QGZVFWFLSA-N tert-butyl N-[[3-formyl-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridin-2-yl]methyl]-N-methylcarbamate Chemical compound C(C)(OC(=O)N(CC1=NC(=CC(=C1C=O)C(=O)N1CCCCC1)N1[C@@H](CCC1)C)C)(C)C QVQXGBGLXBZVJT-QGZVFWFLSA-N 0.000 description 4
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 4
- NBDAUFXJXMBQRC-ZETCQYMHSA-N tert-butyl n-[(2s)-1-oxobutan-2-yl]carbamate Chemical compound CC[C@@H](C=O)NC(=O)OC(C)(C)C NBDAUFXJXMBQRC-ZETCQYMHSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- SKEHRAOAAMPXLD-UHFFFAOYSA-N 4-(hydroxymethyl)-6-[methyl(propan-2-yl)amino]-2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical compound C(C1=NC(=CC2=C1CNC2=O)N(C(C)C)C)O SKEHRAOAAMPXLD-UHFFFAOYSA-N 0.000 description 3
- HBFIERSLJTVAPH-SSDOTTSWSA-N 4-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical compound N1=C(C2=C(C=C1N1[C@@H](CCC1)C)C(=O)NC2)Cl HBFIERSLJTVAPH-SSDOTTSWSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- PDZXVOTYWJTNGV-SECBINFHSA-N CCC(C1=NC(N2[C@H](C)CCC2)=CC2=C1CNC2=O)=O Chemical compound CCC(C1=NC(N2[C@H](C)CCC2)=CC2=C1CNC2=O)=O PDZXVOTYWJTNGV-SECBINFHSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229940125962 HPK1 kinase inhibitor Drugs 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000723792 Tobacco etch virus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- DOFGFNAHJXLQLG-UHFFFAOYSA-N n-(dimethylhydrazinylidene)formamide Chemical compound CN(C)N=NC=O DOFGFNAHJXLQLG-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- IZBIVVVDSAHXNS-YDZHTSKRSA-N tert-butyl N-[[3-[(E)-tert-butylsulfinyliminomethyl]-6-(dimethylamino)-4-(dimethylcarbamoyl)pyridin-2-yl]methyl]-N-methylcarbamate Chemical compound C(C)(OC(=O)N(CC1=NC(N(C)C)=CC(=C1/C=N/S(=O)C(C)(C)C)C(=O)N(C)C)C)(C)C IZBIVVVDSAHXNS-YDZHTSKRSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- PNFVIPIQXAIUAY-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-LURJTMIESA-N 0.000 description 2
- CVYVXURBKURNKE-ZETCQYMHSA-N (4s)-4-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound OC(=O)CC[C@H](C)NC(=O)OC(C)(C)C CVYVXURBKURNKE-ZETCQYMHSA-N 0.000 description 2
- QFOSFXPTXNRRMF-SCSAIBSYSA-N (5r)-5-(bromomethyl)pyrrolidin-2-one Chemical compound BrC[C@H]1CCC(=O)N1 QFOSFXPTXNRRMF-SCSAIBSYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 description 2
- 108700020469 14-3-3 Proteins 0.000 description 2
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- QDSJMVZVUSYEMY-UHFFFAOYSA-N 2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical group N1=CC=C2C(=O)NCC2=C1 QDSJMVZVUSYEMY-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100035634 B-cell linker protein Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000243142 Porifera Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108091006463 SLC25A24 Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 101150062912 cct3 gene Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940126588 endocrine therapeutic agent Drugs 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229940044170 formate Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940050411 fumarate Drugs 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229940045207 immuno-oncology agent Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 239000002584 immunological anticancer agent Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000002535 lyotropic effect Effects 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940014662 pantothenate Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 108010061269 protein kinase D Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 230000005851 tumor immunogenicity Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OLNJKAXRBXUBTB-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-acetamido-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N OLNJKAXRBXUBTB-JYJNAYRXSA-N 0.000 description 1
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- QKNGHJHZTBFFNJ-SSDOTTSWSA-N (5R)-3-(6-bromopyridin-2-yl)-5-(fluoromethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole Chemical compound FC[C@@H]1N2C(C3=NC(Br)=CC=C3)=NN=C2CC1 QKNGHJHZTBFFNJ-SSDOTTSWSA-N 0.000 description 1
- PQIMEADNXCPPQB-ZETCQYMHSA-N (5S)-3-(6-bromopyridin-2-yl)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole Chemical compound C[C@@H]1N2C(C3=NC(Br)=CC=C3)=NN=C2CC1 PQIMEADNXCPPQB-ZETCQYMHSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HRJSRLGPCRFPLV-UHFFFAOYSA-N 2-bromo-6-(4-propyl-1,2,4-triazol-3-yl)pyridine Chemical compound N1(CCC)C=NN=C1C1=NC(Br)=CC=C1 HRJSRLGPCRFPLV-UHFFFAOYSA-N 0.000 description 1
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 description 1
- XRPDDDRNQJNHLQ-UHFFFAOYSA-N 2-ethyl-1h-pyrrole Chemical compound CCC1=CC=CN1 XRPDDDRNQJNHLQ-UHFFFAOYSA-N 0.000 description 1
- FGIJYJBPKNTSJX-UHFFFAOYSA-N 2h-pyran-2-sulfonamide Chemical compound NS(=O)(=O)C1OC=CC=C1 FGIJYJBPKNTSJX-UHFFFAOYSA-N 0.000 description 1
- RFGMSGRWQUMJIR-UHFFFAOYSA-N 3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound COCC(C(O)=O)NC(=O)OC(C)(C)C RFGMSGRWQUMJIR-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- YLSHLPHOYAXYDZ-UHFFFAOYSA-N 4-acetyl-6-[methyl(propan-2-yl)amino]-2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical compound CC(C)N(C)C1=CC(C(NC2)=O)=C2C(C(C)=O)=N1 YLSHLPHOYAXYDZ-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- XURXQNUIGWHWHU-UHFFFAOYSA-N 6-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Br)=N1 XURXQNUIGWHWHU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101710098191 C-4 methylsterol oxidase ERG25 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- LQERXZYSNKIMFN-UHFFFAOYSA-N CCC1N2C(C3=CC=CC(N(CC4=C5C=C(N(C)C(C)C)N=C4C(C)N)C5=O)=N3)=NN=C2CC1 Chemical compound CCC1N2C(C3=CC=CC(N(CC4=C5C=C(N(C)C(C)C)N=C4C(C)N)C5=O)=N3)=NN=C2CC1 LQERXZYSNKIMFN-UHFFFAOYSA-N 0.000 description 1
- TWTWFMUQSOFTRN-UHFFFAOYSA-M CC[Mg]Br Chemical compound CC[Mg]Br TWTWFMUQSOFTRN-UHFFFAOYSA-M 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101150118364 Crkl gene Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102100028570 Drebrin-like protein Human genes 0.000 description 1
- 101100060033 Drosophila melanogaster cic gene Proteins 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 102000054300 EC 2.7.11.- Human genes 0.000 description 1
- 108700035490 EC 2.7.11.- Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102100035261 FYN-binding protein 1 Human genes 0.000 description 1
- 108091011190 FYN-binding protein 1 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000915399 Homo sapiens Drebrin-like protein Proteins 0.000 description 1
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 1
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 1
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101100060035 Mus musculus Cic gene Proteins 0.000 description 1
- 101100393522 Mus musculus Grap2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 101710157230 STE20-like serine/threonine-protein kinase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 1
- 101710183953 Serine/threonine-protein kinase 25 Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000013380 Smoothened Receptor Human genes 0.000 description 1
- 101710090597 Smoothened homolog Proteins 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000007295 Wittig olefination reaction Methods 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001349 alkyl fluorides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- IWHYFYBVTHEJLL-UHFFFAOYSA-N ethyl 3-(1-methylcyclopropyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1(C)CC1 IWHYFYBVTHEJLL-UHFFFAOYSA-N 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005111 flow chemistry technique Methods 0.000 description 1
- 125000006005 fluoroethoxy group Chemical group 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- PUZPICCLXMPMBW-UHFFFAOYSA-A hex-2-enoate Chemical compound CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O.CCCC=CC([O-])=O PUZPICCLXMPMBW-UHFFFAOYSA-A 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- XSKGHSUHOYEBTK-UHFFFAOYSA-N methyl 2,6-dichloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC(Cl)=NC(Cl)=C1 XSKGHSUHOYEBTK-UHFFFAOYSA-N 0.000 description 1
- SGNCOKUHMXLGAH-UHFFFAOYSA-N methyl 6-bromopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Br)=N1 SGNCOKUHMXLGAH-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- LFILDSDQMSCNBV-UHFFFAOYSA-N propane-2-sulfinamide Chemical compound CC(C)S(N)=O LFILDSDQMSCNBV-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000000373 single-crystal X-ray diffraction data Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- LQTPRJROEYAITE-NSHDSACASA-N tert-butyl N-[(3S)-1-[5-(6-bromopyridin-2-yl)-1,3,4-oxadiazol-2-yl]pentan-3-yl]carbamate Chemical compound CC[C@@H](CCC1=NN=C(C2=NC(Br)=CC=C2)O1)NC(OC(C)(C)C)=O LQTPRJROEYAITE-NSHDSACASA-N 0.000 description 1
- SVEFOMFYZHPHTB-GFCCVEGCSA-N tert-butyl N-methyl-N-[[6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydropyrrolo[3,4-c]pyridin-4-yl]methyl]carbamate Chemical compound C(C)(OC(=O)N(CC1=NC(=CC2=C1CNC2=O)N1[C@@H](CCC1)C)C)(C)C SVEFOMFYZHPHTB-GFCCVEGCSA-N 0.000 description 1
- SSEWBRDPNKDOIA-UHFFFAOYSA-N tert-butyl N-methyl-N-[[6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydropyrrolo[3,4-c]pyridin-4-yl]methyl]carbamate Chemical compound N(C)(C(=O)OC(C)(C)C)CC1=NC(=CC2=C1CNC2=O)N(C(C)C)C SSEWBRDPNKDOIA-UHFFFAOYSA-N 0.000 description 1
- RJSZFSOFYVMDIC-UHFFFAOYSA-N tert-butyl n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC(C)(C)C RJSZFSOFYVMDIC-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Abstract
This invention relates to compounds of general Formula
Description
Azalactam Compounds as HPK1 Inhibitors
Field of the Invention
The present invention relates to compounds of Formula I, and their pharmaceutically 5 acceptable salts, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds, salts and compositions of the present invention are HPK1 inhibitors and as such may be used to enhance the activation of the immune system in the treatment or amelioration of abnormal cell proliférative disorders, such as cancer and amelioration of vaccine thérapies.
Backqround
Hematopoietic progenitor kinase 1 (HPK1), also known as mitogen activated protein kinase kinase kinase kinase 1 (MAP4K1), is a member of the mammalian Ste20-like family of serine/threonine kinases that opérâtes via the JNK and ERK signalling pathways. HPK1 is mainly expressed in hematopoietic organs and cells (e.g., T-cells, B-ce!ls, and dendritic cells), suggesting 15 potential involvement of HPK1 in the régulation of signaling in hematopoietic lineages, including lymphocytes. (Shui, et al, “Hematoppietic progenitor kinase 1 negatively régulâtes T cell receptor signaling and T cel-mediated immune responses”, Nature Immunology 8, 84-91 (2006)).
For example, stimulation of the T-Cell Receptor (TCR) induces HPK1 tyrosine 379 phosphorylation and relocation to the plasma membrane. Enzymatic activation of HPK1 is 20 accompanied by phosphorylation of regulatory sites in the HPK1 kinase activation loop. Full activation of HPK1 is dépendent on autophosphorylation of threonine 165 and phosphorylation by protein kinase D (PKD) of serine 171 (Arnold et al., “Activation of Hematopoietic Progenitor Kinase 1 Involves Relocation, Autophosphorylation, and Transphosphorylation by Protein Kinase D1.”, Mol Cell Biol 25 (6), 2364-83 (2005)). HPK1 mediated phosphorylation of adaptor protein SLP76 25 ultimately leads to the destabilization of the TCR signaling complex which impedes and atténuâtes downstream mitogen-activated protein (MAP) kinase signaling events necessary for T-cell activation and prolifération. (Hernandez, et al., “The kinase activity of hematopoietic progenitor kinase 1 isesentialforthe régulation of T cell function”, Cell Reports 25, (1), 80-94, (2018)). HPK1 kinase has also been shown to negatively regulate T-cell signaling by the PG Εξ receptor in a PKA30 dépendent manner. Furthermore, HPK1 kinase has been reported to play rôles in: i) activationinduced cell death (AICD) and JNK activation; ii) régulation of leukocyte function-associated antigen-1 (LFA-1) integrin activation on T-cells by direct compétition with adhesion and degranulation promoting adaptor protein (ADAP) for binding of the SLP76 SH2-domain; and iii) régulation of activation via nuclear factor kB (NF- kB) signaling by interacting with lKK-α and -B. 35 Studies hâve also shown HPK1 negatively regulates MAP kinase pathway signaling and AP-1 transcription in T-cells. (reviewed in Hernandez, et al. 2018).
The research conducted to date on HPK1 kinases suggests that HPK1 inhibition plays a roie in enhancing dendritic and T-cell responses and thereby heightening anti-tumor immunity, virus clearance and response to vaccine therapy.
Summary
The present invention provides, in part, compounds of Formula I, and a pharmaceutically acceptable sait thereof. Such compounds can inhibit the activity of HPK1 kinase, thereby effecting biological functions. Also provided are pharmaceutical compositions and médicaments, comprising the compounds or salts of the invention, alone or in combination with additional anticancer therapeutic agents or palliative agents.
The present invention also provides, in part, methods for preparing the compounds, pharmaceutically acceptable salts and compositions of the invention, and methods of using the foregoing.
In one embodiment, the invention provides a compound of Formula I:
R4 or a pharmaceutically acceptable sait thereof, wherein:
R1 is (CrCeJalkyl, halo(Ci-C6)alkyl, (Ci-C6)alkoxy, halo(Ci-C6)alkoxy, -N(R5)(R6), or (C3Ce)cycloalkyl, wherein said (Ci-Csiaikyl, halo(Ci-Cs)alkyl, and (Ca-Cejcycloalkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, (Ci-Csjalkyl, or (Ci-Ce)alkoxy, wherein:
R5 and Rs are each independently hydrogen or (Ci-C6)alkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (Ci-Cs)alkoxy, cyano, and hydroxy, or
R5 and R6 taken together with the nitrogen to which they are attached form a (4- to 8-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (Ci-Ce)alkyl, halo(CiCs)alkyl, (Ci-Ce)alkoxy, and halo(Ci-Cs)a!koxy;
R2 is N(R7)(R8), wherein:
R7 and Re are each independently hydrogen or (Ci-Cs)alkyl that is substituted with
0, or 1 substituent that is halogen, (Ci-Cs)aikoxy, cyano, or hydroxy; or
R7 is hydrogen or (Ci-Ce)alkyl that is substituted with 0, or 1 substituent that is halogen, (Ci-C6)alkoxy, cyano, or hydroxy; and R8 taken together with the nitrogen to which it is attached and taken together with R3a and the carbon to which it is attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, (Ci-C3)alkyt, halo(Ci-C3)alkyl, (CiC3)alkoxy, and halo(Ci-Cs)alkoxy; or
R7 and R8 taken together with the nitrogen to which they are attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, (Ci-C6)alkyl, halo(Ci-C6)alkyl, (CiCsjalkoxy, and halo(Ci-Ce)alkoxy;
R3a is hydrogen, or (C-i-C3)alkyl that is substituted with 0 or 1 substituent that is hydroxy, or (C-i-C3)alkoxy;
R3b is hydrogen, or (Ci-C3)alkyl, provided that R3a and R3b are not both H when R4 is (R4i);
R4 is (R4-i) or (R4-ii):
wherein:
R4N is (Ci-Cejalkyl, halo(Ci-C6)alkyl, or (C3-C6)cycloalkyl, wherein said (Ci-C6)alkyl is substituted with 0 or 1 substituent that is hydroxy;
R4C is hydrogen, (Ci-C6)alkyl, halo(Ci-Cs)alkyl, (Ci-C0)alkoxy, halo(Ci-Ce)alkoxy, or (C3C6)cycloalkyl, wherein said (Ci-C0)alkyi and halo(Ci-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-C6)alkoxy;
R4D îs hydrogen, (Ci-C6)alkyl, halo(Ci-C6)alkyl, (Ci-C0)alkoxy, halo(Ci-Ce)alkoxy, or (C3Ce)cycloalkyl, wherein said (Ci-Ce)alkyl and halofCi-CsJalkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-Ce)alkoxy;
R4E is hydrogen, halogen, cyano, hydroxy, or (Ci-C0)alkyt; and
R4F is hydrogen, halogen, cyano, hydroxy, (Ci-Cs)alkyl, halo(Ci-C6)alkyl, (Ci-Cs)alkoxy, halo(Ci-Cs)alkoxy, or (Cs-C6)cycioalkyl, wherein said (Ci-Cejafkyf and halo(Ci-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-Cejalkoxy.
The invention also provides therapeutic methods and uses comprising administering a compound of the invention, or a pharmaceutically acceptable sait thereof.
In another embodiment, the invention provides a method for the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof. Compounds of the invention may be adminîstered as single agents, or may be adminîstered in combination with other anti-cancer therapeutic agents, in particular standard of care agents appropriate for the particular cancer.
In a further embodiment, the invention provides a method for the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional anti-cancer therapeutic agent, which amounts are together effective in treating said abnormal cell growth.
In another embodiment, the invention relates to a compound of the invention, or a pharmaceutically acceptable sait thereof, for use as a médicament, in particular a médicament for treatment of cancer.
In another embodiment, the invention relates to a compound of the invention, or a pharmaceutically acceptable sait thereof, for use in the treatment of abnormal cell growth, in particular cancer, in a subject.
In a further embodiment, the invention provides the use of a compound of the invention, or a pharmaceutically acceptable sait thereof, for the treatment of abnormal cell growth, in particular cancer, in a subject.
In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment of abnormal cell growth in a subject in need thereof, which composition comprises a compound of the invention, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
In yet another embodiment, the invention provides the use of a compound of Formula I as described herein, or a pharmaceutically acceptable sait thereof, for the préparation of a médicament for the treatment of abnormal cell or pathogen growth in a subject.
In frequent embodiments of the foregoing compounds, methods and uses, the abnormal cell growth is cancer.
In some embodiments, the methods and uses provided resuit in one or more of the foilowing effects: (1) inhibiting cancer cell prolifération; (2) inhibiting cancer cell invasiveness; (3) inducing apoptosis of cancer cells; (4) inhibiting cancer cell metastasis; (5) inhibiting angiogenesis;
(6) enhancing T-cell responses; or (7) enhancing dendritic and B cell responses; (8) heightenmg of anti-tumor activity; (9) enhancing vaccine thérapies; and (10) enhancing immune-system mediated removal of pathogens such as viruses, bacteria, or parasite (e.g., intestinal worms).
In another embodiment, the invention provides a method for the treatment of HPK1dependent disorders and enhancing an immune response in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder or enhancing said immune response.
In some embodiments, the methods and uses described herein further comprise administering to the subject an amount of an additional anticancer therapeutîc agent, vaccine, antibacterial agent, antiviral agent, or a palliative agent, which amounts are together effective in treating said abnormal cell growth or pathogen. Each ofthe embodiments ofthe compounds of the present invention described below can be combined with one or more other embodiments of the compounds ofthe present invention described herein not inconsistent with theembodiment(s) with which it is combined.
it is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive ofthe invention, as claimed.
In addition, each of the embodiments below describing the invention envisions within its scope the pharmaceutically acceptable salts of the compounds ofthe invention. Accordingly, the phrase “or a pharmaceutically acceptable sait thereof’ is implicit in the description of ail compounds described herein.
Detailed Description
Définitions and Exemplifications
The present invention may be understood more readily by reference to the following detailed description of the preferred embodiments of the invention and the Examples included herein. It is to be understood that the terminology used herein is for the purpose of describing spécifie embodiments only and is not intended to be limiting. It is further to be understood that unless specifically defined herein, the terminology used herein rs to be given its traditional meaning as known in the relevant art.
As used herein, the singular form a, an, and the include plural references unless indicated otherwise. For example, a” substituent includes one or more substituents.
The term “about” refers to a relative term denoting an approximation of plus or minus 10% of the nominal value it refers, in one embodiment, to plus or minus 5%, in another embodiment, to plus or minus 2%. For the field of this disclosure, this level of approximation is appropriate unless the value is specifically stated to require a tighter range.
At various places in the present spécification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term “Ci-e alkyl” is specifically întended to include Ci alkyl (methyl), C2 alkyl (ethyl), C3 alkyl, C4 alkyl, C5 alkyl, and Cs alkyl.
As used herein, a HPK1 antagonist or a HPK1 inhibitor is a molécule that reduces, inhibits, or otherwise diminishes one or more of the biological activities of HPK1 (e.g., serine/threonine kinase activîty, recruitment to the TCR complex upon TCR activation, interaction with a protein binding partner, such as SLP76). Antagonism using the HPK1 antagonist does not necessarily indicate a total élimination of the HPK1 activîty. Instead, the activîty could decrease by a statistically significant amount. For example, a compound of the présent invention may decrease HPK1 activîty by at least about 2.5% to about 100%, from about 10% to about 90%, from about 20% to about 70%, from about 30% to about 60%, from about 40% to about 50% compared to an appropriate control. In some embodiments, the HPK1 antagonist reduces, inhibits, or otherwise diminishes the serine/threonine kinase activity of HPK1. In some of these embodiments, the HPK1 antagonist reduces, inhibits, or otherwise diminishes the HPK1 -mediated phosphorylation ofSLP76 and/or Gads. The presently disclosed compounds bind directiy to HPK1 and inhibit its kinase activity.
The invention described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms comprising, consisting essentially of', and consisting of' may be replaced with either of the other two terms.
The term “(Cx-Cy)alkyl”, as used herein, refers to a saturated, branched- or straight-chain alkyl group containing from x to y carbon atoms. For example, “(Ci-Ce)alkyl, is an alkyl group containing from 1 to 6 carbon atoms and includes, but is not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl. The term “(Ci-C3)alkyr contains from 1 to 3 carbon atoms and is included within “(CrCe)alkyl”.
The term “halo(Cx-Cy)alkyr as used herein, refers to a (Cx-Cy)alkyl group as defined above wherein the alkyl group is substituted with one or more halogen atoms. A representive number of halogen substituents is from 1 to 3 substituents. Représentative examples of a halo(Cx-Cy)alkyl, include, but are not limited to, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, and trifluoroethyl.
The term “(Cx-Cy) alkoxy” as used herein, refers to a (Cx-Cy)alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. Représentative examples of a (Ci-Ce)alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tertbutoxy, pentyloxy, and hexyloxy.
The term ‘‘halofCx-CjJalkoxy” as used herein, refers to a (Cx-Cy)alkoxy group as defined above wherein the alkoxy group is substituted with one or more halogen atoms. A representive number of halogen substituents is from 1 to 3 substituents. Représentative examples of a halo(Cx
Cy)alkoxy, include, but are not limited to, fluoromethoxy, fluoroethoxy, difluoromethoxy, difluoroethoxy, and trifluoromethoxy, trifluoroethoxy.
As used herein, the term “cycloalkyl refers to a cyclic, monovalent hydrocarbon group of formula -CnH^n-i) containing at least three carbon atoms. A “(C3-Cy)cycloalkyl” refers to a cycloalkyl having 3 to y carbon atoms. A “(Cs-Cejcycloalkyl” may be a monocyclic ring, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
A heterocycloalkyl,” as used herein, refers to a cycloalkyl as defined above, wherein at least one of the ring carbon atoms is replaced with a heteroatom selected from nitrogen, oxygen and sulfur. As used herein, the term “n-membered” where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. The term “(4- to 6-membered)heterocycloalkyl” means the heterocycloalkyl substituent contains a total of 4 to 6 ring atoms, at least one of which is a heteroatom. The term “(4- to 8membered)heterocycloalkyr means the heterocycloalkyl substituent contains a total of 4 to 8 ring atoms, at least one of which is a heteroatom. A “(6-membered)heterocycloalkyl” means the heterocycloalkyl substituent contains a total of 6 ring atoms, at least one of which is a heteroatom. A “(5-membered)heterocycloalkyl” means the heterocycloalkyl substituent contains a total of 5 ring atoms at least one of which is a heteroatom. The heterocycloaikyl substituent may be attached via a nitrogen atom having the approprîate valence, or via any ring carbon atom. The heterocycloalkyl moiety may be optionally substituted with one or more substituents, such as (Cr Ce)alkyl, at a nitrogen atom having the approprîate valence, or at any available carbon atom.
Examples of heterocycloalkyl rings include, but are not limited to, azetidinyl, tetrahydrofuranyl, tetrahydropyrazolyl, tetrahydrooxazînyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, tetrahydropyranyl, tetrahydro-oxazolyl, morpholinyl, and oxetanyl.
“halo or halogen”, as used herein, refers to a chlorine, fluorine, bromine, or iodine atom. “hydroxy” or “hydroxyl, as used herein, means an -OH group.
“cyano”, as used herein, means a -CN group, which also may be depicted:
-C=N “Patient” or “subject” refers to warm-blooded animais such as, for example, pigs, cows, chickens, horses, guinea pigs, mice, rats, gerbils, cats, rabbits, dogs, monkeys, chimpanzees, and humans.
“Pharmaceutically acceptable indicates that the substance or composition must be compatible, chemically and/or toxicologically, with the other ingrédients comprising a formulation, and/or the mammal being treated therewith.
The term therapeutically effective amount as used herein refers to that amount of the compound being adminîstered which will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the treatment of an HPK1 kinase-mediated disorder (e.g., cancer), a therapeutically effective amount refers to that amount which has the effect of relieving to some extent (or, for example, eliminating) one or more symptoms associated with the HPK1 kinase-mediated disorder. For example, a therapeutically effective amount refers to that amountwhich hasthe effect of (1) reducing the size ofthe tumor, (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis, (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth or tumor invasiveness, and/or (4) relieving to some extent (or, preferably, eliminating) one or more signs or symptoms associated with the cancer.
The term treating, as used herein, unless otherwise indîcated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term treatment, as used herein, unless otherwise indîcated, refers to the act of treating as treating is defined herein. The term “treating” also includes adjuvant and neo-adjuvant treatment of a subject.
“Isomer” means “stereoisomer and “geometric isomer as defined below.
“Stereoisomer” refers to compounds that possess one or more chiral centers, which may each exist in the R or S configuration. Stereoisomers include ail diastereomeric, enantiomeric and epimeric forms as well as racemates and mixtures thereof.
“Géométrie isomer” refers to compounds that may exist in cis, trans, anti, entgegen (E), and zusammen (Z) forms as well as mixtures thereof.
This spécification uses the terms “substituent,” “radical,” and “group” interchangeably.
If substituents are described as being “independently selected” from a group, each instance of a substituent is selected independent of any other. Each substituent therefore may be identical to or different from the other substituent(s).
Compounds
The compounds of Formula I, as described herein, contain an azalactam (2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-1-one) core wherein the pyrrolo ring is attached via its nitrogen atom to pyridine that is substituted with R4.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4-i);
R4N is (Ci-Ce)alkyl, or (C3-Ce) cycloalkyl; and
R4C is hydrogen, or (Ci-C3)alkyl; wherein R1, R2, R3a, and R3b are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4-i), wherein R1 is -N(R5)(RS), or (C3C6)cycloalkyl, wherein said (C3-Cs)cycloalkyl is cyclopropyl and is substituted with 0 or 1 substituent that is (Ci-Cs)alkyI, wherein said (Ci-Cs)alkyl is methyl;
R5 and R6 are each independently hydrogen or (Ci-C3)alkyl, or
R5 and Rs taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is (Ci-Ce)alkyl;
R2 is N(R7)(R8), wherein R7 and R8 are each independently hydrogen or (CrC6)alkyl that is methyl;
R3a is (Ci-Csjalkyl that is substituted with 0 or 1 substituent that is (Ci-C3)alkoxy; and
R3b is hydrogen, or (Ci-Cs)alkyi.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4-ii);
R4D is hydrogen, (Ci-Cs)alkyl, or halo(Ci-C6)alkyl, wherein said (Ci-C6)alkyl is substituted with 0 or 1 substituent that is hydroxy;
R4E is hydrogen; and
R4F is hydrogen, (Ci-Csjalkyl, or halo(Ci-C6)alkyl, wherein said (Ci-Cs)alkyl is substituted with 0 or 1 substituent that is hydroxy; and wherein R1, R2, R33, and R3b are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4-ii), and wherein R1 is -N(R5)(R6), or (C3-C6)cycloalkyl, wherein said (C3-C6)cycloalkyl is cyclopropyl and is substituted with 0 or 1 substituent that is (Ci-Cejalkyl, wherein said (Ci-Ce)alkyl is methyl;
R5 and R8 are each independently hydrogen or (Ci-C3)alkyl, or
R5 and R6 taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is (Ci-Cs)alkyl;
R2 is N(R7)(R8), wherein R7 and Rs are each independently hydrogen or (Ci-Ce)alkyl that is methyl;
R3a is hydrogen, or (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (Cr C3)alkoxy; and
R3b is hydrogen, or (Ci-C3)aikyl.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R1 is 2-methyl-pyrrolidin-1-yl, or 2(R)-methylpyrrolidin-1 -yl; and wherein R2, R3a, R3b and R4 are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R2 is N(R7)(Re), wherein R7 and Re are each hydrogen, and wherein R1, R3a, R3b and R4 are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceuticaily acceptable sait thereof, wherein R3a is (CrC3)alkyl that is substituted with 0 or
substituent that is (Ci-C3)alkoxy; and wherein R1, R2, R3b and R4 are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R3b is (Ci-C3)alkyl; and R1, Rs, R3a and R4 are 5 as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R2 is N(R7)(RS), wherein R7 and R® are each hydrogen; and wherein R1, R3a, R3b and R4 are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R2 is N(R7)(Re), wherein R7 is hydrogen; and and Rs is (Ci-C3)alkyl; and wherein R1, R3a, R3b and R4 are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula l-A (a compound 15 of Formula I, wherein R4 is (R4-i):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is -N(R5)(R6), or (C3-C6)cycloalkyl, wherein said (C3-Cs)cycloalkyl is cyclopropyl and is substituted with 0 or 1 substituent that is (Ci-C6)alkyl, wherein said (Ci-Ce)alkyl is methyl;
Rs and R6 are each independently hydrogen or (Ci-C3)alkyl, or
R5 and R® taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is (Ci-Ce)alkyl;
R2 is N(R7)(R3), wherein R7 and R® are each independently hydrogen or (Ci-C6)alkyl that is methyl;
R3a is (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (Ci-C3)alkoxy;
R3b is hydrogen, or (Ci-C3)alkyl;
R4N is (Ci-C5)alkyI, or (Ca-Cejcycloalkyl; and
R4C is hydrogen, or (Ci-C3)alkyl.
In another embodiment, the invention provides a compound of Formula l-A, or a pharmaceutically acceptable sait thereof, wherein R3a is (Ci-Cs)alkyl that is substituted with 0 or 1 substituent that is (CrCsJalkoxy; and
R3b is (Ci-C3)alkyl.
In some embodiments, when R4 is (R4-i), the compound of Formula l-A has the absolute stereochemistry as shown in Formula l-A-i or l-A-ii:
or a pharmaceutically acceptable sait thereof, where R1, R2, R3a, R3b, and R4C are defined in any embodiment for Formula l-A.
In another embodiment, the invention provides a compound of Formula l-B (a compound of Formula I, wherein R4 is (R4'ii):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is (Ci-C6)alkyl, halo(Ci-C6)alkyl, (Ci-C6)alkoxy, halo(Ci-C6)alkoxy, -N(RS)(R6), or (C310 C6)cycloalkyl, wherein said (Ci-Ce)alkyl, halo(Ci-C6)alkyl, and (C3-C6)cycloalkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, (CrCs)alkyl, or (Ci-Cs)alkoxy, wherein:
R5 and R® are each independently hydrogen or (Ci-Ce)alkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consistîng of halogen, (Ci-Cs)alkoxy, cyano, and hydroxy, or
R5 and R6 taken together with the nitrogen to which they are attached form a (4- to
8-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (Ci-Cs)alkyl, halo(CiC6)alkyl, (CrC6)alkoxy, and halo(Ci-C6)alkoxy;
R2 is N(R7)(R3), wherein:
R7 and RE are each independently hydrogen or (Ci-C6)aikyl that is substituted with
0, or 1 substituent that is halogen, (Ci-Cs)alkoxy, cyano, or hydroxy; or
R7 is hydrogen or (Ci-Cs)alkyl that is substituted with 0, or 1 substituent that is halogen, (Ci-C6)alkoxy, cyano, or hydroxy; and R3 taken together with the nitrogen to which it is attached and taken together with R3a and the carbon to which it is attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0,1, or 2 substituents independently selected from halogen, hydroxy, (Ci-C3)alkyl, halo(Ci-C3)alkyl, (CiC3)alkoxy, or halo(Ci-Ce)alkoxy; or
R7 and R8 taken together with the nitrogen to which they are attached form a (4- to 6-membered)heterocycloaikyl that is substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, (Ci-C6)alkyl, halo(Ci-Cs)alkyl, (CiC6)alkoxy, and halo(Ci-C6)alkoxy;
R3a is hydrogen, or (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is hydroxy, or (Ci-C3)alkoxy;
R3b is hydrogen, or (Ci-C3)alkyl;
R4D is hydrogen, (CrCejalkyl, halo(Ci-Ce)alkyl, (Ci-Ce)alkoxy, halo(Ci-Ce)alkoxy, or (C3C6)cycloalkyl, wherein said (Ci-Ce)alkyl and halo(Ci-C6)aikyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-Cs)alkoxy;
R4E is hydrogen, halogen, cyano, hydroxy, or (Ci-Cs)alkyl; and
R4F is hydrogen, halogen, cyano, hydroxy, (Ci-Ce)alkyl, halofCi-Csialkyl, (Ci-Ce)alkoxy, halo(Ci-Cs)alkoxy, or (C3-Ce)cycloalkyl, wherein said (Ci-Ce)alkyl and halo(Ci-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-Cs)alkoxy; and wherein R2 is as defined in any ofthe herein described embodiments.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein;
R1 is -N(R5)(RS), or (C3-Ce)cycloalkyl, wherein said (C3-C6)cycloalkyl is substituted with 0 or 1 substituent that is (Ci-C3)alkyl, wherein;
R5 and R6 are each independently hydrogen or (CrC6)alkyl or
R5 and Rs taken together with the nitrogen to which they are attached form a (4- to 8-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents that is (CiCs)alkyl;
R2 is N(R7)(R3), wherein R7 and R3 are each independently hydrogen or (Ci-Cs)alkyl;
R3a is hydrogen, or (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (C 1C3)alkoxy;
R3b is hydrogen, or (C-i-C3)alkyl;
R4D is hydrogen, (Ci-C3)alkyl, or halo(Ci-C3)alkyl, wherein said (Ci-C3)alkyl is substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ct-C3)alkoxy;
R4E is hydrogen; and
R4F is hydrogen, (Ci-C3)alkyl, or halo(Ci-C3)alkyl, wherein said (Ci-C3)alkyl is substituted with 0 or 1 substituent that is hydroxy.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein R3b is hydrogen, or (Ci-C3)alkyl.
In another embodiment, the invention provides a compound of Formula LB, or a pharmaceutically acceptable sait thereof, wherein R4D is hydrogen, (Ci~C3)alkyl, or halo(Cr C3)alkyl, wherein said (Ci-C3)alkyl is substituted with 0 or 1 substituent that is hydroxy; and wherein R1, R3a, R3b, R4E and R4F are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein R3a is (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (CrC3)alkoxy; and
R3b is (Ci-C3)alkyl; and wherein R1, R2, R4D, R4E, and R4F are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein:
R1 is -N(Rb)(R6), or (Cs-Ce)cycloalkyl, wherein the (C3-Cs)cycloalkyl is substituted with 0 or 1 (CrC3)alkyl;
R5 and R6 are each independently selected from the group consisting of (Ci-C6)alkyl, or R5 and R6 taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0 or 1 (Ci-Ceialkyi;
Rz is N(R7)(RS), wherein R7 and Re are each hydrogen;
R3a îs hydrogen, or (Ci-C3)a1kyl, wherein said (Ci-C3)alkyi is substituted with 0 or 1 (Cr C3)alkoxy;
R3b is hydrogen, or (Ci-C3)alkyl;
R4D is hydrogen, or (Ci-C3)alkyl, wherein (Ci-C3)alkyl is substituted with 0 to 1 substituent selected from OH, and F;
R4E is hydrogen; and
R4F is hydrogen, or (CrC3)alkyl.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein:
R1 is -N(R5)(R6), or cyclopropyl that is substituted with 0 ογ 1 substituent that is methyl;
R5 and Rs are each independently hydrogen or (C-i-C3)aikyl, or
Rs and R6 taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is methyl;
R2 is N(R7)(RE), wherein R7 and R8 are each independently hydrogen or methyl;
R3a is (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (Ci-C3)alkoxy; and
R3b is hydrogen, or (Ci-C3)alkyl; and wherein R4D, R4Ë, and R4F are as defined in any ofthe herein described embodiments.
In another embodiment, the invention concerns a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4-ii);
R4D is hydrogen, (Ci-Cejalkyl, or halo(Ci-Cs)alkyl, wherein said (Ci-Cs)alkyi is substituted with 0 or 1 substituent that is hydroxy;
R4E is hydrogen; and
R4F is hydrogen, (Ci-C6)alkyl, or halo(Ci-C6)alkyl, wherein said (Ci-C6)alkyl is substituted with 0 or 1 substituent that is hydroxy; and wherein R1, R3, R3a, and R3b are as defined in any of the herein described embodiments.
In another embodiment, the invention concerns a compound of Formula I, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4-ii);
R4D is hydrogen, methyl, fluoromethyl, hydroxymethyl, or ethyl;
R4E is hydrogen; and
R4F is hydrogen; and wherein R1, R2, R3a, and R3b are as defined in any of the herein described embodiments.
In another embodiment, the invention concerns compounds of Formula I, or a pharmaceutically acceptable sait thereof, having spécifie stereochemistry with regard to the orientation of R2, R3a, and R3b, when R3a is different from R3b. For example, when R3b is hydrogen (R3b is absent), compounds of Formula I would appear as the following:
Formula l(R) Formula l(S)
wherein R1, R3a, and R4, are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula 1(R) or Formula l(S), or a pharmaceutically acceptable sait thereof, wherein:
R1 is -N(RS)(R6), or cyclopropyl that is substituted with 1 substituent that is methyl;
R5 and R0 are each independently hydrogen or (Ci-C3)alkyl, or
R5 and R6 taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is methyl;
R2 is N(R7)(Re), wherein R7 and R3 are each independently hydrogen or methyl;
R3a is (Ci-Cgjaîkyl that is substituted with 0 or 1 substituent that is (Ci-C3)alkoxy;
R3b is hydrogen;
R4 is (R -ii);
R4D is hydrogen, methyl, fluoromethyl, hydroxymethyl, or ethyl;
R4E is hydrogen; and
R4F is hydrogen, or methyl.
In yet another embodiment, the invention concerns compounds of Formula l(R), or a pharmaceutically acceptable sait thereof, wherein R3b îs hydrogen (R3b is absent):
O
and wherein R1, R3a, and R4, are as defined in any ofthe herein described embodiments.
In yet another embodiment, the invention concerns compounds of Formula l(S), or a pharmaceutically acceptable sait thereof, wherein R3b is hydrogen (R3b is absent):
wherein R1, R3a, and R4, are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein R4 is 5-methyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazoi-3-yl, (5R)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]trîazol-3-yl, (5S)-5-methyl6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl, 5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol· 3-yl, (5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl, or (5R)-5-ethyf6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]trîazol-3-yl, wherein said methyl is substituted with 0 or 1 substituent that is F or OH, and wherein R1, R2, R3a, and R3b are as defined in any of the herein described embodiments.
In another embodiment, the invention provides a compound of Formula l-B, or a pharmaceutically acceptable sait thereof, wherein R4 is (5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl, or (5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1 ^Itriazol-S-yl, wherein said methyl is substituted with 0 or 1 substituent that is F or OH, and wherein R1, R2, R3a, and R3b are as defined in any of the herein described embodiments.
Each of the embodiments described herein with respect to Formula I is also applicable to compounds of Formulas l-A-i, l-A-ii, l-B-i, and l-B-ii.
In another embodiment, the invention provides a compound, wherein the compound is: 4[1-aminopropyl]-2-{6-(5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[2methylpyrrolidin-1-yl]-2,3-dihydro-1/7-pyrro!o[3,4-c]pyridin-1-one;
4-[1-aminoethyl]-2-{6-5-ethyl-6,7-dihydro-5/7-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}6-[2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[1-aminoethyl]-2-{6-[5-ethyl-6,7-dihydro-5H-pyrroto[2,1-c][1,2,4]tnazo1-3-yl]pyndin-2-yl}6-[2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[1-aminoethyl]-2-{6-[5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]trîazol-3-yl]pyridin-2-yl}6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[1-aminopropyl]-2-{3-[5-methyl-6,7-dίhydro-5H-pyπΌlo[2,1-c][1,2,4]tπazol·3-yl]phenyl}6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one; or
4-[1-amino-2-methoxyethyl]-6-(1-methylcyclopropyl)-2-{6-[5-methyl-6,7-dihydro-5Hpyrrolo[2,1-c][1I2,4]triazol-3-yl]pyridin-2-yl}-2I3-dihydro-1/-/-pyrrolo[3I4-c]pyridin-1-one; or a pharmaceutically acceptable sait thereof.
For example, the compound ofthe invention is a compound that is 4-((1 R)-1-aminopropyl]2-{6-[(5S)-5-methy[-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrroio[3,4-c]pyridin-1-one;
4-[(1R)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[(1S)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1 H-pyrrolo[3,4-c]pyridin-1-one;
4-((1 R)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrroio[3,4-c]pyridin-1-one;
4-[(1R)-1-amtnopropyl]-2-{3-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]phenyl}-6-[methy!(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3T4-c]pyridin-1-one;
4-[(1R)-1-amino-2-methoxyethyl]-6-(1-methylcyclopropyl)-2-{6-[(5S)-5-methyl-6,7dihydro-5H-pyrroio[2t1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1one;or
4-[(1S)-1-amino-2-methoxyethyl]-6~(1-methylcyclopropyl)-2-{6-((5S)-5~inethyF6,7dihydro-5H-pyrroio[2I1-c][1I2,4]tnazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1one; or a pharmaceutically acceptable sait thereof.
In another embodiment, the invention concerns compounds of Formula I, or a pharmaceutically acceptable sait thereof, wherein the compounds are compounds of Formula l(R) or compounds of Formula l(S), having spécifie stereochemistry with regard to the orientation of R2, R3a, and R3b, when R3a is different from R3b.
In another embodiment, the invention concerns a compound that is 4-[(1R)-1aminopropyl]-2-{6-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yi}-621055
[(2R)-2-methylpyrrolidin-1-yl]-213-dihydro-1 H-pyrrolo[3,4-c]pyridin-1-one; or a pharmaceutically acceptable thereof.
In another embodiment, the invention concerns a compound that is 4-((1 R)-1 -aminoethylj2-{6-[(5S)-5-ethyl-6,7-dihydro-5M-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2methylpyrrolidin-1-yl]-2,3'dihydro-1H-pyrrolo[3I4-c]pyridin-1-one; or a pharmaceutically acceptable thereof.
In another embodiment, the invention concerns compounds that is 4-[(1S)-1-aminoethyl]2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yî]pyrid!n-2~yl}-6-[(2R)-2methylpyrrofidin-1-yl]-2,3-dihydro-1H-pyrrolo[3I4-cjpyridin-1“One; or a pharmaceutically acceptable thereof.
In another aspect, the invention provides a compound selected from the group consisting ofthe compounds exemplified herein, or a pharmaceutically acceptable sait thereof.
The compounds ofthe invention are sélective against HPK1 kinase.
A pharmaceutical composition refers to a mixture of one or more of the compounds described herein, or a pharmaceutically acceptable sait, solvaté, hydrate or prodrug thereof as an active ingrédient, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients.
In some embodiments, the pharmaceutical composition further comprises at least one additional anti-cancer therapeutic agent or a palliative agent. In some such embodiments, the at least one additional agent is an anti-cancer therapeutic agent as described below. In some such embodiments, the combination provides an additive, greater than additive, or synergistic anti-cancer effect.
In one embodiment, the invention provides a method for the treatment of abnormal cell growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof.
In another embodiment, the invention provides a method for the treatment of abnormal cell growth in a subject in need thereof, comprising administering to the subject an amount of a compound ofthe invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional therapeutic agent (e.g., an anticancer therapeutic agent), which amounts are together effective in treating said abnormal cell growth.
In frequent embodiments of the methods provided herein, the abnormal cell growth is cancer. Compounds ofthe invention may be adminîstered as single agents, or may be adminîstered in combination with other anti-cancer therapeutic agents, in particular standard of care agents approprîate for the particular cancer.
In some embodiments, the methods provided resuit in one or more ofthe foîlowing effects: (1 ) inhibiting cancer cell prolifération; (2) inhibiting cancer cell invasiveness; (3) inducing apoptosis of cancer cells; (4) inhibiting cancer cell metastasis; (5) inhibiting angiogenesis; (6) enhancmg Tcell responses; (7) enhancing dendritic and B cell responses; (8) heightening of anti-tumor activity; (9) enhancing vaccine thérapies; and (10) enhancing immune-system mediated removal of pathogens such as viruses, bacteria, worms.
In another aspect, the invention provides a method for the treatment of a disorder mediated by HPK1 kinase activity, in a subject, such as certain cancers, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder.
Unless indicated otherwise, ail référencés herein to the inventive compounds include référencés to salts, solvatés, hydrates and complexes thereof, and to solvatés, hydrates and complexes of salts thereof, including polymorphs, stereoisomers, and isotopically labelled versions thereof.
Compounds of the invention may exist in the form of pharmaceutically acceptable salts such as, e.g., acid addition salts and base addition salts ofthe compounds of Formula I provided herein. As used herein, the term “pharmaceutically acceptable sait” refers to those salts which retain the biological effectiveness and properties of the parent compound. The phrase pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be présent in the compounds of Formula I disclosed herein.
For exampfe, the compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animais, it is often désirable in practice to initially isolate the compound of the présent invention from the reaction mixture as a pharmaceutically unacceptable sait and then simply couvert the latter back to the free base compound by treatment with an alkaline reagent and subsequently couvert the latter free base to a pharmaceutically acceptable acid addition sait. The acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially équivalent amount of the selected minerai or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or éthanol. Upon évaporation of the solvent, the desired solid sait is obtained. The desired acid sait can also be precipitated from a solution ofthe free base in an organic solvent by adding an appropriate minerai or organic acid to the solution.
The acids that may be used to préparé pharmaceutically acceptable acid addition salts of such basic compounds of those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentîsinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1 ,1’-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and 5 methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycoliylarsanilate, heptanoate, hexyne-1,6-dioate, hexyl resorcinate, hydrabamîne, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate, methane-sulfonate, methy Isulfate, monohydrogenphosphate, mucate, napsylate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, phenylbutyrate, phenylpropionate, phthalate, 15 phospate/diphosphate, polygalacturonate, propanesulfonate, propionate, propiolate, pyrophosphate, pyrosulfate, salicylate, stéarate, subacetate, suberate, succinate, sulfate, sulfonate, sulfite, tannate, tartrate, teoclate, tosyiate, triethiodode and vaîerate salts.
Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines and cyclic amines, 20 such as piperidine, morphoiine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnésium, manganèse, iron, copper, zinc, aluminium and lithium.
The compounds ofthe invention that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
Those compounds of the invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali métal or alkaline-earth métal salts and particularly, the sodium and potassium salts. These salts are ail prepared by conventional techniques. The Chemical bases which are used as reagents to préparé the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds herein. These salts may be prepared by any suitable method, for example, treatment ofthe free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali métal hydroxide or alkaline earth métal hydroxide, or the like. These salts can also be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable 35 cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali métal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometnc quantifies of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
The Chemical bases that may be used as reagents to préparé pharmaceutically acceptable base salts ofthe compounds ofthe invention that are acidic in nature are those thatform non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to, those derived from such pharmacologically acceptable cations such as alkali métal cations (e.g., potassium and sodium) and alkaline earth métal cations (e.g., calcium and magnésium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for making pharmaceutically acceptable salts of compounds of the invention are known to one of skill in the art.
Salts of the present invention can be prepared according to methods known to those of skill rn the art. A pharmaceutically acceptable sait of the inventive compounds can be readily prepared by mixing together solutions of the compound and the desired acid or base, as appropriate. The sait may precipitate from solution and be collected by filtration or may be recovered by évaporation of the solvent. The degree of ionization in the sait may vary from completely ionized to almost non-ionized.
ft will be understood by those of skill in the art that the compounds of the invention in free base form having a basic functionality may be converted to the acid addition salts by treating with a stoichiometric excess of the appropriate acid. The acid addition salts of the compounds of the invention may be reconverted to the corresponding free base by treating with a stoichiometnc excess of a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a température of between about 0° C and 100° C. The free base form may be isolated by conventional means, such as extraction with an organic solvent. In addition, acid addition salts of the compounds of the invention may be interchanged by taking advantage of différentiel solubilities of the salts, volatilities or acidifies of the acids, or by treating with the appropriately loaded ion exchange resin. For exampie, the interchange may be affected by the réaction of a sait of the compounds of the invention with a slight stoichiometric excess of an acid of a lower pK than the acid component of the starting sait. This conversion is typically carried out at a température between about Û°C and the boiling point ofthe solvent being used as the medium for the procedure. Similar exchanges are possible with base addition salts, typically via the intermediacy of the free base form.
The compounds of the invention may exîst in both unsolvated and solvated forms. When the solvent or water is tightly bound, the complex will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm. The term ‘solvaté’ is used herein to describe a molecular complex comprising the compound ofthe invention and one or more pharmaceutically acceptable solvent molécules, for example, éthanol. The term ‘hydrate’ is employed when the solvent is water. Pharmaceutically acceptable solvatés in accordance with the invention include hydrates and solvatés wherein the solvent of crystallization may be isotopically substituted, e.g. DsO, de-acetone, ds-DMSO.
Also included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvatés, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975), the disclosure of which is incorporated herein by reference in its entirety.
The invention also relates to prodrugs ofthe compounds of Formula I provided herein. Thus, certain dérivatives of compounds of the invention which may hâve little or no pharmacological activity themselves can, when administered to a patient, be converted into the inventive compounds, for example, by hydrolytic cleavage. Such dérivatives are referred to as ‘prodrugs’. Further information on the use of prodrugs may be found in 'Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T Higuchi and W Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disciosures of which are incorporated herein by reference in their entireties.
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the inventive compounds with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H Bundgaard (EIsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety.
Some non-limiting examples of prodrugs in accordance with the invention include:
(i) where the compound contains a carboxylic acid functionality (-COOH), an ester thereof, for example, replacement ofthe hydrogen with (Ci-Ce)alkyl;
(ii) where the compound contains an alcohol functionality (-OH), an ether thereof, for example, replacement of the hydrogen with (Ci-Cs)alkanoyloxymethyl, or with a phosphate ether group; and (iii) where the compound contains a primary or secondary amino functionanty (-NH2 or -NHR where R 4 H), an amide thereof, for example, replacement of one or both hydrogens with a suitably metabolicafly labile group, such as an amide, carbamate, urea, phosphonate, sulfonate, etc.
Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned référencés.
Finally, certain inventive compounds may themselves act as prodrugs of other of the inventive compounds.
Also included within the scope of the invention are metaboNtes of compounds of Formula I as described herein, i.e., compounds formed in vivo upon administration of the drug.
The compounds of Formula I provided herein may hâve asymmetric carbon atoms. The carbon-carbon bonds ofthe compounds ofthe invention may be depicted herein using a solid line (------), a solid wedge or a dotted wedge ( I 111). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers (e.g. spécifie enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers are meant to be included and the attached stereocenter. For example, unless stated otherwise, it is intended that the compounds of the invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is présent.
Compounds of the invention that hâve chiral centers may exist as stereoisomers, such as racemates, enantiomers, or diastereomers.
Stereoisomers of the compounds of Formula I herein can include cis and trans isomers, optical isomers such as (R) and (S) enantiomers, diastereomers, géométrie isomers, rotational isomers, atropisomers, conformational isomers, and tautomers ofthe compounds ofthe invention, including compounds exhibiting more than one type of îsomerism; and mixtures thereof (such as racemates and diastereomeric pairs).
Also included are acid addition or base addition salts wherein the counterion is optically active, for example, d-iactate or l-lysine, or racemic, for example, dl-tartrate or dl-arginine.
When any racemate crystallizes, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
The compounds ofthe invention may exhibitthe phenomena oftautomerism and structural isomerism. For example, the compounds may exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and géométrie isomers and mixtures thereof. Ail such tautomeric forms are included within the scope of compounds of the invention. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer prédominâtes. Even though one tautomer may be described, the présent invention includes ali tautomers ofthe compounds of Formula I provided.
In addition, some of the compounds of the invention may form atropisomers (e.g., substituted biaryls). Atropisomers are conformational stereoisomers which occurwhen rotation about a single bond in the molécule is prevented, or greatly slowed, as a result of steric interactions with other parts of the molécule and the substituents at both ends of the single bond are unsymmetrical. The interconversion of atropisomers is slow enough to allow séparation and isolation under predetermined conditions. The energy barrier to thermal racemization may be determined by the steric hindrance to free rotation of one or more bonds forming a chiral axis.
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or résolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high pressure liquid chromatography (HPLC) or superfluid critical chromatography (SFC).
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art.
Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerÎcally-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration ofthe eluate affords the enriched mixture.
Stereoisomeric conglomérâtes may be separated by conventional techniques known to those skilled in the art; see, for example, “Stereochemistry of Organic Compounds” by E L Eliel · (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
The enantiomeric purity of compounds described herein may be described in terms of enantiomeric excess (ee), which indicates the degree to which a sample contains one enantiomer in greater amounts than the other. A racemic mixture has an ee of 0%, while a single completely
pure enantiomer has an ee of 100%. Similarly, diastereomeric purity may be described in ternis of diasteriomeric excess (de).
The présent invention also includes isotopically-labeled compounds, which are identicai to those recited in one of Formula I provided, but for the fact that one or more atoms are replaced 5 by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled 10 reagent otherwise employed.
Exampies of isotopes that may be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, 2H, 3H, 13C, 14C, 15N, 1βΟ, 170,31P, 32P, 35S, 18F, and 36CI. Certain isotopically-labeled compounds of the invention, for example those into which radioactive isotopes such as 3H and 15 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and détectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some 20 circumstances. Isotopically-labeled compounds of the invention may generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Préparations below, by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.
Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products, or mixtures thereof. They may be obtained, for example, as 25 solid plugs, powders, or films by methods such as précipitation, crystai lization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds of the invention may exist in a continuum of solid States ranging from fully amorphous to fully crystalline. The term ‘amorphous’ refers to a state in which the material lacks long range order at the molecular level and, dependîng upon température, may exhibit the physical 30 properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heatîng, a change from solid to liquid properties occurs which is characterised by a change of State, typically second order ('glass transition’). The term ‘crystalline’ refers to a solid phase in which the material has a regular ordered internai structure at the molecular level and gives a 35 distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order (‘melting point').
The compounds of Formula I may also exist in a mesomorphic State (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic State is intermediate between the true crystalline state and the true liquid State (either melt or solution). Mesomorphism arising as the resuit of a change in température is described as ‘thermotropic’ and that resulting from the addition of a second component, such as water or another solvent, is described as ‘lyotropic’. Compounds that hâve the potential to form lyotropic mesophases are described as 'amphiphilic’ and consist of molécules which possess an ionic (such as -COO‘Na+, -COO’K+, or -SOa Na4) or non-ionic (such as -N'N+(CH3)3) polar head group. For more information, see Crystals and the Polarizinq Microscope by N, H, Hartshorne and A. Stuart, 4tfl Edition (Edward Arnold, 1970).
The compounds of Formula I may exhibit polymorphism and/or one or more kinds of isomerism (e.g. optical, géométrie or tautomeric isomerism). The compounds of Formula I may also be isotopically iabelled. Such variation is implicit to the compounds of Formula I defined as they are by reference to their structural features and therefore within the scope of the invention.
Therapeutic Methods and Uses
The invention further provides therapeutic methods and uses comprising administering the compounds of the invention, or pharmaceutically acceptable salts thereof, alone or in combination with other therapeutic agents or palliative agents.
In one embodiment, the invention provides a method for the treatment of abnormal cell growth in a subject comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof. In frequent embodiments, the abnormal cell growth is cancer.
In another embodiment, the invention provides a method for the treatment of cancer in a subject comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional anticancer therapeutic agent, which amounts are together effective in treating said cancer.
Compounds of the invention include compounds of Formula I as described herein, or a pharmaceutically acceptable sait thereof.
In still another embodiment, the invention provides a method of inhibiting cancer cell prolifération in a subject, comprising administering to the subject an effective amount of a compound ofthe invention, or a pharmaceutically acceptable sait thereof.
In another embodiment, the invention provides a method of inhibiting cancer cell invasiveness in a subject, comprising administering to the subject an effective amount of a compound ofthe invention, or a pharmaceutically acceptable sait thereof, in another embodiment, the invention provides a method of causing cell death in cancer cells in a subject, comprising administering to the subject an effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof.
In still another embodiment, the invention provides a method of enhancmg vaccine thérapies in a mammal, comprising administering to the mammal a therapeutically effective amount of a vaccine, and further comprising administering to the mammal a therapeutically effective amount of a compound of any of claims 1 to 16, or a pharmaceutically acceptable sait thereof.
In still another embodiment, the invention provides a method of improving the immune system’s ability to clear a viral infection, bacterial infection, or pathogen (including parasitic worms) in a subject, comprising administering to the subject an effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof. The invention provides a method for enhancing immune-system mediated removal of pathogens, comprising administering to the mammal a therapeutically effective amount of a compound of any of claims 1 to 16, or a pharmaceutically acceptable sait thereof. The method includes administering the compound of the invention as monotherapy or in combination with other agents to treat the infection or pathogen.
The presently disclosed compounds find use in inhibiting the activity of the HPK1 kinase. HPK1, also referred to as mitogen activated protein kinase kinase kinase kinase 1 or MAP4K1, is a member of the germinal center kinase subfamily of Ste20-related serine/threnonine kinases. HPK1 kinase fonctions as a MAP4K by phosphorylating and activatlng MAP3K proteins, including MEKKI, MLK3 and TAK1, leading to the activation of the MAPK Jnk.
HPK1 polynucleotides and polypeptides are known in the art (Hu et al. (1996) Genes Dev, 10: 2251-2264, which is herein incorporated by reference in its entirety). HPK1 polypeptides comprise a variety of conserved structural motifs. HPK1 polypeptides comprise an amino-terminal Ste20-like kinase domain that spans amino acid residues 17-293, which includes the ATP -binding site from amino acid residues 23-46. The kinase domain is followed by four pro line-rich (PR) motifs that serve as binding sites for SH3 -containing proteins, such as CrkL, Grb2, HIP-55, Gads, Nek, and Crk. The four PR motifs span amino acid residues 308-407, 394-402, 432-443, and 468477, respectively. HPK1 becomes phosphorylated and activated in response to TCR or BCR stimulation. TCR- and BCR- induced phosphorylation of the tyrosine at position 381, located between PR1 and PR2, médiates binding to SLP-76 in T cells or BLNK in B cells via a SLP-76 or BLNK SH2 domain, and is required for activation of the kinase. A citron homology domain found in the C-terminus of HPK1, approximately spanning residues 495-800, may act as a regulatory domain and may be involved in macromolecular interactions.
The presentiy disclosed compounds bind dîrectly to HPK1 and inhibit its kinase activity. In some embodiments, the presently disclosed compounds reduce, inhibit, or otherwise diminish the H PK1-mediated phosphorylation of SLP76 and/or Gads. The presently disclosed compounds may or may not be a spécifie HPK1 inhibitor. A spécifie HPK1 inhibitor reduces the biological activity of HPK1 by an amount that is statistically greater than the inhibitory effect of the inhibitor on any other protein (e.g., other serine/threonine kinases). In certain embodiments, the presently disclosed compounds specifically inhibit the serine/threonine kinase activity of HPK1.
The presently disclosed compounds can be used in a method for inhibiting HPK1. Such methods comprise contacting HPK1 with an effective amount of a presently disclosed compound. The term contacting” means bringing the compound within close enough proximity to an isolated HPK1 enzyme or a cell expressing HPK1 (e.g., T cell, B cell, dendritic cell) such that the compound is able to bind to and inhibit the activity of HPK1. The compound can be contacted with HPK1 in vitro or in vivo via administration of the compound to a subject.
Any method known in the art to measure the kinase activity of HPK1 may be used to détermine if HPK1 has been inhibited, including in vitro kinase assays, immunoblots with antibodies spécifie for phosphorylated targets of HPK1, such as SLP76 and Gads, or the measurement of a downstream biological effect of HPK1 kinase activity, such as the recruitment of 14-3-3 proteins to phosphorylated SLP7 and Gads, release ofthe SLP76-Gads-14-3-3 complex from LAT-containing microclusters, or T or B cell activation.
The presently disclosed compounds can be used to treat a HPK1-dependent disorder. As used herein, a HPK1-dépendent disorder is a pathological condition in which HPK1 activity is necessary for the genesis or maintenance of the pathological condition.
The presently disclosed compounds also fmd use in enhancing an immune response in a subject in need thereof. Such methods comprise administering an effective amount of a presently disclosed compound (i.e., any ofthe compounds of Formula I, or a pharmaceutically acceptable sait, prodrug, métabolite, or dérivative thereof). The term enhancing an immune response refers to an improvement in any immunogenic response to an antigen. Non-limiting examples of improvements in an immunogenic response to an antigen include enhanced maturation or migration of dendritic cells, enhanced activation of T cells (e.g., CD4 T cells, CD8 T cells), enhanced T cell (e.g., CD4 T cell, CD8 T cell) prolifération, enhanced B cell prolifération, increased survival of T cells and/or B cells, improved antigen présentation by antigen presenting cells (e.g., dendritic cells), improved antigen clearance, increase in production of cytokines by T cells (e.g., interleukin-2), increased résistance to prostaglandin E2- or adenosine induced immune suppression, and enhanced priming and/or cytoiytic activity of CD8 T cells. In some embodiments, the CD8 T cells in the subject hâve enhanced priming, activation, prolifération and/or cytoiytic activity relative to prior to the administration ofthe compound of Formula I, or a pharmaceutically acceptable sait, prodrug, métabolite, or dérivative thereof. In some embodiments, the CD8 T cell priming is characterized by elevated CD44 expression and/or enhanced cytoiytic activity in CD8 T cells. In some embodiments, the CD8 T cell activation is characterized by an elevated frequency of IFNy* CD8 T cells. In some embodiments, the CD8 T cell is an antigen-specific T-cell.
In some embodiments, the antigen presenting cells in the subject hâve enhanced maturation and activation relative to prior to the administration ofthe compound of Formula I, or a pharmaceutically acceptable sait, prodrug, métabolite, or dérivative thereof. In some embodiments, the antigen presenting cells are dendritic cells. In some embodiments, the maturation ofthe antigen presenting cells is characterized by an increased frequency of CD83+ dendritic cells. In some embodiments, the activation of the antigen presenting cells is 5 characterized by elevated expression of CD80 and CD86 on dendritic cells.
Engagement ofthe TCR leads to HPK1 activation, which functions as a négative regulator of TCR-induced AP-1 response pathway. It is believed that HPK1 negatively régulâtes T cell activation by reducing the persistence of signalling microciusters by phosphorylating SLP76 at Ser376 (Di Bartolo et al. (2007) JEM 204:681-691) and Gads at Thr254, which leads to the 10 recruitment of 14-3-3 proteins that bind to the phosphorylated SLP76 and Gads, releasing the SLP76-Gads-14-3-3 complex from LAT-containing micro clusters, which leads to T cell dysfunction, including anergy and exhaustion (Lasserre et al. (2011) J Cell Biol 195(5):839-853). The term dysfunction in the context of immune dysfunction, refers to a State of reduced immune responsiveness to antigenic stimulation. The term includes the common éléments of both 15 exhaustion and/or anergy in which antigen récognition may occur, but the ensuing immune response is ineffective to control infection or tumor growth.
The term dysfunctional, as used herein, also includes refractory or unresponsive to antigen récognition, specifically, impaired capacity to translate antigen récognition into downstream T-cell effector functions, such as prolifération, cytokine production (e.g., lL-2, 20 gamma-IFN) and/or target cell killing.
The term anergy refers to the state of unresponsiveness to antigen stimulation resulting from incomplète or insufficient signais deiivered through the T-cell receptor {e.g. increase in intracellular Ca in the absence of ras-activation). T cell anergy can also resuit upon stimulation with antigen in the absence of co-stimulation, resulting in the cell becoming refractory to 25 subséquent activation by the antigen even in the context of costimulation. The unresponsive state can often be overriden by the presence of lnterleukin-2. Anergie T-celis do not undergo clonal expansion and/or acquire effector functions.
The term exhaustion refers to T cell exhaustion as a State of T cell dysfunction that arises from sustained TCR signalling that occurs during many chronic infections and cancer. It is 30 distinguished from anergy in that it arises not through incomplète or déficient signalling, but from sustained signalling. It is defined by poor effector function, sustained expression of inhibitory receptors and a transcriptional state distinct from that of functional effector or memory T cells. Exhaustion prevents optimal control of infection and tumors. Exhaustion can resuit from both extrinsic négative regulatory pathways (e.g., im mu no regulatory cytokines) as well as cell intrinsic 35 négative regulatory (costimulatory) pathways (PD-1, B7-H3, B7-H4, etc.).
Enhancing T cell function means to induce, cause or stimulate a T cell to hâve a sustained or amplified biological function, or renew or réactivais exhausted or inactive T cells.
Examples of enhancing T cell function include: increased sécrétion of cytokines (e.g., gammainterferon, IL-2, IL-12, and TNFa), increased prolifération, increased antigen responsiveness (e.g., viral, pathogen, or tumor clearance) relative to such levels before the intervention, and increased effector granule production by CD8 T cells, such as granzyme B.
Accordingly, the presently disclosed compounds of Formula i, or pharmaceutically acceptable salts, prodrugs, metaboiites, or dérivatives thereof are useful în treating T cell dysfunctionai disorders. A T cell dysfunctional disorder is a disorder or condition of T cells characterized by decreased responsiveness to antigenic stimulation. In a particular embodiment, a T cell dysfunctional disorder is a disorder that is specifically associated with increased kinase activity of HPK1. In another embodiment, a T cell dysfunctional disorder is one in which T cells are anergie or hâve decreased ability to secrete cytokines, protiferate, or execute cytolytic activity. In a spécifie aspect, the decreased responsiveness results in ineffective control of a pathogen or tumor expressing an immunogen. Examples of T cell dysfunctional disorders characterized by Tcell dysfunction include unresolved acute infection, chronic infection and tumor immunity.
Thus, the presently disclosed compounds can be used in treating conditions where enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer. Immunogenecity refers to the ability of a particular substance to provoke an immune response, Tumors are immunogenic and enhancing tumor immunogenicity aids in the clearance of the tumor cells by the immune response.
Tumor immunity refers to the process in which tumors évadé immune récognition and clearance. Thus, as a therapeutic concept, tumor immunity is treated when such évasion is attenuated, and the tumors are recognized and attacked by the immune system. Examples of tumor récognition include tumor binding, tumor shrinkage and tumor clearance.
In one aspect, provided herein is a method for treating of cancer in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable sait, prodrug, métabolite, or dérivative thereof. In some embodiments, the subject has melanoma. The melanoma may be at early stage or at late stage. In some embodiments, the subject has colorectal cancer. The colorectal cancer may be ai early stage or at late stage. In some embodiments, the subject has non-small cell lung cancer. The nonsmall cell lung cancer may be at early stage or at late stage. In some embodiments, the subject has pancreatic cancer. The pancreatic cancer may be at early stage or late State. In some embodiments, the subject has a hematological malignancy. The hematologicai malignancy may be at early stage or late stage. In some embodiments, the subject has ovarian cancer. The ovarian cancer may be at early stage or at late stage. In some embodiments, the subject has breast cancer. The breast cancer may be at early stage or at late stage. In some embodiments, the subject has rénal cell carcinoma. The rénal cell carcinoma may be at early stage or at late stage. In some embodiments, the cancer has eîevated levels of T-cell infiltration.
In some embodiments, the treatment results in a sustained response in the subject after cessation of the treatment. Sustained response refers to the sustained effect on reducing tumor growth after cessation of a treatment. For example, the tumor size may remain the same orsmaller as compared to the size at the beginning of the administration phase.
The treatment methods disclosed herein may resuit in a partial or complété response. As used herein, complété response” or CR refers to disappearance of ail target lésions, partial response or PR refers to at least a 30 percent decrease in the sum of the longest diameters (SLD) of target lésions, taking as reference the baseline SLD; and stable disease or SD refers to neither sufficient shrinkage of target lésions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started. As used herein, overall response rate (ORR) refers to the sum of complété response (CR) rate and partial response (PR) rate.
The treatment methods disclosed herein can lead to an increase in progression free survival and overall survival of the subject administered the HPKI antagonist. As used herein, progression free survival (PFS) refers to the length of time during and after treatment during which the disease being treated (e.g., cancer) does not get worse. Progression-free survival may include the amount of time patients hâve experienced a complété response or a partial response, as well as the amount of time patients hâve experienced stable disease.
As used herein, overall survival refers to the percentage of subjects in a group who are likely to be alive after a particular duration of time.
In some embodiments ofthe methods provided herein, the abnormal cell growth is cancer, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma or adenocarcinoma), esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer (including RCC), liver cancer (including HCC), pancreatic cancer, stomach (e.g., gastric) cancer and thyroid cancer. In further embodiments of the methods provided herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.
In some embodiments, the cancer is selected from the group consisting of breast cancer and ovarian cancer.
In some embodiments, the cancer is ovarian cancer.
In other embodiments, the cancer is breast cancer, including, e.g., ER-positive/HR-positive breast cancer, HER2-negative breast cancer; ER-positive/HR-positive breast cancer, HER2positive breast cancer; triple négative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer is endocrine résistant breast cancer, trastuzumab résistant breast cancer, or breast cancer demonstrating primary or acquired résistance to CDK4/CDK6 inhibition. In some embodiments, the breast cancer is advanced or metastatic breast cancer.
In some embodiments, the compound of the invention is administered as first line therapy. In other embodiments, the compound of the invention is administered as second (or later) line therapy. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with an endocrine therapeutic agent and/or a CDK4/CDK6 inhibitor. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with an endocrine therapeutic agent. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with a CDK4/CDK6 inhibitor. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with one or more chemotherapy regimens, e.g., including taxanes or platinum agents. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with HER2 targeted agents, e.g., trastuzumab.
The terms “abnormal cell growth” and “hyperproliferative disorder are used interchangeably in this application.
“Abnormal cell growth, as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). Abnormal cell growth may be benign (not cancerous), or malignant (cancerous).
Abnormal cell growth includes the abnormal growth of tumors that are résistant to endocrine therapy, HER2 antagonists or CDK4/6 inhibition.
The term “additional anticancer therapeutic agent” as used herein means any one or more therapeutic agent, other than a compound of the invention, that is or can be used in the treatment of cancer, such as agents derived from the following classes: mitotic inhibitors, alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase I and II inhibitors, plant alkaloids, hormonal agents and antagonists, growth factor inhibitors, radiation, inhibitors of protein tyrosine kinases and/or serine/threonine kinases, cell cycle inhibitors, biological response modifiers, enzyme inhibitors, antisense oligonucleotides or oligonucleotide dérivatives, cytotoxics, and immunooncology agents (immuno-oncology agents include monoclonal antibodies, bispecific antibodies, cytokines, CAR-t cells).
As used herein “cancer1’ refers to any malignant and/or invasive growth or tumor caused by abnormal cell growth. Cancer includes solid tumors named for the type of cells that form them, cancer of blood, bone marrow, or the lymphatic system. Examples of solid tumors include sarcomas and carcinomas. Cancers of the blood include, but are not limited to, leukemia, lymphoma and myeloma. Cancer also includes primary cancer that originales at a spécifie site in the body, a metastatic cancer that has spread from the place in which it started to other parts of the body, a recurrence from the original primary cancer after remission, and a second primary cancer that is a new primary cancer in a person with a history of previous cancer of a different type from the latter one.
In some embodiments ofthe methods provîded herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung 5 cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.
Dosage Forms and Reqimens
Administration of the compounds of the invention may be effected by any method that enables delivery of the compounds to the site of action. These methods include oral rouies, intraduodenal routes, parentéral injection (including intravenous, subcutaneous, intramuscular, 10 intravascular or infusion), topical, and rectal administration.
Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, severai divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parentéral compositions in dosage unit form 15 for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrète units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The spécification for the dosage unit forms of the invention are dictated by and directly dépendent on (a) the unique 20 characteristîcs of the chemotherapeutic agent and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inhérent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
Thus, the skilled artisan would appreciate, based upon the disclosure provîded herein, that the dose and dosing regimen is adjusted in accordance with methods well-known in the 25 therapeutic arts. That is, the maximum tolerable dose can be readily established, and the effective amount providing a detectabie therapeutic benefit to a patient may also be determîned, as can the temporal requirements for administering each agent to provide a detectabie therapeutic benefit to the patient. Accordingly, while certain dose and administration regimens are exemplified herein, these examples in no way limit the dose and administration regimen that may be provided to a 30 patient in practicing the present invention.
It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is to be further understood that for any particular subject, spécifie dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the 35 administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice ofthe claimed composition. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamie parameters, which may include clinical effects such as toxic effects and/or laboratory values. Thus, the présent invention encompasses intra-patient dose-escalation as determined by the skilled artisan. Determining appropriate dosages and regimens for administration of the chemotherapeutic agent are well-known in the relevant art and would be understood to be encompassed by the skilled artisan 5 once provided the teachings disclosed herein.
The amount of the compound of the invention administered will be dépendent on the subject being treated, the severity ofthe disorder or condition, the rate of administration, the disposition ofthe compound and the discrétion ofthe prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably 10 about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.1 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adéquate, while in other cases stîll larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day. 15
Formulations and Routes of Administration
As used herein, a pharmaceutically acceptable carrier refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties ofthe administered compound.
The pharmaceutical acceptable carrier may comprise any conventional pharmaceutical carrier or excipient. The choice of carrier and/or excipient will to a large extent dépend on factors such as the particular mode of administration, the effect ofthe carrier or excipient on solubility and stability, and the nature of the dosage form.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic 10 solvents (such as hydrates and solvatés). The pharmaceutical compositions may, if desired, contain additional ingrédients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citrîc acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Examples, without limitation, of excipients 15 include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose dérivatives, gelatin, vegetable oils and polyethylene glycols. Additionally, lubricating agents such as magnésium stéarate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard fiIled gelatin capsules. Non-limiting examples of materials, therefore, include lactose or milk sugar and high molecular 20 weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening orflavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, éthanol, propylene glycol, glycerin, or combinations thereof.
The pharmaceutical composition may, for example, be in a form suitable for oral 25 administration as a tablet, capsule, pill, powder, sustained release formulations, solution suspension, for parentéral injection as a stérile solution, suspension or émulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
Exemplary parentéral administration forms include solutions or suspensions of active compounds in stérile aqueous solutions, for example, aqueous propylene glycol or dextrose 30 solutions. Such dosage forms may be suitably buffered, if desired.
The pharmaceutical composition may be in unit dosage forms suitable for single administration of précisé dosages.
Pharmaceutical compositions suitable for the delivery of compounds of the invention and methods for their préparation will be readily apparent to those skilled in the art. Such compositions 35 and methods for their préparation can be found, for example, in ‘Remington's Pharmaceutical Sciences’, 19th Edition (Mack Publishing Company, 1995), the disclosure of which is incorporated herein by reference in its entirety.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enfers the gastrointestinal tract, or buccal or sublingual administration may be empfoyed by which the compound enfers the blood stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and élixirs. Such formulations may be used as fillers in soft or hard capsules and typically include a carrier, for example, water, éthanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001), the disclosure of which is incorporated herein by reference in its entirety.
For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% ofthe dosage form.
Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
Tablets may also optionally include surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as Silicon dioxide and talc. When present, surface active agents are typically in amounts of from 0.2 wt% to 5 wt% of the tablet, and glidants typically from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnésium stéarate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnésium stearate with sodium lauryl sulphate. Lubricants generally are present in amounts from 0,25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.
Other conventional ingrédients include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.
Exemplary tablets contain up to about 80 wt% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congeaied, or extruded before tableting. The final formulation may include one or more layers and may be coated or uncoated; or encapsulated.
The formulation of tablets is discussed in detail in “Pharmaceutical Dosage Forms: Tablets, Vol. 1”, by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X), the disclosure of which is incorporated herein by reference in its entirety.
Solid formulations for oral administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Suitable modified release formulations are described în U.S. Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles can be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298. The disclosures of these references are incorporated herein by reference in their entireties.
Parentéral Administration
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internai organ. Suitable means for parentéral administration include intravenous, intraarteriai, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parentéral administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
Parentéral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a stérile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as stérile, pyrogen-free water.
The préparation of parentéral formulations under stérile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility ofcompounds oftheinvention used in the préparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
Formulations for parenteral administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified re|ease of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.
The compounds ofthe invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, minerai oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Pénétration enhancers may be incorporated; see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999). Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and micro needle or needle-free (e.g. Powderject™, Bioject™, etc.) injection. The disclosures of these references are incorporated herein by reference in their entireties.
Formulations for topical administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aérosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitabie propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may include a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurized container, pump, spray, atomizer, or nebulizer contains a solution or suspension of the compound(s) of the invention comprising, for example, éthanol, aqueous éthanol, or a suitabie alternative agent for dispersing, solubilizing, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acîd, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronized to a size suitabie for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriais comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix ofthe compound ofthe invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannîtol, or magnésium stéarate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitable solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from 1 pg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 pL to 10OpL. A typical formulation includes a compound ofthe invention, propylene glycol, stérile water, éthanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention întended for inhaled/intranasal administration.
Formulations for inhaled/intranasal administration may be formulated to be immédiate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGl_A). Modified release formulations include delayed-, sustained-, pulsed-, controlied-, targeted and programmed release.
(n the case of dry powder inhalers and aérosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or “puff” containing a desired mount of the compound of the invention. The overall daily dose may be administered in a single dose or, more usually, as divided doses throughout the day.
Compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Formulations for rectal/vaginal administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlied-, targeted and programmed release.
Compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronized suspension or solution in isotonie, pH-adjusted, stérile saline. Other formulations suitable for ocular and aurai administration include ointments, biodégradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular Systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a celiulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethyl cellulose, or methyl cellulose, or a heîeropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
Formulations for ocular/aural administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.
Other Technologies
Compounds ofthe invention may be combined with soluble macromoiecular entities, such as cyclodextrin and suitable dérivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailabiiity and/or stability for use in any ofthe aforementioned modes of administration.
Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubilizer. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in PCT Publication Nos. WO 91/11172, WO 94/02518 and WO 98/55148, the disclosures of which are incorporated herein by reference in their entireties.
Dosage
The amount ofthe active compound administered will be dépendent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discrétion of the prescribing physician. However, an effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7000 mg/day, preferably about 0.1 to about 2500 mg/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adéquate, while in other cases still larger doses may be used without causing any harmful side effect, with such larger doses typically divided into several smaller doses for administration throughout the day.
Kit-of-Parts
Inasmuch as it may désirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus, the kit of the invention includes two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
The kit ofthe invention is particularly suitable for administering different dosage forms, for example, oral and parentéral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically includes directions for administration and may be provided with a memory aid.
Combination Therapy
As used herein, the term “combination therapy” refers to the administration of a compound of the invention together with an at least one additional pharmaceutical or médicinal agent (e.g., an anti-cancer agent, vaccine, antibacterial agent, antiviral agent, or antiparasitic agent), either sequentially or simultaneously.
As noted above, the compounds ofthe invention may be used in combination with one or more additional agents, such as anti-cancer agents. The efficacy of the compounds of the invention in certain tumors may be enhanced by combination with other approved or experimental cancer thérapies, e.g., radiation, surgery, chemotherapeutic agents, targeted thérapies, agents that inhibit other signaling pathways that are dysregulated in tumors, and other immune enhancing agents, such as PD-1 antagonists and the like.
When a combination therapy is used, the one or more additional agents may be administered sequentially or simultaneously with the compound of the invention. In one embodiment, the additional agent is administered to a mammal (e.g., a human) prior to administration of the compound of the invention. In another embodiment, the additional agent is administered to the mammal (e.g., a human) after administration ofthe compound ofthe invention. In another embodiment, the additional agent is administered to the mammal (e.g., a human) simultaneously with the administration ofthe compound ofthe invention.
The invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, which comprises an amount of a compound of the invention, as defined above (including hydrates, solvatés, polymorphs, isomers, prodrugs, and/or métabolites of said compound or pharmaceutically acceptable salts thereof), in combination with one or more (preferably one to three) anti-cancer therapeutic agents.
In particular embodiments, a compound of the invention may be administered in combination with one or more: targeted agents, such as inhibitors of PI3 kinase, mTOR, PARP, Kras, IDO, TDO, ALK, ROS, MEK, VEGF, FLT3, AXL, ROR2, EGFR, FGFR, Src/Abl, RTK/Ras, Myc, Raf, PDGF, AKT, c-Kit, erbB, CDK2, CDK4, CDK4/CDK6, CDK5, CDK7, CDK9, SMO, CXCR4, HER2, GLS1, EZH2 or Hsp90, or immunomodulatory agents, such as PD-1 antagonists, PD-L1 antagonists, CTLA-4 antagonists, 0X40 agonists, 4-1BB agonists, or CD80 agonists.
In other embodiments, a compound ofthe invention may be adminîstered in combination with a standard of care agent, such as tamoxifen, docetaxel, paclitaxel, cisplatin, capecitabine, gemcitabine, vinorelbine, exemestane, letrozole, fulvestrant, anastrozole or trastuzumab.
Synthetic Methods
The compounds of Formula l, may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art [such as those methods disclosed in standard reference books such as the Compendium of Organic Synthetic Methods, Vol. l-Xlll (published by Wiley-lnterscience)]. Preferred methods include, but are not limited to, those described below.
During any of the foilowing synthetic sequences it may be necessary and/or désirable to protect sensitive or réactivé groups on any ofthe molécules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
Compounds of Formula I, or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above.
Isolation and purification ofthe products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
It will be understood by one skilied in the art that the various symbols, superscripts, and subscripts used in the schemes, methods, and examples are used for convenience of représentation and/or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts, or subscripts in the appended claims. Additionally, one skilied in the art will recognize that in many cases, these compounds will be mixtures and enantiomers that may be separated at various stages of the synthetic schemes using conventional techniques, such as, but not limited to, crystallization, normal-phase chromatography, reversed-phase chromatography, and chiral chromatography, to afford single enantiomers. The schemes are représentative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.
Compounds ofthe invention are prepared according tothe exemplary procedures provided herein and modifications thereof known to those of skill in the art.
The foilowing abbreviations are used throughout the Examples: “Ac means acetyl, “ACN” means acetonitrile, “BOC”, “Boc” or “boc” means N-tert-butoxycarbonyl, “Bu” means butyl, “tBu means tert-butyl, “DCM” (CH2CI2) means methylene chloride, “de” means diastereomeric excess, DMF means A/,A/-dimethyl formamide, “DMSO means dimethylsulfoxide, “ee means enantiomeric excess, “Et means ethyl, “EtOAc means ethyl acetate, “EtOH” means éthanol, “iPr or u'Pr” means isopropyl, “Me” means methyl, “MeOH” means methanol, “MS” means mass 5 specirometry, MTBE means methyl tert-butyl ether, “Ph” means phenyl, “THF” means tetra hydrofuran, “SFC” means supercritical fluid chromatography, “TLC” means thin layer chromatography, “RF means rétention factor, means approximately, RT” means room température that includes ambient température (generally 200 to 25 O), h” means hours, “min” means minutes, “equiv means équivalents, sat. means saturated.
The compounds of Formula I can be prepared by the procedures described in the general
Methods presented below or by routine modifications thereof. Unless otherwise indicated, the substituents in the Methods are as defined herein. Although R4 is in the compounds of Formula I, it will be clear from the intermediates used within the respective synthetic route whether R4 is R4-i or R4-ii. The present invention also encompasses any one or more of these processes for preparing the compounds of Formula I, in addition to any novel intermediates used therein. The person skilled in the art will appreciate that the following reactions may be cooled, heated thermally, heated under microwave irradiation or run under under flow chemistry conditions. It will be further appreciated that it may be necessary or désirable to carry out the transformations in a different order from that described in the Methods, or to modify one or more of the transformations, 20 to provide the desired compound of the invention.
Method A présents a préparation of compounds of Formula I, where R3b is hydrogen. In Method A, cross coupling or nucleophilic aromatic substitution between requisite coupling partner 25 or amine, providing R1 is as in Formula I (or protected version thereof), yields A-2. For the dichloropyridine of formula A-1, V is N(CH3)2, OH, piperidine, morpholine, OMe, OEt, or OiPr.
Formylation of A-2 then provides aldéhyde A-3. Subséquent condensation with Ellman’s sulfinamide provides the compound of formula A-4. Réduction and base-mediated cyclization of the compound of formula A-4 furnishes the compound of formula A-5. Alternatively, compounds of Formula I, wherein R1 is cyclopropylmethyl, compound of formula A-5 can be prepared using 5 the synthetic route described in making intermediate 15c described herein. In a next step, iridium and nickel-mediated decarboxylative photoredox coupling between the chloropyridine of the formula A-5 and the carboxylic acid of the formula A-6 provides the compound of the formula A7. In this step, the R3a substituent of A-6 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof. Additionally, the R7 and R3 10 substituent can be H, Boc, alternative protecting group or alkyl; or alternatively, the R33 and R3 substituents can be part of a cyclic system as is desired in the final product, Formula I. Coupling ofthe compound oftheformula A-7 with the bromopyridinetriazole A-8 underpalladium or copper catalysis followed by cleavage of any protecting group(s) under standard conditions provides the pyrrolo[3,4-c]pyridin-1-one of the Formula I. In this step, the R4N substituent of A-8 should be 15 represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof.
Hydrazinolysis of bromopyridine ester A-9 (J. Med. Chem., 60(2), 722-748; 2017) followed by reaction ofthe corresponding hydrazide A-10 with dimethylformamide dimethyl acetal provides 20 the formamidine A-11. Condensation of the formamidine A-11 with an amine gives the triazole A-8.
Method B
Method B présents a préparation of compounds of Formula I, where R3a and R3b are 25 hydrogen. In a first step of Method B, from the compound of formula A-3 (V = N(CH3)2, OH, piperidine, morpholine, OMe, OEt, or OiPr), Negishi cross coupling with the requisite aminoalkylzincate provides the compound of formula B-1. In this step the R7 and Rs substituents are either H, alkyl as represented in Formula I, or Boc or alternative protecting group. Subséquent condensation with EHman’s sulfonamide, réduction and base-mediate cyctization furntshes the compound of formula B-2. Coupling with the bromopyridine triazole B-3 under palladium or copper catalysis and subséquent cleavage of any protecting group(s) under standard conditions yields pyrrolo[3,4-c]pyridin-1-one of Formula I, In this step, the R4D substituent of formula B-3 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof.
The lactam ofthe formula B-4 is converted to an O-alkyl imidate ofthe formula B-5. In this step, the R4D substituent of formula B-4 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof. Cyclizatîon ofthe O-alkyl imidate of the formula B-5 with the acyl hydrazine of the formula A-10 provides the compound of the formula B-3.
Method C
Method C présents a préparation of compounds of Formula I, where R3b is methyl. In a first step of Method C, palladium-mediated cross coupling between the compound of the formula A-5 and the boronic ester ofthe formula C-1 followed by iron-mediated hydroazidation ofthe olefin or alkene, réduction and optional protection ofthe resulting amine, provides the compound of the formula C-2. In this step, the R3a substituent of formula C-1 and the R1 substituent of A-5 should be as represented in the desired product, Formula I, or a protected version thereof. Cross coupling ofthe compound ofthe formula C-2 with the bromopyridine triazole A-8 under palladium or copper catalysis followed by cleavage of any protecting group(s) under standard conditions provides the pyrrolo[3,4-c]pyridin-1-one ofthe Formula I. In this step, the R4N substituent of A-8 should be represented by the same moiety as is desired in R4 of the final product, Formula I, or a protected variation thereof.
Method D
C-2
Method D présents a préparation of compounds of Formula I, where R3b is methyl. In the first step of Method D, coupling ofthe compound ofthe formula C-2 with the bromopyridine D-1 under copper or palladium catalysis provides the compound of the formula D-2. In this step, the 5 R1, R7, Re, and R3a substituents of C-2 and the R4C substituent of D-1 should be represented by the same moiety as is desired in the final product, D-3, or a protected variation thereof. R7 and/or R8 can also optionally be represented by protecting groups in this step. Reaction of the compound of formula D-2 with the requisite amine provides the compound of the formula D-3. In this step, the R4N substituent should be represented by the same moiety as is desired in the final product, 10 D-3, or a protected variation thereof. Cleavage of any protecting group(s) in the compound of formula D-3, ultimately provides the pyrrolo[3,4-c]pyridin-1-one ofthe Formula l-A.
A-10
To access the compound of formula D-1, the compound of the formula A-10 undergoes reaction with the appropriate acyl chloride to provide the compound of the formula D-4. In this step, the R4C substituent ofthe acyi chloride is as represented in the final product, Formula I, or a protected version thereof. Cyclization of the compound of the formula D-4 provides the compound of formula D-1.
Method E
A-5
Method E présents a préparation of compounds of Formula I, where R3b is hydrogen. In the first step of Method E, either
i. Palladium-mediated cross coupling between the compound of the formula A-5 and tributyl( 1 -ethoxyvinyl)tin, followed by hydrolysis of the vinyl ether, provides the ketone of the formula E-1, where the R3a substituent should be represented by the same moiety as is desired in the final product, Formula I or ii. Palladium-mediated cross coupling between the compound of theformula A-5 and zinc cyanide, followed by reaction with alkyl Grignard reagent, provides the ketone of the formula E-1 where the R3a substituent should be represented by the same moiety as is desired in the final product, Formula I.
In this step, the R1 substituent of A-5 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof.
From the compound of the formula E-1, either
i. Réduction of the ketone, followed by activation as the mesyîate or chloride, displacement with azide and réduction and optionai protection provides the compound of formula A-7 (R7 and Rs are both H or R7 is H and R3 is Boc or an alternative protecting group), or ii. Réduction of the ketone, followed by activation as the mesyîate or chloride, displacement with an alkyl amine and optionai protection provides the compound of formula A-7 (R7 and/or R8 are H, alkyl, Boc or an alternative protecting group), or iii. Condensation with a sulfinamide followed by réduction provides the compound of formula A-7 (R7 rs H and R8 is SOtBu).
Coupling of the compound of the formula A-7 with the bromopyridine triazole A-8 under palladium or copper catalysis followed by cleavage of any protecting group(s) under standard conditions provides the pyTrolo[3,4-c]pyridin-1-one of the Formula I. In this step, the R4N substituent of A-8 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof, within R4.
Method F
Method F présents a préparation of compounds of Formula I, where R3b is hydrogen. In Method F, coupling of the compound of the formula A-7 with the bromopyridine triazole B-3 under palladium or copper catalysis followed by cleavage of any protecting group(s) under standard conditions provides the pyrrolo[3,4-c]pyridin-1-one of the Formula I. In this step the R4C substituent of B-3 and the R1, R7, R3 and R3a substituents of formula A-7 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof.
In this step, the R7 and/or R3 substituents of formula A-7 may also be represented by Boc or another protecting group.
Method G
Re
D-1 G-1 a-7 Formula I
Method G présents a préparation of compounds of Formula I, where R3b is hydrogen. in the first step of Method G, a bromopyridine of the formula D-1 undergoes reaction with the requisite amine to provide the compound of the formula G-1. In this step, the R4C and R4N substituents should be represented by the same moiety as is desîred in the final product, Formula I, or a protected variation thereof. Coupling of the compound of the formula G-1 with A-7 under 10 palladium or copper catalysis followed by cleavage of any protecting group(s) under standard conditions provides the pyrrolo[3,4-c]pyndin-1-one of the Formula I. In this step, the R1, R7, RÊ and R3a substituents of formula A-7 should be represented by the same moiety as is desîred in the final product, Formula I, or a protected variation thereof. In this step, the R7 and/or RB substituents of formula A-7 may also be represented by Boc or another protecting group.
Formula I
Method H présents a préparation of compounds of Formula I, where R3b is methyl. In a first step of Method H, coupling ofthe compound ofthe formula C-2 with the bromopyridine triazole B-3 under palladium or copper catalysis followed by cleavage of any protecting group(s) under 20 standard conditions providesthe pyrrolo[3,4-c]pyridin-1-one ofthe Formula I. In this step, the R1, R7, Rs, and R3a substituents of C-2 and the R4D substituent of B-3 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof. R7 and/or Reof formula C-2 can also optionally be represented by a protecting group in this step.
Method I
C-2
G-1
Formula I
Method I présents a préparation of compounds of Formula I, where R3b is methyl. In the first step of Method I, coupling ofthe compound ofthe formula C-2 with the bromopyridine trîazole G-1 under palladium or copper catalysis followed by cleavage of any protecting group(s) under 5 standard conditions provides the pyrrolo[3,4-c]pyridin-1-one of the Formula I where R3b is methyl. In this step, the R1, R7, R8, and R3a substituents of C-2 and the R4C and R4N substituents of G-1 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof. R7 and/or Re of formula C-2 can also optionally be represented by a protecting group in this step.
Method J
OH
J-1 o
X
X
J-2
Method J présents a préparation of compounds of Formula I, where R3b is hydrogen. In the first step of Method J, the alcohol of formula J-1 is protected to provide the compound of formula J-2 (e.g. X= OTBDMS). The compound of formula J-2 rs converted to an O-alkyi imidate 15 of the formula J-3. Cyclrzation of the O-alkyl imidate ofthe formula J-3 with the acyl hydrazine of the formula A-10 provides the compound of the formula J-4. The compound of the formula J-4 undergoes coupling with the compound of the formula A-7 under palladium or copper followed by cleavage of any protecting group(s) under standard conditions to yield the pyrrolo[3,4-c]pyridin-1one of Formula I. in this step, the R1, R7, R3 and R3a substituents of A-7 should be represented 20 by the same moiety as is desired in the final product, Formula I, or a protected variation thereof. In this step, the R7 and/or R3 substituents of formula A-7 can also optionally be represented by a protecting group.
Alternative^, to obtain compounds of Formula I, where R4 is R4-ii and R4D is alkyl substituted by a F atom (X = fluorine), from the compound of formula J-4 (X is protected hydroxy group) cleavage ofthe protecting group provides the compound offormula J-4 where X is hydroxy. The alcohol can then be converted to an alkyl fluoride to provide the compound of formula J-4 5 where X is fluorine.
Method K
J-4
B-2
Formula I
Method K présents a préparation of compounds of Formula I, where R3a and R3b are hydrogen. In Method K, the compound of the formula J-4 (X is fluorine) undergoes coupling with 10 the compound of the formula B-2 under palladium or copper catalysis to followed by cleavage of the protecting group(s) under standard conditions yields the pyrrolo[3,4-c]pyridin-1-one of Formula I. In this step the R1, R7 and Rs substituents of B-2 and the X substituent of formula J-4 should be represented by the same moiety as is desired in the final product, Formula I, or a protected variation thereof. R7 and/or Ra of formula B-2 can also optionally be represented by a 15 protecting group in this step.
Method L
NHBoc
L-1
EtO2C
R4F NHBoc ho2cYvr40 r4f NHBoc
A-10
L-2
Μ&1Λ r4D N Y / H r4F NHBoc
L-6
A-7 or
B-2 or
C-2
In the first step of Method L, the compound of the formula L-1 undergoes Wittig olefination to provide the compound of formula L-2. Réduction and subséquent saponification of the compound of the formula L-2 provides the compound of the formula L-3. In these steps, the R4D substituent of L-1, and the R4D and R4F substituents of L-2 and L-3, and subséquent intermediates, are as represented in the final product, Formula I (as within R4), or a protected version thereof. Alternatively, some compounds of the formula L-3 are commercially available. In a next step, the compound of formula L-3 undergoes reaction with the compound of formula A-10 to provide the compound of formula L-4. Cyclization of the compound of formula L-4 provides the oxadiazole of formula L-5. A subséquent cyclization preceded by thermal or acid-mediated deprotection of the compound of formula L-5 provides the compound of formula L-6. The compound of the formula L-6 undergoes coupling with the compound ofthe formula A-7, B-2, or C-2 under palladium or copper followed by cleavage of any protecting group(s) under standard conditions to yield the pyrrolo[3,4-clpyridin-1-one of Formula I. The R1, R2, R3a, and R3b substituents of Formula I dépend on their définitions in previous Methods for A-7, B-2, or C-2, or a protected version thereof.
Method M
Method M présents a préparation of compounds of Formula I, where R3a and R3b are hydrogen. In Method M, coupling ofthe compound ofthe formula B-2 with the bromopyridine triazole A-8 under palladium or copper catalysis provides the protected pyrrolo[3,4-c]pyridin-1-one of Formula I. In this stepthe R1, R7 and R8 substituents oftheformula B-2 andthe R4N substituent of formula A-8 should be represented by the same moiety as is desired in the final product, Formula I, or as a protected variation thereof or as a protecting group (ex. R7 = Boc). Cleavage of any protecting group(s) under standard conditions yields the pyrrolo[3,4-c]pyridin-1-one of
Formula I.
Préparation of Synthetic Intermediates
For the intermediates and Examples prepared herein, where the stereochemistry is known, the stereochemistry is as drawn and the name désignâtes spécifie stereochemistry as (R) or (S). The stereochemistry as assigned herein is known because the compound was synthesized from * 52 known, chiral starting materials, or racemic mixtures were separated and the stereochemistry of certain examples or intermediates was confirmed using X-ray crystallography. in the case ofthe latter, the stereochemistry of other examples or intermediates would then be inferred based on the known chiralîty of the aforementioned examples or intermediates and the synthetic route.
Where stereochemistry is not known but enantiomers are separated, “or1or “or2” is at the chiral carbon atom. In the name, the carbon with the resolved but not confirmed stereochemical center, is identified with the symbol “ξ. The bond drawn at that carbon is a représentation of the stereochemistry; meaning, the carbon would hâve that bond configuration drawn (solid wedge) or the opposite configuration (hashed wedge). See, e.g., Example 6a and Example 6b. Racemic 10 compounds are indicated by the annotation “&Γ and the bond is drawn as a defined stereochemistry meaning that the carbon would hâve that bond configuration drawn (solid wedge) and the opposite configuration (hashed wedge). See, e.g. Intermediate 15.
Intermediate 1: 2-bromo-6-(4-ethyl-4H-1,2,4-triazo!-3-yl)pyridme '^Yn
Step 1: 6-bromopyridine-2-carbohydrazide (1a)
To a solution of methyl 6-bromo-2-pyridinecarboxylate (16.0 g, 74.0 mmol) in MeOH (120 mL) was added hydrazine monohydrate (5.23 g, 88.8 mmol, 85%) and the mixture was stirred for 16 hours at RT. The résultant solution was concentrated to approximately half the volume and then triturated by adding 40 mL of methyl ieri-butyl ether and stirring for 10 min. The résultant white solid was filtered and dried under vacuum to provide the title compound (1a) (15 g, 94%). Ή NMR (400 MHz, CDCI3) δ 8.82 (br. s, 1H), 8.13 (dd, J = 0.9, 7.5 Hz, 1H), 7.76-7.71 (m, 1H), 7.64 (dd, J = 0.9, 8.0 Hz, IH), 4.08 (br. s, 2H). m/z (ESI) for (C6H6BrN3O) 217.5 (M+H)+.
Step 2: W-[(6-bromopyridin-2-yl)carbûnyl]-N,N-dimethylhydrazonoformamide (1b)
A solution of 6-bromopyndîne-2-carbohydrazide (1a) (15.0 g, 69.4 mmol) in dimethyl formamide dimethyl acetal (80 mL) was stirred at 80 °C for 16 hours. The resulting mixture was concentrated under reduced pressure to give a residue. Methyl fert-butyl ether (60 mL) was added to this residue and it was stirred for 40 min. The résultant yellow solid was filtered and dried to provide the title compound (1b) (16 g, 85 %). Ή NMR (400 MHz, DMSO-cfe) δ 10.74 (s, 1H), 8.06 (s, 1 H), 8.01 -7.97(m, 1H), 7.91 (t, J = 7.7 Hz, 1H), 7.80 (dd, J = 1.0, 7.8 Hz, 1H), 2.84 (s, 6H). m/z (ESI) for (CgHnBr^O) 272.7 (M+H)+.
Step 3: Intermediate 1
A flask was charged with N’-[(6-bromopyridin-2-yl)carbonyl]-A/,W dimethylhydrazonoformamide (1b) (2.0 g, 7.4 mmol), ethylamine (0.5 mL, 333 mg, 7.4 mmol), acetic acid (3 mL) and MeCN (15 mL, 0.5 M). The solution was heated for 16 h at 95 °C. EtOAc (10 mL) and HaO (10 mL) were added. Solid K2CO3 was added until the pH of the aqueous layer was ~pH 8. The layers were separated, and the aqueous layer was extracted with EtOAc (3 x 30
mL). The combined organic layers were washed with brine (30 mL), dried over NazSCL, filtered, and concentrated to dryness. The residue was slurried with EtOAc (0.3 mL) and petroleum ether (3 mL) for 5 min. The solids were collected by filtration to provide Intermediate 1 (1.5 g, 80%) as a pale-yellow solid. Ή NMR (400 MHz, DMSO-ds) δ 8.75 (s, 1H), 8.19 (dd, J= 7.7, 0.9 Hz, 1H), 5 7.99 - 7.90 (m, 1H), 7.79 (dd, J = 8.0, 0.9 Hz, 1H), 4.47 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.2 Hz,
3H); m/z (APCI+) for (CgHgBrN^, 252.7 (M+H)+.
Intermediate 2
c][1,2,4]triazole (5S)-3-(6-bromopyridin-2-yl)-5-methyl·6,7-dihydro-5^/-pyrrolo[2,1-
Step 1 : tert-butyl {(2S)-5-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-5-oxopentan-2-yl}carbamate (2a)
A solution of (4S)-4-[(tert-butoxycarbonyl)amino]pentanoic acid (600 mg, 2.76 mmol) in
THF (13.8 mL, 0.2 M) was cooled to 0 °C. Propylphosphonic anhydride solution (50% solution in
EtOAc, 3.62 mL, 6.08 mmol) was added to the solution at 0 °C before the bath was removed and the reaction mixture was stirred for 30 min at RT. Then, Λ/,/V-diisopropylethylamine (2.89 mL, 16.6 mmol) and 6-bromopicolinohydrazide (656 mg, 3.04 mmol) were added and the reaction mixture was stirred at RT for 22 h. LCMS analysis showed consumption of the starting material. The reaction was quenched with water (15 mL) and transferred to a separatory funnel with EtOAc (20 mL). The layers were separated, and the organic phase was washed sequentîally with 20% citric acid (20 mL), a saturated solution of NaHCO3 (20 mL), and brine (20 mL). The organic extract was then dried over MgSO4, filtered, and concentrated to dryness to provide the title compound (2a) (1.07 g, 93% yield) as an off-white solid, which was taken on without further purification. 1H NMR (400 MHz, CDCh) δ 9.76 (br. s, 1H), 9.36 (br. s, IH), 8.15 (dd, J = 0 9, 7.5 Hz, 1H), 7.77 -
7.71 (m, 1H), 7.69 - 7.64 (m, 1H), 4.45 (br. d, J = 1.0 Hz, 1H), 3.91 (br. s, 1H), 2.47 - 2.35 (m,
2H), 2.00 - 1.89 (m, 1H), 1.75 - 1.66 (m, 1H), 1.48 (s, 9H), 1.22 (d, J = 6.6 Hz, 3H). LCMS m/z (APCI) for (CnHisBrN^), 315.0 (M+H-Boc)+.
Step 2: tert-butyl {(2S)-4-[5-(6-bromopyridin-2-yl)-1,3,4-oxadiazol-2-yl]butan-2-yl}carbamate (2b)
To a solution of tert-butyl {(2S)-5-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-5oxopentan-2-yl}carbamate (2a) (290 mg, 0.698 mmol) in DCM (2.8 mL, 0,25 M) was added triethylamine (0.292 mL, 2.09 mmol) and p-toluenesulfonyl chloride (160 mg, 0.838 mmol). The reaction was stirred at RT for 16 h. LCMS analysis showed consomption ofthe starting material. Ethylènediamine (0.047 mL, 0.698 mmol) was added to scavenge excess p-toluenesulfonyl chloride; during the addition, a precipitate formed immediately. After stirring at RT for 30 min, the reaction was washed with 20% citric acid (5 mL) and the layers were separated. The aqueous layer was extracted with DCM (5 mL), then the combined organic layers were washed with brine (10 mL), dried over MgSO4, fîltered and concentrated to dryness to provide the title compound (2b) (274 mg, 98% yield) as a light yellow solid, which was taken on without further purification. Ή NMR (400 MHz, CDCI3) 6 8.21 (dd, 0.9, 7.6 Hz, 1H), 7.76-7.69 (m, 1H), 7.68-7.65 (m, 1H), 4.39 (br. s, 1H), 3.85 (br. s, 1H), 3.08-3.01 (m, 2H), 2.17-2.03 (m, 1H), 2.03- 1.90 (m, 1H), 1.44 (s, 9H), 1.22 (d, J = 6.6 Hz, 3H). LCMS m/z (APCI) for (CnHnBrlW), 297.0 (M+HBoc)+.
Step 3: Intermediate 2
A microwave vial was charged with tert-butyl {(2S)-4-[5-(6-bromopyridin-2-yl)-1,3,4oxadiazol-2-yl]butan-2-yl}carbamate (2b) (150 mg, 0.378 mmol) and trifluoroethanol (1.89 mL, 0.2 M) and was sealed before heating in the microwave to 180 °C for 30 min. LCMS analysis showed consumption ofthe starting material. The reaction mixture was concentrated, and the residue was purified by flash chromatography (S1O2, 100% heptane to 1:10 MeOH/EtOAc) to provide Intermediate 2 (74.3 mg, 71% yield) as a tan, gummy solid. 1H NMR (400 MHz, CDCI3) 6 8.38 (d, J = 7.7 Hz, 1H), 7.74 (t, J = 7.8 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 5.22-5.08 (m, 1H), 3.21 - 3.16 (m, 1H), 3.16-3.02 (m, 2H), 2.55-2.44 (m, 1H), 1.60 (d, J= 6.6 Hz, 3H). LCMS m/z (APCI) for (CnHnBrN4), 279.1 (M+H)+. Determined to be a single enantiomer by SFC (10-60% methanol (0.5% NH3) in carbon dioxide @ 400-450 bar, gradient time = 2 min, flow rate = 4 mL/min, Chiralpack IC-U 50mm*3mm*1.6pm column). Stereochemistry of Intermediate 2 was assigned based on use of (4S)-4-[(tert-butoxycarbonyl)amino]pentanoic acid in step 1.
Absolute configuration of Intermediate 2 was unambiguously established by small molécule X-ray crystallography. The single crystal X-ray diffraction studies were carried out on a Bruker APEX II Ultra CCD diffractometer equipped with Mo Ka radiation (λ = 0,71073). Crystal where used as received (grown by vapor diffusion from dichloromethane) A 0.200 x 0.075 x 0.060 mm coloriess crystal was mounted on a Cryoloop with Paratone oil. Data were collected m a nitrogen gas stream at 100(2) K) using φ and στ scans. Crystal-to-detector distance was 45 mm using exposure time 1s (depending on the 2 frange) with a scan width of 0.80°. Data collection was 100.0% complété to 25.242° in Θ. The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SHELXT) produced a complété phasing model consistent with the proposed structure. Ail nonhydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-2014). AH carbon bonded hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the appropriate HFIX command in SHELXL-2014. Positions of the C-H, N-H and O-H hydrogen atoms hâve been refined using appropriate HFIX commands. Crystallographic data are summarized in Table 1.
Table 1 | |
Molecular formula | Cn Hn Br N4 |
Formula weight Température Wavelength Crystal system Space group Unit cell dimensions | 279.15 100.15 K 0.71073 A Monoclinic P2i a = 7.772(2) A a = 90°. b = 13.571(4) A β = 96.191(6)°. c = 10.676(3) A γ = 90°. |
Volume | 1119.5(5) A3 |
Z | 4 |
Density (calculated) | 3 1.656 Mg/m |
Absorption coefficient F(000) | 3.649 mm'1 560 |
Crystal size Crystal color, habit Thêta range for data collection Index ranges Reflections collected | 3 0.2 x 0.075 x 0.06 mm coloriess block 1.919 to 26.755°. -9<=h<=9i -17<=k<=17, -13<=l<=13 19401 |
Independent reflections Completeness to thêta = 25.242° Absorption correction Max. and min. transmission | 4760 [Rht = 0.0524] 100.0 % Semi-empirical from équivalents 0.4910 and 0.3848 |
Refinement method
Data / restreints / parameters
Goodness-of-fit on F3
Final R indices [l>2sigma(l)] R indices (ail data)
Absolute structure parameter
Largest diff. peak and hole
Full-matrix least-squares on F3
4760/1 /291
1.013
R1 = 0.0243, wR2 = 0.0582
R1 = 0.0258, wR2 = 0.0589
-0.012(6)
0.300 and -0.219 e.A'3
Intermediate 3: (5S)-3-(6-bromopyridin-2-yl)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole
Step 1: tert-butyl {(2S)-1-[methoxy(methyl)amino]-1-oxobutan-2-yl}carbamate (3a)
O
Mex A ^Et N y OMe NHBoc 3a
A solution of (2S)-2-((tert-butoxycarbonyl)amino]butanoic acid (2.0 g, 9.84 mmol) in THF (49.2 mL, 0.2M) was cooled to 0 “C. Propylphosphonic anhydride solution (50% solution in EtOAc, 12.9 mL, 21.6 mmol) was added to the solution at 0 °C before the bath was removed and the reaction mixture was aliowed to warm to RT and stirred for 30 min. Then, Λ/,Νdiisopropylethylamine (10.3 mL, 59.0 mmol) and methoxy(methyi)amine hydrochloride (1.06 g, 10.8 mmol) were added and the reaction mixture was stirred at RT for 18 h. LCMS analysis showed consomption of the starting material. The reaction was quenched with water (40 mL) and transferred to a separatory funnel with EtOAc (40 mL). The layers were separated, and the organic phase was washed sequentially with 20% citric acid (40 mL), a saturated solution of NaHCOa (40 mL), and brine (40 mL). The organicextract wasthen dried overMgSO4, fïltered, and concentrated to dryness to provide the title compound (3a) (1.29 g, 53% yield) as a yellow oil, which was taken on without further purification. 1H NMR (400 MHz, CDCL) 5 5.28 - 5.12 (m, 1H), 4.74 - 4.52 (m, 1H), 3.79 (s, 3H), 3.23 (s, 3H), 1.85 - 1.73 (m, 1H), 1.64-1.54 (m, 1H), 1.46 (s, 9H), 0.96 (t, J = 7.5 Hz, 3H). LCMS m/z (APCI) for (CnH22N2O4), 247.1 (M+H)+.
Step 2: tert-butyl (S)-(1-oxobutan-2-yI)carbamate (3b)
Ο
NHBoc 3b
A solution of tert-butyl {(2S)-1-[methoxy(methyl)amino]-1-oxobutan-2-yl}carbamate (3a) (1.29 g, 5.25 mmol) in THF (26.2 mL, 0.2M) was cooled to 0 ’C. Lithium aluminum hydride (2.3 M solution in 2-MeTHF, 2.51 mL, 5.77 mmol) was added dropwise to the solution at 0 °C. The reaction mixture was stirred for 40 min at 0 °C. LCMS analysis showed consumption of the starting material. The reaction was quenched with EtOAc (10 mL) and 1 M HCl (10 mL) and transferred to a separatory funnel. The layers were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic extracts were then dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, 100% heptane to 100% EtOAc) to provide to provide the title compound (3b) (0,575 g, 59% yield) as a white solid. 1H NMR (400 MHz, CDCb) δ 9.60 (s, 1H), 5.09 (br. s, 1H), 4.22 (br. s, 1H), 2.04-1.90 (m, 1H), 1,73 - 1.64 (m, 2H), 1.48 (s, 9H), 0.99 (t, J = 7.5 Hz, 3H).
Step 3: ethyl (2E14S)-4-[(tert-butoxycarbonyl)amino]hex-2-enoate (3c)
EtO2C^^Et
NHBoc 3c
To a solution of tert-butyl (S)-(1-oxobutan-2-yl)carbamate (3b) (575 mg, 3.07 mmol) in DCM (6.14 mL, 0.5 M) was added (ethoxycarbonylmethylene)triphenylphosphorane (1.60 g, 4.61 mmol). The reaction mixture was stirred at RT for 17 h. LCMS analysis showed consumption of the starting material. The reaction was concentrated to dryness before isopropanol (8.5 mL, 0.36 M) and zinc chloride (1.26 g, 9.21 mmol) were added to precipitate the triphenylphosphine oxide. After stirring at RT for 30 min, the reaction mixture was filtered and concentrated to dryness. The residue was purified by flash chromatography (SiOz, 100% heptane to 100% EtOAc) to provide the title compound (3c) (653 mg, 83% yield, >20:1 ratio of E/Z isomers) as a colorless oil. 1H NMR (400 MHz, CDCb) δ 6.86 (dd, J = 5.4, 15.6 Hz, IH), 5.94 (dd, J= 1.7, 15.7 Hz, 1H), 4.50 (br. s, 1H), 4.31 -4.16 (m, 3H), 1.65 - 1.63 (m, 1H), 1.60 - 1.51 (m, 1H), 1.47 (s, 9H), 1,32 - 1.30 (m, 3H), 0.99-0.95 (m, 3H). LCMS m/z (APCI) for (C8Hi5NCb), 158.2 (M+H-Boc)+.
Step 4: ethyl (4S)-4-[(tert-butoxycarbonyl)amino]hexanoate (3d)
EtO2C^^Et
NHBoc 3d
To a solution of ethyl (2E,4S)-4-[(tert-butoxycarbonyl)amino]hex-2-enoate (3c) (653 mg, 2.54 mmol) in methanol (12.7 mL, 0.2 M) was added palladium on carbon (10% w/w, 270 mg, 0.254 mmol). The reaction vial was evacuated and refilled with H2 under dynamic vacuum for 10 seconds. Then the reaction mixture was stirred at RT under 1 atm H2 for 18 h. The mixture was stirred at RT for 17 h. LCMS analysis showed consumption ofthe starting material. The reaction was filtered over Celite® and concentrated to dryness. The residue was purified by flash chromatography (SiO2, 100% heptane to 100% EtOAc) to provide the title compound (3d) (589 mg, 90% yield) as a colorless oil. Ή NMR (400 MHz, CDCh) δ 4.37 - 4.23 (m, 1H), 4.20 - 4.11 (m, 2H), 3.61 -3.46 (m, 1H), 2.42-2.33 (m, 2H), 1.93-1.82 (m, 1H), 1.71 -1.62 (m, 1H), 1.57 -1.51 (m, 1H), 1.46 (s, 9H), 1.44-1.38 (m, 1H), 1.30- 1.26 (m, 3H), 0.94 (t, J = 7.4 Hz, 3H).
Step 5: (4S)-4-[(tert-butoxycarbonyl)amino]hexanoic acid (3e)
HOzC^^^Et
NHBoc 3θ
To a solution of ethyl (4S)-4-[(tert-butoxycarbonyl)amino]hexanoate (3d) (589 mg, 2.27 mmol) in THF (11.4 mL, 0.2 M) and MeOH (5.7 mL, 0.4 M) was added a solution of LiOH (544 mg, 22.7 mmol) in water (2.84 mL, 0.8 M). The reaction mixture was stirred at RT for 24 h. The reaction was concentrated before the addition of water and 1M HCl until a pH of 5 was reached. The aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to dryness to provide the title compound (3e) (260 mg, 50% yield) as a iight-yellow oil, which was taken on without further purification.
Step 6: tert-butyl {(3S)-6-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-6-oxohexan-3-yl}carbamate (3f)
A solution of (4S)-4-[(tert-butoxycarbonyl)amino]hexanoic acid (3e) (260 mg, 1.12 mmol) in THF (5.6 mL, 0,2 M) was cooled to 0 qC. Propylphosphonic anhydride solution (50% solution in EtOAc, 1.47 mL, 2.47 mmol) was added to the solution at 0 °C before the bath was removed and the reaction mixture was stirred for 30 min at RT. Then, /V,A/-diisopropylethylamine (1.17 mL, 6.74 mmol) and 6-bromopicolinohydrazide (267 mg, 1.24 mmol) were added and the reaction mixture was stirred at RT for 18 h. The reaction was quenched with water (15 mL) and transferred to a separatory funnel with EtOAc (20 mL). The layers were separated, and the organic phase was washed sequentially with 20% citric acid (20 mL), a saturated solution of NaHCO3 (20 mL), and brine (20 mL). The organic extract was then dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (S1O2, 100% heptane to 100% EtOAc) to provide the title compound (3f) (241 mg, 50% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 9.76 (br. s, 1H), 9.29 (br. s, 1H), 8.15 (d, J- 6.8 Hz, 1H), 7.76-7.71 (m, 1H), 7.68-7.64 (m, 1H), 4.45-4.31 (m, 1H), 3.69 (br. s, 1H), 2.45 -2.37 (m, 2H), 2.04- 1.94 (m, 1H), 1.69- 1.62 (m, 1Η), 1.49 (s, 9Η), 1.45 (br. d, J = 7.3 Hz, 2H), 0.99 (t, J = 7.5 Hz, 3H). LCMS m/z (APCI) for (Ci2H17BrN4O2), 329.0 (M+H-Boc)+.
Step 7: tert-butyl {(3S)-1-[5-(6-bromopyndin-2-yl)-1,3,4-oxadiazol-2-yl]pentan-3-yl}carbamate (3g)
To a solution of tert-butyl {(3S)-6-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-6-oxohexan3-yl}carbamate (3f) (241 mg, 0.561 mmol) in DCM (2.2 mL, 0.25 M) was added triethylamine (0.235mL, 1.68 mmol) and p-toluenesulfonyl chloride (128 mg, 0.673 mmol). The reaction was stirred at RT for 16 h. LCMS analysis showed consomption of the starting materiai. Ethylènediamine (0.038 mL, 0.561 mmol) was added to scavenge excess p-toluenesulfonyl chloride; during the addition a precipitate formed immediately. After stirring at RT for 30 min, the réaction was washed with 20% citric acid (5 mL) and the layers were separated. The aqueous layer was extracted with DCM (5 mL) then the combined organic layers were washed with brine (10 mL), dried over MgSO4, fîltered and concentrated to dryness. The residue was purified by flash chromatography (SiO21 100% heptane to 100% EtOAc) to provide the title compound (3g) (178 mg, 77% yield) as a white solid. 1H NMR (400 MHz, CDCh) δ 8.22 (dd, J = 0.7, 7.6 Hz, 1H), 7.77-7.72 (m, 1H), 7.68-7.65 (m, 1H), 4.35 (br. d, J = 8.2 Hz, 1H), 3.65 (br. s, 1H), 3.07 (dt, J = 6.1, 10.0 Hz, 2H), 2.21 -2.11 (m, 1H), 1.93 - 1.83 (m, IH), 1.65-1.61 (m, 1H), 1.53- 1.48 (m, 1H), 1.46 (s, 9H), 0.98 (t, J = 7.4 Hz, 3H). LCMS m/z (APCI) for (Ci2Hi5BrN4O), 311.0 (M+HBoc)+.
Step 8: Intermediate 3
A microwave vial was charged with tert-butyl {(3S)-1-[5-(6-bromopyridin-2-yl)-1,3,4oxadiazol-2-yl]pentan-3-yl}carbamate (3g) (178 mg, 0.431 mmol) and trifluoroethanol (2.16 mL, 0.2 M) and was sealed before heating in the microwave to 180 °C for 60 min. LCMS analysis showed consomption of the starting materiai. The reaction mixture was concentrated, and the residue was purified by flash chromatography (SiO2, 100% heptane to 1:10 MeOH/EtOAc) to provide Intermediate 3 (116 mg, 91% yield) as a coloriess oil. 1H NMR (400 MHz, CDCI3) δ 8.26 (dd, J = 0.7, 7.7 Hz, 1 H), 7.67 (t, J = 7.9 Hz, 1 H), 7.49 (dd, J = 0.7, 7.8 Hz, 1 H), 4.90 - 4.83 (m, 1H), 3.07-2.89 (m, 3H), 2.58-2.49 (m, 1H), 2.04 - 1.97 (m, 1H), 1.83-1.70 (m, 1H), 0.96 (t, J = 7.5 Hz, 3H). LCMS m/z (APCI) for (Ci2Hi3BrN4), 293.0 (M+H)+. Determined to be 97.4% ee by SPC (10-60% methanol (0.5% NH3) in carbon dioxide @ 400-450 bar, gradient time = 2 min, flow
I 61 rate = 4 mL/min, Kromasil (R,R)Whelk-O 50mm*3mm*1,8pm column). Stereochemistry was assigned based on use of (2S)-2-[(tert-butoxycarbonyl)amino]butanoic acid in the first step. Absolute configuration of Intermediate 3 was unambiguously established by small molécule Xray crystallography.
Table 2 provides the single crystal X-ray diffraction studies carried out on a Bruker APEX
Il Ultra CCD diffractometer equipped with Mo Ka radiation (λ = 0.71073). Crystal were used as received (grown by vapor diffusion from ethyl acetate: methanol (10:1). A 0.180 x 0.065 x 0.055 mm coîorless crystal was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K) using φ and τσ scans. Crystal-to-detector distance was 45 mm using exposure time 2s (depending on the 2 frange) with a scan width of 0.80°. Data collection was 100.0% complété to 25.242° in Θ. The data were integrated using the Bruker SAINT software program and sealed using the SADABS software program. Solution by direct methods (SHELXT) produced a complété phasing model consistent with the proposed structure. Ali nonhydrogen atoms were refîned anisotropically by fulLmatrix least-squares (SHELXL-2014). AH carbon bonded hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the approprîate HFIX command in SHELXL-2014. Positions of the C-H, N-H and O-H hydrogen atoms hâve been refined using approprîate HFIX commands.
Table 2 | |||
Molecular formula | C12 Hu Br N4 | ||
20 25 | Formula weight Température Wavelength Crystal system Space group Unit cell dimensions | 293.17 100.15 K 0.71073 A Orthorhombic P2i2i2i a = 7.1319(2) A | a = 90°. |
30 35 | Volume Z Density (calculated) Absorption coefficient F(000) Crystal size Crystal color, habit Thêta range for data collection Index ranges | b = 11.2187(3) A c= 15.5538(5) A 1244.47(6) A3 4 1.565 Mg/m3 3.286 mm3 592 0.18 x 0.065 x 0.055 mm coîorless irregular 2.238 to 27.108°. -9<=h<=9, -14<=k<=14, | β = 90°. γ = 90°. 3 1 g<=i<=i9 |
Reflections collected Independent reflections Completeness to thêta = 25.242° Absorption correction Max. and min. transmission
Refinement method
Data / restraints ! parameters Goodness-of-fit on F 2 Final R indices [l>2sigma(l)] R indices (ail data)
Absolute structure parameter Largest diff. peak and hoîe
19687
2740 [Rint = 0.0697]
100.0%
Semi-empirical from équivalents 0.4851 and 0.4153
Full-matrix least-squares on F^ 2740/0/ 155
1.047
R1 = 0.0237, wR2 = 0.0570
R1 = 0.0261, wR2 = 0.0581
-0.003(7)
0.307 and -0.255 e.A'3
Intermediate 4: (S,S)-2-methyl-N-[(1R)-1-{6-[(2Fî)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dfhydro-1Hpyrrolo[3,4-c]pyridin-4-yl}ethyl]propane-2-sulfinamide
Step 1: {2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]pyridin-4-yl}(piperidin-1-yl)methanone (4a)
A solution of (2,6-dichloropyridin-4-yl)(piperidin-1-yÎ)methanone (600 mg, 2.32 mmol) and (2R)-2-methyîpyrrolidine (591 mg, 6.95 mmol) in DMF (1.5 mL) was stirred at 100 °C for 16 h. LCMS analysis showed consumption ofthe starting material. The reaction was cooled to RT, H2O (40 mL) was added, and the reaction was extracted with DCM (3 x4 OmL). The combined organic layers were dried over NazSO4, filtered, and concentrated. The residue was purified by flash chromatography (24 g SiO2, 0-20% EtOAc/heplane) to provide the title compound (4a) (664 mg, 93% yield). Ή NMR (400 MHz, CDCb) δ 6.44 (d, J = 1.0 Hz, 1H), 6.21 (d, J- 1.0 Hz, 1H), 4.12 (q, J= 7.1 Hz, 1H), 3.72-3.62 (m, 2H), 3.54 (ddd, J = 10.5, 7.6, 2.9 Hz, 1H), 3.40-3.28 (m, 2H),
2.10 - 2.04 (m, 2H), 1.75 - 1.62 (m, 4H), 1.26 (t, J = 7.2 Hz, IH), 1.21 (d, J = 6.3 Hz, 2H); m/z (APCI+) for (C16H22CIN3O), 308.2 (M+H)+.
Step 2: 2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]'4-(piperidine-1-carbonyl)pyridine-3carbaldehyde (4b)
To a solution of DMF (473 mg, 6.47 mmol) in DCM (3.0 mL) was added POCb (992 mg, 6.47 mmol). The mixture was stirred for 10 min and then a solution of {2-chloro-6-[(2R)-2methylpyrrolidin-1-yl]pyridin-4-yl)(piperidin~1-yl)methanone (4a) (664 mg, 2.16 mmol) in DCM (3.0 mL) was added. The mixture was stirred at reflux for 15 h. LCMS analysis showed consumption of the starting material. The reaction was concentrated to dryness and slowly poured into a saturated solution of NaHCCb (30 mL). The mixture was extracted with DCM (3 x 30 mL). The combined organics were dried over NaaSCU, filtered, and concentrated. The residue was purified by flash chromatography (24 g SiO2, 0-40% EtOAc/heptane) to provide the title compound (4b) (568 mg, 78 % yield). 1H NMR (400 MHz, CDCb) δ 10.07 (s, 1H), 5.99 (s, 1H), 4.13 - 4.65 (m, 1H), 3.68 - 3.83 (m, 1H), 3.55 - 3.68 (m, 2H), 3.35 - 3.55 (m, 1H), 2.98 - 3.20 (m, 2H), 1.88 2.17 (m, 3H), 1.71 - 1.83 (m, 2H), 1.55- 1,67 (m, 3H), 1.46-1.55 (m, 1H), 1.31 - 1.42 (m, 1H), 1,17-1.26 (m, 3H); m/z (APCI+) for (C17H22CIN3O2), 336.1 (M+H)+.
Step 3: A/-[(E)-{2-chloro-6-[(2R)-2-methyîpyrrolidin-1-yl]-4-(pipendine-1-carbonyl)pyridin-3yl}methylidene]-2-methylpropane2-sulfinamide (4c)
A mixture of 2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridine-3carbaldehyde (4b) (432 mg, 1.29 mmol), (R)-(+)-2-methyl-2-propanesulfinamide (187 mg, 1,54 mmol), and Ti(OEt)4 (880 mg, 3.86 mmol) in THF (10.0 mL) was stirred at 45 °C for 16 h. LCMS analysis showed ~25% remaining starting material. Additional batches of (R)-(+)-2-methyl-2propanesulfinamide (62.4 mg, 0.515 mmol), and Ti(OEt)4 (293 mg, 1.29 mmol) were added and the mixture was stirred at 50 °C for 16 h. LCMS analysis showed consumption of the starting material. The reaction was cooled to RT. The mixture was diluted with DCM (50 mL) and washed with a saturated solution of NaHCO3 (35 mL) and brine (35 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to provide the title compound (4c) (495 mg, 88% yield) as a white gum, which was taken on without further purification, m/z (APCI+) for (C2iH3iCIN4O2S)T 440.2 (M+H)h.
Step 4: 4-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one (4d)
A solution of /V-[(E)-{2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(pipendine-1carbonyl)pyridin-3-yl}methylidene]-2-methylpropane-2-sulfinamide (4c) (495 mg, 1.13 mmol) in THF (15.0 mL) was cooled to 0 °C and then a solution of LiBH4 (2.0 M in THF, 620 mL, 1.24 mmol) was added. The mixture was stirred at 0 °C for 2 h and then a solution of NaOMe (25% in MeOH, 2.5 mL, 10.1 mmol) was added. The reaction was allowed warm to RT and then stirred for 16 h. The reaction was diluted with DCM (60 mL) and washed with saturated aqueous NH4CI (60 mL) and brine (60 mL). The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (SiO2, 50-100% EtOAc/heptane) to provide the title compound (4d) (199 mg, 70% yield) as a colorless foam. NMR (400 MHz, CDCL) δ 6.68 (s, 1H), 6.45 (s, 1H), 4.35 (s, 2H), 4.21 -4.14 (m, 1H), 3.58 (ddd, J = 10.5, 7.6, 2.8 Hz, 1H), 3.39 (q, 4=8.9 Hz, IH), 2.13-1.97 (m, 2H), 1.75 (dt, J = 5.2, 2.6 Hz, 1H), 1.23 (d, J = 6.3 Hz, 3H). One hydrogen atom assumed obscured by water peak; m/z (APCI+) for (Ci2Hi4CIN3O), 252.3 (M+H)+. Step 5: 6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-4-carbonitrile (4e)
A mixture of 4-chloro-6-[(2R)-2-methyipyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin1-one(4d) (438 mg, 1.74 mmol), Zn(CN)2(306 mg, 2.6 mmol), DMF (15 mL) and Pd(PPh3)4 (100 mg, 0.09 mmol) was heated to 140 °C in the microwave for 30 min. The reaction was diluted with DCM and filtered. The filter cake was washed with DCM. The filtrate was concentrated in vacuo and the crude compound was purified by flash chromatography (SiO2, 0-100% 1:1 EtOAc:DCM/heptane) to the title compound (4e) as a yellow solid (375 mg, 89% yield). 1H NMR (400 MHz, CDCI3) δ 7.00-6.94 (m, 1H), 6.46 - 6.32 (m, 1H), 4.55 (s, 2H), 4.29-4.19 (m, 1H),
3.61 (ddd, J = 2.6, 7.6, 10.3 Hz, 1H), 3.46 - 3.34 (m, 1H), 2.22- 2.02 (m, 3H), 1.86- 1.72 (m, 1 H), 1.25 (d, J =6.4 Hz, 3H); m/z (APCI+) for (CiaHw^O), 243.1 (M+H)+.
Step 6: 4-acetyl-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrroio[3,4-clpyridin-1-one (4f)
To a solution of 6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4c]pyridine-4-carbonitrile (4e) (355 mg, 1.47 mmol) in THF (15 mL) at ice/water bath was added MeMgBr (4.88 mL, 14.7 mmol, 3.0 M in THF), The resulting mixture was stirred al this température for 10 min, then allowed warmed to RT and allowed to stir for 2 h. The mixture was quenched with 2 N HCl (6 mL) at 0 °C and stirred at RT for 15 min. The mixture was neutralized with a saturated solution of NaHCO3 and extracted with DCM (3 x 40 mL). The combined organic layers were dried over NasSCu fîltered, and concentrated. The crude compound was purified by flash chromatography (SiO2, 20-50% EtOAc/heptane) to provide the title compound (4f) as a yellow solid (190 mg, 50% yield). Ή NMR (400 MHz, CDCh) 6.98 (s, 1H), 6.59 (br. s, 1H), 4.70 (s, 2H), 4.28 (br.t, J = 5.7 Hz, 1H), 3.64 (ddd, J = 2.6, 7.5, 10.1 Hz, 1 H), 3.48 - 3.38 (m, 1H), 2.70 (s, 3H), 2.19-2.10 (m, 2H), 2.08-2.01 (m, 1H), 1.79 (td, J = 2.6, 5.0 Hz, 1H), 1.30 (d, J = 6.2 Hz, 3H); m/z (APCI+) for (CuH17N3O2), 260.2 (M+H)+.
Step 7: Intermediate 4
To a 40 mL vial was added 4-acetyl-6-[(2R)-2-methylpyrrolid!n-1-yl]-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-1-one (4f) (200 mg, 0.77 mmol), (S)-tert-butylsulfinamide (187 mg, 1.54 mmol), THF (1.54 mL) and Ti(OEt)4 (1.54 mmol, 0.323 mL). The vial was capped and heated to 80 °C for 48 h. The reaction was then cooled to -78 °C (dry ice/acetone bath) and L-selectride (1.54 mmol, 1.54 mL, 1.0 M in THF) dropwise. The resulting mixture was stirred at -78 °C for 3 hr. The mixture was warmed to RT and quenched with saturated NH4CI (2 mL) dropwise, then added DCM (20 mL) and brine (20 mL). The mixture was fîltered through Celite® and washed with DCM (40 mL). The organic layer was collected, and the aqueous layer was extracted with DCM (20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude was purified by flash chromatography (SiO2, solvent 0-10% MeOH in EtOAc) to provide Intermediate 4 as a yellow foam (127 mg, 45% yield). m/z (APCI+) for (Cw^sNæbS), 365.3 (M+H)+. Stereochemistry was assigned based on use of (2R)-2-methylpyrrolidine in step 1 and (S)-tert-butylsulfinamide in step 7.
Intermediate 5: (S,R)-2-methyl-/\/-[(1R)-1-{6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-4~yl}propyl]propane-2-sulfinamide
Step 1: 6-[(2R)-2-methylpyrrolidin-1-yl]-4-propanoyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one (5a)
A solution of 6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1/7-pyrrolo[3,4-c]pyridine4-carbonitrile (4e) (808 mg, 3.33 mmoî) in THF (8.0 mL) was cooled to 0 °C and then treated with a solution of ethylmagnesîum bromide (3.0 M in Et2O, 11.1 mL, 33.3 mmol). The mixture was stirred at RT for 1 h. LCMS analysis showed consumptîon ofthe starting material. The reaction was cooled to 0 °C and quenched by addition of 2 N HCl. The mixture was stirred at RT for 10 min, neutralized by addition of a saturated solution of NaHCCh, and then extracted with DCM (2 x 30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (24 g SiO2l 0-100% EtOAc/heptane) to provide the title compound (5a) (646 mg, 71% yield) as a yellow oil. Ή NMR (400 MHz, CDCh) δ 7.01 (s, 1H), 6.41 (br. s, 1H), 4.73 (s, 2H), 4.39 - 4.22 (m, IH), 3.66 (ddd, J = 2.6, 7.4, 10.1 Hz, 1H), 3.52 3.38 (m, 1H), 3.30 - 3.14 (m, 2H), 2.26-2.10 (m, 2H), 2.06-2.01 (m, 1H), 1.81 (td, J = 2.5, 5.1 Hz, 1H), 1.31 (d, J = 6.2 Hz, 3H), 1.24 (t, J = 7.3 Hz, 3H); m/z (APCI+) for (C1SH13N3O2), 274.2 (M+H)+.
Step 2: (S,S)-2-methyl-N-[(1E)-1-{6-[(2/?)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrro!o[3,4-c]pyridin-4-yl}propylidene]propane-2-sulfinamide (5b)
To a solution of 6-[(2R)-2-methylpyrrolidin-1-yl]-4-propanoyl·2,3-dίhydro-1/-Apyrroîo[3,4c]pyridin-1-one (5a) (640 mg, 2.34 mmol) in THF (2.0 mL) were added (S)-(-)-2-methyl-2propanesulfinamide (568 mg, 4.68 mmol) and Ti(OEt)4 (2.14 g, 9.37 mmol). The mixture was stirred at 90 °C for 23 h. LCMS analysis showed consomption ofthe startmg material. The mixture was cooled to RT and brine (40 mL) and DCM (30 mL) were then added. The mixture was stirred for 10 min and then filtered through Celite®. The layers were separated. The aqueous layer was extracted with DCM (30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to provide the title compound (5b) (779 mg, 88% yieid) as a white foam which was directly taken on in the next step. m/z (APCI+) for (CisHaeN^tOaS), 377.2 (M+H)+.
Step 3: Intermediate 5
A solution of (S,S)-2-methyl-/\/-[(1£)-1-{6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro1H-pyrrolo[3,4-c]pyridin-4-yj}propylidene]propane-2-sulfinamide (5b) (654 mg, 1.40 mmol) in THF (12.0 mL) was cooled to -78 °C and then treated dropwise with a solution of L-selectride (1.0 M in THF, 2.5 mL, 2.5 mmol). The mixture was stirred at -78 °C for 1.5 h. Additional L-selectride (1.0 M, 0.417 mL, 0.417 mmol) was added and the mixture was stirred at -78 °C for a further 1.5 h. The mixture was quenched with MeOH, diluted with brine (50mL), and extracted with DCM (2 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated, The residue was purified by flash chromatography (12 g S1O2, 0-10% MeOH/DCM) to provide Intermediate 5 (300 mg, 57% yieid) as a yellow gum. 1H NMR (400 MHz, DMSO-Λ) δ 8.66 (s, 1H), 6.48 (s, 1H), 5.14 (d, J = 6.6 Hz, 1H), 4.35 ($, 2H), 4.27-4.14 (m, 2H), 3.59-3.44 (m, 1H), 3.29-3.18 (m, 1H), 2.14-2.01 (m, 2H), 1.98-1.81 (m, 3H), 1.73- 1.60 (m, 1H), 1.20 (d, J = 6.2 Hz, 3H), 1.07 (s, 9H), 0.86 - 0.73 (m, 3H); m/z (APCI+) for (C19H30N4O2S), 379.2 (M+H)*.
Stereochemistry was assigned based on use of (2R)-2-methylpyrrolidine in step 1 of the synthesis of Intermediate 4 and (S)-(-)-2-methyl-2-propanesulfinamide in step 2. Absolute configuration of Intermediate 5 was unambiguously established by small molécule X-ray crystaîlography.
Table 3 provides X-ray diffraction data confirming the stereochemistry of Intermediate 5. The single crystal X-ray diffraction studies were carried out on a Bruker Microstar APEX II CCD diffractometer equipped with Cu Ka radiation (A =1.54178 A). Absolute stereochemistry was conclusively assigned (Flack = 0.003(12)). Crystals of Intermediate 5 were grown from ether/pentane at 4 ’C. A 0.12 x 0.04 x 0.02 mm piece of a colorless crystal was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using φ and ro scans. Crystal-to-detector distance was 45 mm and exposure time was 4, 6, 8, 10, 14, or 20 seconds depending on the 20 range per frame using a scan width of 1.25°. Data collection was 97.0 % complété to 67.500° in Θ, The data were integrated using the Bruker SAINT Software program and scaled using the SADABS software program. Solution by direct methods (SHELXT) produced a complété phasing model consistent with the proposed structure. Ail nonhydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-2014). Ail carbon bonded hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the appropriate HFIX command in SHELXL-2014.
• | 69 | |
5 | Empirical formula: Molecular weight Température Wavelength | Table 3 Cia H30 N4 O2 S 378.53 100.0 K 1.54178 A |
10 15 | Crystal System Space group Unit cell dimensions: Volume Z Density (calculated) Absorption coefficient F(000) | Triclinic P1 a = 8.3400(3) A a= 92.724(2)°. b = 9.4731(3) A β= 104.495(2)°. c = 15.3569(5) A y = 115.416(2)°. 1044.18(6) A3 2 1.204 Mg/m3 1.532 mm-1 408 |
20 | Crystal size Crystal color, habit Thêta range for data collection Index ranges Reflections collected | 0.12x0.04x0.02 mm3 colorless plank 3.020 to 68.664°. -10<=h<=10, -11<=k<=11, -18<=l<=18 21109 |
25 | Independent reflections Completeness to thêta = 67.500° Absorption correction Max. and min. transmission Refinement method | 7199 [R(int) = 0.0654] 97.0 % Semi-empirical from équivalents 0.5210 and 0.4220 Fuli-matrix least-squares on F2 |
30 | Data / restraints / parameters Goodness-of-fit on F2 Final R indices [l>2sigma(l)] R indices (ail data) Absolute structure parameter | 7199/3/479 1.038 R1 = 0.0626, wR2 = 0.1561 RI = 0.0774, wR2 = 0.1686 0.003(12) |
Extinction coefficient Largest diff. peak and hole | n/a 0.593 and -0.326 e.A'3 |
Intermediate 6: 4-(2-aminopropan-2-yl)~6-[(2f?)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1F735 pyrrolo[3,4-c]pyridin-1-one
To a suspension of 6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4c]pyridine-4-carbonitrile (4e) (213 mg, 0.88 mmol) in THF (9 mL) at RT was added lanthanum(lll) chloride bis(lithium chloride) complex (1.76 mmol , 2.93 mL, 0.6 M). The resulting mixture was stirred at RT for 30 min, and then was cooled to -78 °C (dry ice/acetone bath) and methyllithium (3.52 mmol, 2.20 mL, 1.6 M) was added dropwise. The resulting mixture was stirred at -78 °C for 1 h, then allowed warm to RT. The mixture was quenched with saturated NH4CI (20 mL), and brine (20 mL) and DCM (20 mL) were then added. The mixture was stirred at RT for 5 min and filtered through Celite®. The organic layer was collected, and the aqueous layer was extracted with DCM (20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (SiO2, solvent 0-10% MeOH in DCM) to provide Intermediate 6 as a pale brown color solid (157 mg, 65% yield). 1H NMR (400 MHz, DMSO-cfe) δ 8.60 (s, 1H), 6.42 (s, 1H), 4.56 (s, 2H), 4.17 (br. t, J = 5.7 Hz, 1H), 3.50 (ddd, J= 2.4, 7.2, 9.8 Hz, 1H), 3.30-3.22 (m, 1H), 2.07-2.02 (m, 1H), 2.00-1.92 (m, 2H), 1.68 (td, J = 2.4, 4.9 Hz, 1H), 1.41 (s, 3H), 1.40 (s, 3H), 1.20 (d, J = 6.2 Hz, 3H); m/z (APCI+) for (Ci5H22N4O), 275.2 (M+H)*.
Intermediate 7: (5R)-3-(6-bromopyridin-2-yl)-5-(fluoromethyl)-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazole
Step 1 : (5R)-5-(fiuoromethyl)pyrrolidin-2-one (7a)
A solution of (5R)-5-(bromomethyl)pyrrolidin-2-one (600 mg, 3.37 mmol) in CH3CN (6.74 mL, 0.5 M) was covered with aluminum foil to exclude light. To this solution was added a suspension of AgF (1.07 g, 8.43 mmol) in CH3CN (12.5 mL, 0.27 M) in one portion. The reaction was stirred at RT in the dark for 36 h. The reaction was filtered over Celite® and concentrated to dryness. The crude residue was purified by flash chromatography (SiO2, 100% EtOAc to 1:1 EtOAc/acetone) to provide the title compound (7a) (173 mg, 44% yield) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 7.17 (br. s, 1H), 4.49 - 4.17 (m, 2H), 4.01 - 3.84 (m, 1H), 2.44 - 2.28 (m, 2H), 2.27-2.16 (m, 1H), 1.88-1.75 (m, 1H). 19F NMR (376 MHz, CDCI3) δ-224.58 (s, 1F).
Step 2: tert-butyl (2R)-2-(fluoromethyl)-5-oxopyrrolidine-1-carboxylate (7b)
7b
To a solution of (5R)-5-(fluoromethyl)pyrrolidin-2-one (7a) (170 mg, 1.45 mmol) in CH3CN (6.74 mL, 0.5 M) was added Boc2O (348 mg, 1.60 mmol) and 4-(dimethylamino)pyridine (17.7 mg, 0.145 mmol). The reaction was stirred at RT for 2 h. TLC analysis (2:1 EtOAc:acetone) showed consomption ofthe starting materiai. The reaction mixture was concentrated and purified by flash chromatography (SiO2, 100% heptane to 100% EtOAc) to provide the title compound (7b) (277 mg, 88% yield) as a colorless oil. Ή NMR (400 MHz, CDCI3) δ 4.78 - 4.42 (m, 2H), 4.40 - 4.25 (m, 1H), 2.76-2.62 (m, 1H), 2.50- 2.39 (m, 1H), 2.29-2.14 (m, 1H), 2.13-2.03 (m, 1H), 1.56 (s, 9H). 19F NMR (376 MHz, CDCI3) δ -233.52 (s, 1 F).
Step 3: tert-butyl [(2R)-1-fluoro-5-hydrazinyl-5-oxopentan-2-yl]carbamate (7c)
Boc 7c
To a solution of tert-butyl (2R)-2-(fluoromethyl)-5-oxopyrrolidine-1-carboxylate (7b) (1.78 g, 8.19 mmol) in THF (41.0 mL, 0.2 M) was added hydrazine monohydrate (1.3 mL, 41.0 mmol) via syringe. The reaction was stirred at RT for 30 min. TLC analysis (1:1 heptane:EtOAc) showed consomption of the starting materiai. The reaction mixture was concentrated and then EtOAc (50 mL) and saturated aqueous NH4CI (50 mL) were added. The layers were separated, and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over MgSO4, fîltered, and concentrated to dryness to provide the title compound (7c) (1.6 g, 78% yield) as a white solid, which was taken on without further purification. 1H NMR (400 MHz, CDCI3) δ 5.15-5.00 (m, 1H), 4.52-4.44 (m, 1H), 4.39-4.33 (m, 1H), 3.93-3.75 (m, 1H), 2.40 (br. s, 2H), 2.00 - 1.81 (m, 2H), 1.46 (s, 9H). 19F NMR (376 MHz, CDCI3) δ -232.02 (s, 1 F).
Step 4: tert-butyl {(2R)-5-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-1-fluoro-5-oxopentan-2yl}carbamate (7d)
A solution of 6-bromopyridine-2-carboxylic acid (1.4 g, 6.93 mmol) in THF (34.7 mL, 0.2 M) was cooled to 0 “C. Propylphosphonic anhydride solution (50% solution in EtOAc, 9.1 mL, 15.2 mmol) was added to the solution at 0 °C before the bath was removed and the reaction mixture was stirred for 30 min at RT. Then, A/,/\/-diisopropylethylamine (7.24 mL, 41.6 mmol) and tert-butyl
[(2R)-1-fluoro-5-hydrazinyl-5-oxopentan-2-yl]carbamate (7c) (1.90 g, 7.62 mmol) were added and the reaction mixture was stirred at RT for 17 h. LCMS analysis showed consumption ofthe starting material. The reaction was quenched with water (30 mL) and transferred to a separatory funnei with EtOAc (50 mL). The layers were separated, and the organic phase was washed sequentially with 20% citric acid (30 mL), a saturated solution of NaHCCb (30 mL), and brine (30 mL). The organic extract was then dried over MgSCU, filtered, and concentrated to dryness to provide the title compound (7d) (2.37 g, 78% yield) as a yellow solid, which was taken on without further purification. 1H NMR (400 MHz, CDCb) δ 9.74 (br. s, 1H), 9.15 (br. s, 1H), 8.14 (d, J = 7.5 Hz, IH), 7.77-7.71 (m, 1H), 7.70 -7.65 (m, 1H), 4.95 (br. d, J = 9.2 Hz, 1H), 4.62 -4.36 (m, 2H), 4.12 - 3.98 (m, 1H), 2.49 - 2.37 (m, 2H), 2.03 - 1.95 (m, 2H), 1.49 (s, 9H). 19F NMR (376 MHz, CDCb) δ -232.01 (s, 1F). LCMS m/z (APCI) for (CnH14BrFN4Cb), 333.1 (M+H-Boc)+.
Step 5: tert-butyl {(2R)-4-[5-(6-bromopyridin-2-yl)-1,3,4-oxadiazol-2-yl]-1-fluorobutan-2yl}carbamate (7e)
To a solution of tert-butyl {(2R)-5-[2-(6-bromopyridine-2-carbonyl)hydrazinyl]-1-fluoro-5oxopentan-2-yl)carbamate (7d) (2.3 g, 5.3 mmol) in DCM (21.2 mL, 0.25 M) was added triethyiamine (2.22 mL, 15.9 mmol) and p-toluenesulfonyl chloride (1.21 g, 6.37 mmol). The reaction was stirred at RT for 1.5 h. LCMS analysis showed consumption ofthe starting material. Ethylènediamine (0.355 mL, 5.31 mmol) was added to scavenge excess p-toluenesulfonyl chloride, during the addition a precipitate formed immediately. After stirring at RT for 30 min, the reaction was washed with 20% citric acid (20 mL) and the layers were separated. The aqueous layer was extracted with DCM (40 mL) then the combined organic layers were washed with brine (25 mL), dried over MgSO4, filtered and concentrated to dryness to provide the title compound (7e) (2.07 g, 94% yield) as a yellow solid, which was taken on without further purification. 1H NMR (400 MHz, CDCb) δ 8.21 (d, J= 7.6 Hz, 1H), 4.90 -4.69 (m, 1H), 4.55 (br. d, J = 2.8 Hz, 1H), 4.43 (br. s, 1H), 4.08 -3.84 (m, 1H), 3.15- 3.05 (m, 2H), 2.29-2.06 (m, 2H), 1.45 (s, 9H), 19F NMR (376 MHz, CDCb) δ -231.82 (s, 1F). LCMS m/z (APCI) for (CnHi2BrFN4O), 315.0 (M+HBoc)+.
Step 6: Intermediate 7
A microwave vial was charged with tert-butyl {(2R)-4-[5-(6-bromopyridin-2-yl)-1,3,4oxadiazol-2-yl]-1-fluorobutan-2-yl}carbamate (7e) (1.00 g, 2.41 mmol) and trifluoroethanol (10.4 mL, 0.17 M) and was seaied before heating in the microwave to 180 C for 30 min. LCMS analysis showed consumption of the starting material. The reaction mixture was concentrated, and the residue was purified by flash chromatography (S1O2, 100% heptane to 1:10 MeOH/EtOAc) to provide Intermediate 7 (564 mg, 78% yield) as a yellow oil. 1H NMR (400 MHz, CDCh) δ 8.40 (d, J = 7.3 Hz, 1H), 7.79-7.73 (m, 1H), 7.58 (d, J = 7.9 Hz, 1H), 5.26-5.01 (m, 2H), 4.89-4.71 (m, 1 H), 3.25 - 3.08 (m,3H), 2.96-2.85 (m, 1H). 19F NMR (376 MHz, CDCh) δ-235.95 (s, 1F). LCMS m/z (APCI) for (CnHioBrFNty 297.0 (M+H)+. Stereochemistry was assigned based on use of (5R)-5-(bromomethyl)pyrrolidin-2-one in step 1.
Intermediate 8: tert-butyl methyl({6-[(2R)-2-methyipyrrolidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-4-yl}methyl)carbamate
Step 1 : tert-butyl ({3-formyl-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridin-2yl}methyl)methylcarbamate (8a)
A solution of 2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridine-3carbaldehyde (4b) (600 mg, 1.79 mmol) and PdCb(dppf) (261 mg, 0.357 mmol) in 1,4-dîoxane (25.0 mL) was sparged with N2 for 5 min and then heated to 80 °C. A solution of {[(te/tbutoxycarbonyl)(methyl)amino]methyl}(chlondo)zinc* (0.158 M in THF, 39.6 mL) was added at 80 °C and the mixture was stirred a further 35 min at the same température. LCMS analysis showed consumption of the starting material. The mixture was cooled to 30 °C and filtered through Celite®. The filter cake was washed with DCM (5x10 mL) and the filtrate was concentrated to dryness. The residue was combined with the crude material obtained from a parallel reaction run in identical fashion with 100 mg 2-chloro-6-[(2R)-2-methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridine-321055 carbaldehyde. The mixture purified by flash chromatography (SiO2, 1:1 EtOAc/petroleum ether) to provide the title compound (8a) (900 mg, 97% yield) as a yellow gum. 1H NMR (400 MHz, DMSO-ds) δ 9.84 (s, 1H), 6.40 - 6.06 (m, 1H), 4.91 - 4.45 (m, 2H), 4.52-3.92 (m, 1H), 3.69 3.47 (m, 3H), 3.21 - 3.00 (m, 2H), 2.98-2.84 (m, 3H), 2.22- 1.82 (m, 3H), 1.83- 1.66 (m, 1H), 5 1.59 (s, 4H), 1.41 (s, 7H), 1.19 (d, J = 18.2 Hz, 8H). m/z (ESI+) for (C24H36N4O4), 445.4 (M+H)* *as prepared în: Angew. Chem. Int. Ed. 2014, 53, 2678.
Step 2: tert-butyl methyl{[3-{(E)-[(2-methylpropane-2-sulfinyi)imino]methyl}-6-[(2/?)-2methylpyrrolidin-1-yl]-4-(piperidine-1-carbonyl)pyridin-2-yl]methyl)carbamate (8b)
A mixture of tert-butyl ({3-formyl-6-[(2R)-2-methylpyrrolîdin-1-yl]-4-(piperidine~1carbonyl)pyridin-2-yi)methyl)methylcarbamate (8a) (1.40 g, 3.15 mmol), Ti(OEt)4 (1.44 g, 6.30 mmol), and (S)-(-)-2-methyl-2-propanesulfinamide (573 mg, 4.72 mmol) in THF (50.0 mL) was stirred at 50 °C for 18 h, Additional batches of Ti(OEt)4 (359 mg, 1.57 mmol) and (S)-(-)-2-methyl2-propanesulfinamide (115 mg, 0.945 mmol) were added and the mixture was stirred at 50 °C for 15 an additional 20 h. LCMS analysis showed consumption of the starting material. The reaction was quenched with a saturated solution of Na2CO3 (150 mL) and DCM (100 mL) was added. The mixture was filtered through Celite® and the layers were separated. The aqueous layer was extracted with DCM (100 mL). The combined organic layers were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated to provide the title compound (8b) (1.7 g, >99% yield) as a yellow solid. m/z (ESI+) for (C2aH45N5O4S), 548.5 (M+H)+.
Step 5: Intermediate 8
To a solution of tert-butyl methyl{[3-{(E)-[(2-methylpropane-2-sulfinyl)imino]methyl}-6[(2R)-2-methylpyrrolidin-1-yl]-4-(pipendine-1-carbonyl)pyridin-2-yl]methyl}carbamate (8b) (1.72 g. 3.41 mmol) in THF (20.0 mL) at 0 °C was added LiBH4 (68.6 mg, 3.15 mmol). The reaction was 25 stirred at 0 °C for 1 h. TLC analysis showed consumption ofthe starting material. The mixture was warmed to RT and a solution of NaOMe (30% in MeOH, 6.24 g, 34.6 mmol) was added. The mixture was stirred for 16 h. LCMS analysis showed formation of the desired product mass. The reaction was concentrated to dryness. The residue was dissolved in EtOAc (40 mL) and washed with H2O (40 mL). The aqueous layer was extracted with EtOAc (30 mL). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (S1O2, EtOAc) to provide Intermediate 8 (750 mg, 66% yield) as a white solid. 1H NMR (400 MHz, CDCb) δ 7.04-6.79 (m, 1H), 6.68 (s, 1H), 4.56-4.43 (m, 2H), 4.43-4.33 (m, 2H), 4.27-4.16 (m, 1H), 3.58 (ddd, J = 2.5, 7.3, 10.0 Hz, 1H), 3.45 5 3.30 (m, 1H), 3.01 -2.91 (m, 3H), 2.17 - 1.96 (m, 3H), 1.80 - 1.72 (m, 1H), 1.53- 1.37 (m, 9H), .26 - 1.23 (m, 3H); m/z (ESI+) for (Ci9H23N4O3), 361.2 (M+H)T
Stereochemistry was assigned based on use of (2R)-2-methyipyrrolidine in step 1 of the synthesis of Intermediate 4.
Intermediate 9: tert-butyl methyl({6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H pyrrolo[3,4-c]pyridin-4-yl}rïiethyl)carbamate
Step 1: 2-chloro-A/,/\/-dimethyl-6-[methyl(propan-2-yl)amino]pyridine-4-carboxamide (9a)
Cl 9a
A mixture of 2,6-dichloro-A/1/V-dimethylpyridine-4-carboxamide (30.0 g, 137 mmol) and N15 methylpropan-2-amine (50.1 g, 685 mmol) in MeCN (120 mL) was portioned among three sealed reaction vessels and each was stirred at 100 °C for 60 h. LCMS analysis showed consumption of the starting material. The reaction mixtures were combined and concentrated to dryness. The residue was purified by flash chromatography (SiO2, 1:1 EtOAc/petroleum ether) to provide the title compound (9a) (30.5 g, 87% yield) as a yellow solid. 1H NMR (400 MHz, CDCI3) δ 6.45 (d, J 20 = 0.9 Hz, 1H), 6.31 (d, J= 1.0 Hz, 1H), 4.82 (p, J = 6.8 Hz, 1H), 3.08 (s, 3H), 2.97 (s, 3H), 2.83 (s, 3H), 1.16 (d, J = 6.7 Hz, 6H); m/z (ESI+) for (Ci2HieCIN3O), 255.9 (M+H)+.
Step 2: 2-chloro-3-formyl-A/,/\Ldimethyl-6-[methyl(propan-2-yl)amino]pyridine-4-carboxamide (9b) Ά ° x YY γ
Y il
Cl O 9b
To a solution of DMF (21.9 g, 299 mmol) in DCE (120 mL) was added POCI3 (45.9 g, 299 25 mmol) dropwise at 5-15 °C. The mixture was stirred at RT for 15 min and 2-chloro-/V,A/-dimethyl
6-[methyl(propan-2-yl)amino]pyridine-4-carboxamide (9a) (25.5 g, 99.7 mmol) was added. The réaction was stirred at 65 °C for 16 h. LCMS analysis showed consumption ofthe starting materiai. The reaction was cooled to RT and added dropwise to saturated aqueous Na2CO3 (900 mL). The mixture was extracted with DCM (2 x 300 mL). The combined organic layers were washed with brine (5 x 500 mL), dried over Na2SO4, fîltered, and concentrated. The residue was purified by flash chromatography (SiO2, 1:1 EtOAc/petroleum ether) to provide the title compound (9b) (23.7 g, 84% yield) as a brown solid. 1H NMR (400 MHz, CDCI3) δ 10.19 (s, 1H), 6.25 (br. s, 1H), 3.12 (s, 3H), 3.02 - 2.85 (m, 3H), 2.77 (s, 3H), 1.22 (br. d, J = 6.5 Hz, 6H); m/z (ESI+) for (C13H13CIN3O2), 283.9 (M+H)+.
Step 3: 2-chloro-A/,/V-dimethyl-3-{(E)-[(2-methylpropane-2--sulfinyl)imino]methyl}-6[methyl(propan-2-yl)amino]pyridine-4-carboxamide (9c)
A mixture of 2-chloro-3-formyi-W,A/-dimethyl-6-[methyl(propam2-yl)amino]pyridine-4carboxamide (9b) (23.7 g, 83.5 mmol), (R)-(+)-2-methyl-2-propanesulfinamide (12.1 g, 100 mmol), and Ti(OEt)4 (38.1 g, 167 mmol) in THF (250 mL) was stirred at 50 °C for 20 h. LMCS analysis showed consumption of the starting materiai. The reaction was concentrated to dryness. The residue was stirred with a saturated solution of NaHCO3 (300 mL) for 30 min. The mixture was fîltered. The filter cake was rinsed with H2O (3 x 80 mL) and petroleum ether (3 x 50 mL) and dried under vacuum to provide the title compound (9c) (32.3 g, 99% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-de) δ 9.07 (s, 1H), 6.74 (s, 1H), 5.36-5.10 (m, 1H), 3.30 (s, 3H), 3.26 (s, 3H), 3.10 (s, 3H), 1.54 (d, J = 6.7 Hz, 6H), 1.49 (s, 9H); m/z (ESI+) for (Ci7H27CIN4O2S), 387.2 (M+H)+.
Step 4: 4-chloro-6~[methyl(propan-2-yl)amino]-2,3-dihydro-1/-/-pyrrolo[3,4-c]pyridin-1-one (9d)
A solution of 2-chloro-/\/,/\/-dimethyl-3-{(E)-[(2-methylpropane-2-sulfinyl)imino]methyl}-6[methyl(propan-2-yl)amino]pyrÎdine-4-carboxamide (9c) (32.3 g, 83.5 mmol) in THF (200 mL) was cooled to 0 °C and LiBH4 (1.82 g, 83.5 mmol) was added. The mixture was stirred at RT for 1 h. LCMS analysis showed consumption of the starting materiai. NaOMe (165 g, 919 mmol) was added and the mixture was stirred at RT for 16 h. The reaction mixture was fîltered and the filter cake was washed with EtOAc (3 x 200 mL). The combined filtrate was concentrated to dryness.
The residue was dissolved in DCM (300 mL) and washed with H2O (500 mL). The aqueous layer was extracted with DCM (2 x 300 mL). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated. The solid was slurried in a mixture of DCM (50 mL) and petroleum ether (120 mL) for 30 min. The solids were collected by filtration. The filter cake was dried under vacuum to provide the title compound (9d) (11.3 g, 56% yield) as an offwhite solid. 1H NMR (400 MHz, CDCI3) δ 7.19 (s, 1H), 6.79 (s, 1H), 4.82 (p, J = 6.7 Hz, 1H), 4.35 (d, J = 1.2 Hz, 2H), 2.88 (s, 3H), 1.18 (d, J = 6.7 Hz, 6H); m/z (ESI+) for (CnH14CIN3O), 239.9 (M+H)*.
Step 5: methyl 6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1 H-pyrrolo[3,4-c]pyridine-4carboxylate (9e)
A mixture of 4-chloro-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3,4-clpyridin1-one (9d) (11.3 g, 47.1 mmol), PdCI2(dppf) (2.16 g, 2.95 mmol), and TEA (14.3 g, 141 mmol) in MeOH (200 mL) was stirred at 80 °C for 40 h under an atmosphère of CO at 50 psi. TLC analysis (1:1 EtOAc/petroleum ether) showed consumption of the starting material. The reaction was concentrated to dryness. The residue was dissolved in H2O (200 mL) and extracted with DCM (2 x 150 mL). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated. The residue was slurried in DCM (50 mL) for 30 min. The solids were collected by filtration. The filter cake was washed with petroleum ether (3x5 mL) and dried under vacuum. The filtrate was purified by flash chromatography (SiO2, 40-70 % EtOAc/DCM). The product-containing fractions were concentrated to dryness and combined with the above filter cake to provide the title compound (9e) (12.3 g, 99% yield) as a yellow solid. 1H NMR (400 MHz, CDCI3) ô 7.12 (s, 1H), 6.79 (s, 1H), 4.89 (p, J = 6.6 Hz, 1H), 4.68 (d, J = 1.1 Hz, 2H), 3.97 (s, 3H), 2.96 (s, 3H), 1.21 (d, J = 6.7 Hz, 6H); m/z (ESI+) for (C13H17N3O3), 263.9 (M+H)+.
Step 6: 4-(hydroxymethyl)-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1one (9f)
To a mixture of methyl 6-[methyl(propan-2-yi)amino]-1“Oxo-2,3-dihydro-1H-pyrrolo[3,4c]pyridine-4-carboxylate (9e) (1.0 g, 3.80 mmol) in THF (60 mL) was added a solution of LÎAIH4 (2.5 M in THF, 1.67 mL, 4,18 mmol) dropwise at 0 C. The mixture was stirred at 0 °C for 1 h and then at 20 °C for 16 h. TLC analysis (1:1 EtOAc/petroleum ether) showed consumption of the starting material, The mixture was quenched by addition of 20% aqueous NaOH (0.5 mL). To the mixture was added Na2SO4 (4 g). The mixture was stirred for 30 min and then filtered. The filtrate was concentrated to dryness to provide the title compound (9f) (890 mg, 99% yield) as a yellow solid. ήΗ NMR (400 MHz, CDCI3) δ 7,04 (s, 1H), 6.82 (s, 1 H), 4.85 (p, J = 6.6 Hz, 1H), 4,67 (d, J = 4.7 Hz, 2H), 4.33 (s, 2H), 4.09 (t, J = 4.6 Hz, 1H), 2.92 (S, 3H), 1.20 (d, J = 6.7 Hz, 6H); m/z (ESI+) for (C12Hi7N3O2), 236.0 (M+H)+.
Step 7: {6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl}methyl methanesutfonate (9g)
To a mixture of 4-(hydroxymethyl)~6-[methyl(propan-2-yl)amino]-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-1-one (9f) (890 mg, 3.78 mmol) and TEA (957 mg, 9.46 mmol) in THF (20.0 mL) was added MsCI (953 mg, 8.23 mmol) dropwise at 0 °C under an atmosphère of N2. The mixture was stirred at 0 °C. LCMS analysis showed consumption of the starting material. The réaction was diluted with saturated aqueous Na2CO3 (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to provide the title compound (9g) (1.2 g, 99% yield) as a yellow solid, which was taken on without further purification, m/z (ES1+) for (Ci3HigN3O4S), 314.0 (M+H)+.
Step 8: 4-[(methylamino)methyl]-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1/7-pyrrolo[3,4c]pyndin-1-one (9h)
To a mixture of {6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-cjpyridin4-yl}methyl methanesulfonate (9g) (1,18 g, 3.78 mmol) in THF (20.0 mL) was added a solution of methylamine (2.0 M in THF, 37.8 mL, 75.6 mmol). The mixture was stirred for 1 h. LCMS analysis indicated consumption of the starting material. The mixture was concentrated to dryness to provide the title compound (9h) (940 mg, 99% yield) as a brown solid, which was taken on without further purification, m/z (ESI+) for (C13H20N4O), 249.0 (M+H)+.
Step 9: Intermediate 9
To a solution of 4-[(methylamino)methyl]-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1/-/pyrrolo[3,4-c]pyridin-1-one (9h) (940 mg, 11.4 mmol) and TEA (1.15 g, 11.4 mmol) in DCM (20.0 mL) was added Boc2O (1.65 mg, 7.57 mmol). The mixture was stirred for 30 min. LCMS analysis 5 showed consumptîon of the starting material. The reaction was concentrated to dryness. The residue was purified by flash chromatography (SiO2, EtOAc) to provide Intermediate 9 (600 mg, 46% yield) as a yellow solid. Ή NMR (400 MHz, CDCh) δ 6.81 (s, 1H), 6.57-6.42 (m, 1H), 4.91 (p, J = 6.6 Hz, 1H), 4.48 (s, 2H), 4.35 (d, J = 12.4 Hz, 2H), 2.92 (s, 3H), 2.88 (s, 3H), 1.48 (s, 5H), 1.41 (s, 4H), 1.17 (d, J = 6.7 Hz, 6H); m/z (ESI+) for (C1SH23N4O3), 349.2 (M+H)+.
Intermediate 10: (S,S)-2-methyl-N-[(1f?)-1-{6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-4-yl}propyl]propane-2-sulfinamide
Step 1: 6-[methyl(propan-2-yf)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-4-carbonitrile
Y θ 'Y
CN iûa
A mixture of 4-chloro-6-[methyl(propan-2-yl)amino]-2I3-dihydro-1H-pyrrolo[3,4-c]pyridin1-one (9d) (706 mg, 2.95 mmol), Zn(CN)2 (519 mg, 4.42 mmol), DMF (10 mL) and Pd(PPh3)4 (170 mg, 0.147 mmol) was heated to 140 aC in the microwave for 30 min. The reaction was diluted with DCM and filtered. The filter cake was washed with DCM. The filtrate was concentrated in vacuo to provide the title compound (10a) as a yellow solid (544 mg, 80% yield) which was used without further purification. 1H NMR (400 MHz, DMSO-d6) 9.01 (s, 1H), 7.13 (s, 1 H), 4.80 (td, J =6.7, 13.4 Hz, 1H), 4.47 (s, 2H), 2.89 (s, 3H), 1.15 (d, J = 6.7 Hz, 6H); m/z (APC l+) for (C12H14N4O), 231.2 (M+Hf.
Step 2: 6-[methyl(propan-2-yl)amino]-4-propanoyl-2,3-dihydro-1 H-py rro lo[3,4-c] py rid i n-1 -one (10b)
A suspension of 6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1/-/-pyrrolo[3,4c]pyridine-4-carbonitrile (10a) (511 mg, 2.22 mmol) in THF (20.0 mL) was cooled to 0 °C and then treated with a solution of ethylmagnesium bromide (3.0 M in Et2O, 7.40 mL, 22.2 mmol). The 5 mixture was stirred at RT for 1 h. LCMS analysis showed consumption ofthe starting material. The reaction was cooled to 0 °C and quenched by addition of saturated NH4CI (60 mL) and then extracted with DCM (2 x 80 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (24 g SiO2, 0-100% EtOAc/heptane) to provide the title compound (10b) (125 mg, 22% yieid) as a yellow foam, m/z 10 (APCI+) for (C14Hi9N3O2), 262.2 (M+H)+,
Step 3: Intermediate 10
To a solution of 6-[methyi(propan-2-yl)amino]-4-propanoyl-2,3-dihydro-1H-pyrrolo[3,4c]pyridin-1-one (10b) (124 mg, 0.475 mmol) in THF (6.0 mL) were added (S)-(-)-2-methyl-2propanesulfinamide (92 mg, 0.759 mmol) and Ti(OEt)4 (433 mg, 1.90 mmol). The mixture was 15 stirred at reflux for 42 h, LCMS analysis showed consumption of the starting material. The mixture was cooled to -78 °C and then treated dropwise with a solution of L-selectride (1.0 M in THF, 1.9 mL, 1.90 mmol). The mixture was stirred at -78 'C for 4 h. The mixture was quenched with MeOH, diluted with brine (30 mL), and extracted with DCM (20 x 2 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 20 chromatography (12 g SiO2, 0-10% MeOH/DCM) to provide Intermediate 10 (72 mg, 41% yieid) as a yellow solid. ηΗ NMR (400 MHz, DMSO-Λ) δ 8.67 (s, 1H), 6.64 (s, 1H), 5.25 (d, J = 6.7 Hz, 1H), 4.94 (quin, J = 6.7 Hz, 1H), 4.34 (s, 2H), 4.21 (q, J = 6.7 Hz, 1H), 2.84 (s, 3H), 1.98 - 1.80 (m, 2H), 1.13 (dd, J = 3.6, 6.7 Hz, 6H), 1.06 (s, 9H), 0.83 (t, J = 7.3 Hz, 3H). m/z (APCI+) for (Ci8H3oN402S), 367.2 (M+H)*. Stereochemistry was assigned based on use of (S)-(-)-2-methyl25 2-propanesulfinamide in step 2.
Intermediate 11: terf-butyl {[6-(dimethylamino)-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4yl]methyl}methylcarbamate
Step 1: 2-chloro-6-(dimethylamino)-A/,/V-dimethylpyridîne“4-carboxamide (11a)
ci 11a
To a 3.0 L round-bottom flask charged with methyl 2,6-dichloropyridine-4-carboxylate (58.0 g, 281 mmol) under an atmosphère of N2 was added N,ΛΖ-dimethylamine (38.1 g, 845 mmol) at 0-10 °C. THF (200 mL) was added. A solution of /-PrMgCI (2.0 M in THF, 352 mL, 704 mmol) was added over 3 h, maintaining the reaction température at 0-10 °C. The reaction was stirred a further 10 min at 0 °C and then at 25 °C for 18 h. LCMS analysis showed consumption of the starting material. The reaction was cooled in an ice bath and quenched by addition of cold saturated aqueous NH4CI (500 mL), maintaining the reaction température <20 C. EtOAc (500 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (500 mL). The combined organic layers were washed with brine, dried over Na2SO4, fîltered, and concentrated. The résultant oil was taken up in heptane (200 mL) and concentrated on a rotary evaporator until solids formed. The suspension was stirred for 0.5 h and the solids were collected by filtration. The filter cake was washed with hexanes (3 x 50 mL). The fiiter cake was slurried in 1:20 EtOAc/petroleum ether (100 mL) and the solids were collected by filtration. The filter cake was washed with 1:20 EtOAc/petroleum ether (3 x 30 mL) and then dried under vacuum to provide the title compound (11a) (51 g, 80% yield) as a light-yellow solid. Ή NMR (400 MHz, CDCh) δ 6.49 (d, J =0.7 Hz, 1 H), 6.35 (d, J = 0.9 Hz, 1H), 3.13-3.09 (m, 9H), 2.98 (s, 3H); m/z (ESI+) for (CwHmCINsO), 227.9 (M+H)+.
Step 2: 2-chloro-6-(dimethylamino)-3-formyl-/V,/\/-dimethylpyridine-4-carboxamide (11b)
Cl o 11b
Two sets of reactions were run in parallel. To a round-bottom flask containing DMF (250 mL), with stirring, was added POOL (85.9 g, 560 mmol) at 15-25 °C. The mixture was stirred at
15-25 °C for 15 min and then 2-chloro-6-(dÎmethylamino)-/V,A/-dimethylpyridtne-4-carboxamide (11a) (25.5 g, 112 mmol) was added. The mixture was stirred at 50 °C for 16 h. LCMS analysis showed consumption of the starting material. The two reactions were combined and then quenched by slowly pouring into cold aqueous saturated Na2CO3, maintaining the pH -9. The mixture was extracted with EtOAc (4 x 1.0 L). The combined organics were washed with brine (5 x 600 mL), dried over Na2SO4, filtered, and concentrated. The crude product was combined with two additional reactions run in identical fashion with 7.5 g and 5.0 g 2-chloro-6-(dimethylamino)/V,ALdimethylpyridine-4-carboxamide. The material was taken up in EtOAc (200 mL) and slurried for 20 min. The suspension was filtered. The filter cake was washed with EtOAc (2 x 50 mL). The filter cake was slurried in 1:1 Petroleum ether/EtOAc (80 mL) for 20 min. The suspension was filtered and the filter cake was washed with 1:1 petroleum ether/EtOAc (60 mL). The filter cake was dried under vacuum. The combined filtrate was concentrated to dryness. The residue was slurried with 1:1 petroleum ether/EtOAc (100 mL) for 30 min. The suspension was filtered and the filter cake was washed with 1:1 petroleum ether/EtOAc (2 x 50 mL) and dried under vacuum. The combined dried solids were slurried in petroleum either (200 mL) for 10 min and the solids were collected by filtration. The filter cake was washed with petroleum ether (100 mL) and then concentrated under vacuum. The combined filtrate was concentrated under vacuum to -50 mL and then let stand for 2 d. The résultant solids were collected by filtration and the filter cake was washed with 3:2 petroleum ether/EtOAc (2 x 50 mL). The solids were combined to the title compound (11b) (52 g, 73% yield for the combined set of reactions) as a yellow solid. Ή NMR (400 MHz, CDCh) δ 10.21 (d, J= 0.6 Hz, 1H), 6.28 (d, J = 0.6 Hz, 1H), 3.19 (s, 6H), 3.13 (s, 3H), 2.77 (s, 3H); m/z (ESI+) for (Ο^ΗμΟΙ^Ος), 255.9 (M+H)+.
Step 3: tert-butyl {[6-(dimethylamino)-4-(dimethylcarbamoyl)-3-formylpyridin-2yl]methyl}methylcarbamate (11c)
A mixture of tert-butyl dimethylcarbamate (3.41 g, 23.5 mmol) and Ν,Ν,Ν,Νtetramethylenediamine (3.27 g, 28.2 mmol) in 135 mL THF was cooled to -55 °C under an atmosphère of N2. A solution of s-BuLi (1.4 M rn cyclohexane, 20.1 mL, 28.2 mmoL) was added slowly maintaining the solution température at less than -52 °C (internai). The mixture was stirred for an additional 30 min at -55 °C and then treated with a solution of ZnCI2 (1.9 M in 2methyltetrahydrofuran, 14.8 mL, 28.2 mmol), maintaining the reaction température at less than °C. The solution was stirred for an additional 40 min at -55 °C and then warmed to RT to provide a solution of {[(tert-butoxycarbonyl)(methyl)amino]methyl}(chlondo)zinc (c = 0.195 M). A portion ofthe pre-formed zincate solution (90.2 mL, 17.6 mmoL) wastransferred to an oven-dried 250 mL round bottom flask under an atmosphère of N2 and concentrated to dryness to provide a white foam. The flask was back-filled with N2. A separate flask was charged with 2-chloro-6(dimethylamino)-3-formyl-A/,A/-dimethyipyridine-4-carboxamide (11b) (3.0 g, 10 mmol), PdCb(dppf) (0.858 g, 1.17 mmol), 1,4-dioxane (50 mL) and H2O (0.159 g, 8.8 mmol). The suspension was transferred to the flask containing the zincate via cannulation and then the mixture was stirred at 80 °C for 80 min. LCMS showed formation of a product mass with some remaining starting material. An additional aliquot of {[(tertbutoxycarbonyl)(methyl)amino]methyl}(chlorido)zinc solution (2.0 mL) was added and the mixture was stirred at 80 °C for 20 min. No additional conversion was observed. The reaction was cooled to 0 qC and quenched by addition of saturated aqueous NH4CI (10 mL) and H2O (20 mL), The mixture was stirred at 0 °C for 20 min and then filtered through a pad of Celite®. The filtrate was extracted with EtOAc (4x). The combined organics were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (80 g SiO2, 0-100% EtOAc/heptane. The résultant white foam was triturated with MTBE and concentrated under vacuum to provide the title compound (11c) (3.8 g, 95% yield) as a light-yellow solid. ’H NMR (400 MHz, DMSO-ds) δ 9.84 (d, J = 6.8 Hz, 1H), 6.45 (s, 1H), 4.71 (s, 2H), 3.15 (s, 6H), 2.99 (s, 3H), 2.90 (s, 3H), 2.75 (s, 3H), 1.33 (d, J = 69.8 Hz, 9H); m/z (ESI+) for (Ci3H2eN4O4), 365.3 (M+H)+,
Step 4: te/f-butyl {[6-(dimethylamino)-4-(dimethylcarbamoyl)-3-{(H)-[(2-methylpropane-2sulfïnyl)imino]methyl}pyridin-2-yl]methyl}methylcarbamate (11 d)
To a solution of tert-butyl {[6-(dimethylamino)-4-(dimethylcarbamoyl)-3-formylpyridin-2yl]methyl}methylcarbamate (11c) (3.0 g, 8.0 mmol) and (R)-(+)-2-methyl-2-propanesulfinamide (1.2 g, 9.88 mmol) in THF (40 mL) was added Ti(OEt)4 (5.63 g, 24.7 mmol). The mixture was stirred at 50 °C ovemight. The reaction was cooled to RT, diluted with DCM (50 mL), and quenched by addition of a saturated solution of NaHCO3 (20 mL). The solution was vigorously stirred for 20 min and then filtered through a pad of Celite®. The Celite® was washed with DCM (3x). The combined filtrate was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (80 g SiO2, 0-100% EtOAc/heptane) to provide the title compound (11 d) (3.89 g, 97% yield) as a colorless foam. 1H NMR (400 MHz, DMSO-cfe) δ 8.39 (s, 1H), 6.46 (s, 1H), 4.77 - 4.55 (m, 2H), 3.12 (s, 6H), 2.95 (s, 3H), 2.93 (s, 3H), 2.74 (s, 3H), 1.41 (s, 4H), 1.20 (s, 5H), 1.12 (s, 9H); m/z (ESI+) for (C22H37N5O4S), 468.4 (M+H)*.
Step 5: Intermediate 11
To round-bottom flask charged with tert-butyl {[6-(dimethylamino)-4-(dimethylcarbamoyl)3-{(E)-[(2-methylpropane-2-sulfinyl)imino]methyl}pyridin-2-yl]methyl}methylcarbamate (11 d) (3.89, 8.32 mmol) under an atmosphère of N2 was added THF (42 mL). The mixture was cooled to 0 °C and then treated with a solution of LiBH4 (2.0 M in THF, 4.37 mL, 8.73 mmol). The mixture was stirred at 0 °C for 1 h and then a solution of NaOMe (25% in MeOH, 17.1 mL, 74.9 mmol) was added at the same température. The reaction was allowed to warm slowly to RT and stirred for 16 h. LCMS analysis indîcated consumption of the starting material. The mixture was diluted with DCM and washed with saturated aqueous NH4CI and brine. The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (80 g SiO2, 0-100% EtOAc/heptanes) to provide Intermediate 11 (1.7 g, 64% yield) as a colorless foam. 1H NMR (400 MHz, DMSO-cfe) δ 8.68 (s, 1H), 6.68 (s, 1H), 4.42 (s, 2H), 4.23 (s, 2H), 3.06 (s, 6H), 2.86 (s, 3H), 1.36 (m, 9H); LCMS m/z (ESI+) for (CiËH24N4O3), 321.2 (M+H)+.
Intermediate 12: 2-bromo-6-(4-propyl-4H-1,2,4-triazol-3-yl)pyridine
A mixture of /V-[(6-bromopyridin-2-yl)carbonyl]-/V,A/-dimethylhydrazonoformamide (1b) (29.0 g, 106.8 mmol) and propan-1-amine (31.6 g, 534 mmoL) in MeCN (440 mL) and acetic acid (110 mL) was stirred at 95 °C for 16 h. LCMS analysis showed consumption of the starting material. The reaction was concentrated to dryness. The residue was taken up in H2O (50 mL) and basified to pH -9 with 1 N NaOH (-500 mL). The mixture was extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated. The residue was slurried with EtOAc (50 mL) for 10 min and the solid was collected by filtration. The filter cake was washed with petroleum ether (2 x 50 mL) and dried in vacuum to provide the title compound (Intermediate 12) (21.0 g, 74% yield) as a yellow solid. Ή NMR (400 MHz, DMSO-cfe) δ 8.74 (s, 1H), 8.20 (dd, 4= 0.7, 7.8 Hz, 1H), 7.98-7.91 (m, 1H), 7.78 (dd, 4 = 0.7, 8.0 Hz, 1 H), 4.45 - 4.36 (m, 2H), 1.77 (sxt, 4 = 7.4 Hz, 2H), 0.87 (t, 4 = 7.4 Hz, 3H); m/z (ESI+) for (CioHnBrN4), 266.7 (M+H)*.
Intermediate 13: (S,S)-2-methyl-N-[(1R)-1-{6-[methyl(propan-2-yl)amino]-1-oxo-2,3dîhydro-1/-Apyrrolo[3,4-c]pyridin-4-yl}ethyl]propane-2-sulfinamide
Step 1: 4-acetyl-6-(isopropyl(methyl)amino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
Méthylmagnésium bromide (9.11 g, 76.4 mmol, 25.9 mL, 3.0 M) was added to a solution of 6-(isopropyl(methyl)amino)-1-oxo-2l3-dihydro- 1H-pyrrolo[3,4-c]pyridine-4-carbonitriie (Intermediate 10a) (1.76 g, 7.64 mmol) in THF (70 mL, c=0.11 M) at 0 °C . The mixture was stirred at this température for 10 min and then allowed to warm to RT and allowed to stir for 3 h. The mixture was then quenched with 2 M HCl (7 mL) dropwise at RT and allowed to stir for 30 min. A saturated solution of NaHCO3 (70 mL) was added to neutralize the solution and it was extracted with DCM (3 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by flash chromatography (40 g SiO2, 10-40% EtOAc/heptane) to provide the title compound (13a) as a yellow solid (553 mg, 29% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.82 (s, 1H) 7.06 (s, 1H)4.88 (br. d, J = 6.72 Hz, 1H) 4.49 (s, 2H) 2.94 (s, 3H) 2.61 (s, 3H) 1.19 (d, J = 6.60 Hz, 6H); m/z (APC1+) for (Ci3Hi7N3O2), 248.2 (M+H)+.
Step 2: Intermediate 13
A mixture of 4-acetyl·6-[methyl(pΓopan-2-yl)amino]-2,3-dihydro-1 /7-pyrrolo[3,4-c]pyridin-1 one (13a) (8.10 g, 32.75 mmol ), (S)-tert-butylsulfinamide (7.94 g, 65.5 mmol) in Ti(0Et)4 (29.9 g, 131 mmol) in THF (100 mL) under N2 was heated at 90 °Cfor72 h and the reaction was monitored by LCMS. The reaction was then cooled to 0 °C and L-selectride (1 M in THF, 131 mmol, 131 mL) was added dropwise at 0 °C. The mixture was stirred at 0 °C for 3 h. The mixture was quenched with saturated NH4CI (200 mL) and brine (200 mL) at 0-5 °C. The suspension was fîltered through a pad of Celite® and the filter cake was washed with DCM (500 mL). The filtrate layers were separated, and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layers were washed with brine (250 mL), dried over Na2SO4, fîltered and concentrated. The residue was purified by flash chromatography (SiO2, 0-10% MeOH/DCM) to provide Intermediate 13 as a yellow solid (10 g, 87%). 1H NMR (400 MHz, CDCI3) δ 6.83 (br. s, 1H), 6.75 (s, 1H), 4.89 — 4.76 (m, 1H), 4.48 -4.39 (m, 1H), 4.37-4.26 (m, 3H), 2.83 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H), 1.19 - 1.07 (m, 15H). m/z (APCI+) for (C17H2BN4O2S), 353.2 (M+H)+. Stereochemistry was assigned based on use of (S)-fert-butylsulfinamide in step 1.
Intermediate 14: (S,R)-2-methyl-N-[(1S)-1-{6-[(2R)-2-methylpyrrolidin-1-yi]-1-oxo-2,3-dihydro1/-Lpyrrolo[3,4-c]pyridin-4-yl}ethyl]propane-2-sulfinamide
A mixture of 4-acety[-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro~1H-pyrrolo[3,4-c]pyridin1-one (4f) (4000 mg, 15.43 mmol), (R)-2-methylpropane-2-sulfinamide (2240 mg, 18.5 mmol) in Ti(OEt)4 (20 mL) was stirred at 100 °C for 20 h under N2. LCMS analysis showed consumption of the starting material. The yellow solution was cooled to 0 °C and was diluted with THF (50 mL). L-Selectride (38.6 mmoi, 38.6 mL, 1M in THF) was added dropwise at 0 °C. The mixture was then stirred at 10 °C for 20 h. LCMS showed starting material remaining. Additional L-Selectride (38.6mmol, 38.6 mL 1M in THF) was added dropwise at 0 C and the mixture was stirred at 10 °C for an additional 2 h. TLC analysis showed consumption ofthe starting material. The mixture was quenched with saturated aqueous NH4Cl (200 mL) at 0-5 °C. The suspension was filtered through a pad of Celite® and the cake was washed with EtOAc (2 x 50 mL). The filtrate layers were separated, and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated to provide a residue. The residue was first purified by flash chromatography (SiO2, EtOAc/MeOH = 10:1) and then further purified by prep HPLC (ACSSH-CA; Method column: YMC Triart C18 250*50mm*7pm; water (0.05% ammonia hydroxide v/v)-ACN to provide Intermediate 14 (2.5 g, 44%) as an off-white solid. Ή NMR (400 MHz, CDCh) δ 6.70 (s, 1 H), 6.47 (br. s, 1 H), 4.57 - 4.34 (m, 4H), 4.20 (br. t, 7=5.9 Hz, 1H), 3.64-3.53 (m, 1H), 3.47-3.35 (m, 1H), 2.20-1.99 (m, 3H), 1.77 (br. dd, J = 2.5, 4.7 Hz, 1 H), 1.64 (d, J = 6.5 Hz, 3H), 1.28 (d, J = 6.2 Hz, 3H), 1.22 (s, 9H). m/z (ESI) for (CisHaa^OzS), 365.1 (M+H)+. Stereochemistry was assigned based on use of (R)tert-butylsulfinamide.
Intermediate 15: tert-butyl {2-methoxy-1-[6-(1-methylcyc!opropyl)-1-oxo-2,3-dihydro-1Hpyrro!o[3,4-c]pyridin-4-yt]ethyl}carbamate
V 0 ^ÇdNH Boc
H
Step 1: ethyl 3-cyano-2-hydroxy-6~(1-methylcyclopropyl)pyridine-4-carboxylate (15a)
V7 0 ^YY^OEt N γΟΝ
OH 15a
A mixture of 2-cyanoacetamide (10.0 g, 119 mmol) and TEA (12.0 g, 119 mmol) in EtOH (50 mL) was heated to 65 °C (internai température) until the solids dissolved and then ethyl 3-( 1 methylcyclopropyl)-3-oxopropanoate (24.6 g, 124 mmol) was added. The mixture was stirred at 65 °C for 2 h. TLC analysis (1:10 EtOAc/petroleum ether) showed consumption ofthe starting material. The reaction was cooled to 10 °C. The résultant precipitate was collected by filtration. The filter cake was washed with MTBE (3 x 10 ml) and dried under vacuum. The fîltrate was concentrated to dryness. EtOH (10 mL) was added and then MTBE (30 mL) was added. The résultant solids were collected by filtration. The filter cake was washed with EtOH (5 mL) and MTBE (2x10 mL) and dried under vacuum. The solids were combined to provide the title compound (15a) (25.0 g, 85% yield) as a yellow solid. Ή NMR (400 MHz, DMSO-ds) δ 12.74 (br. s, 1H), 6.63 (br. s, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.45 - 1.27 (m, 6H), 1.16-1.06 (m, 2H), 0.92 0.75 (m, 2H).
Step 2: ethyl 2-chloro-3-cyano-6-(1-methytcyclopropyl)pyridine-4-carboxylate (15b)
To a solution of ethyl 3-cyano-2-hydroxy-6-(1-methylcyclopropyl)pyridine-4-carboxylate (15a) (24.0 g, 97.5 mmol) in MeCN (487 mL) was added POCI3 (74.7 g, 487 mmol) dropwise at 30 °C. The mixture was stirred at 65 °C for 60 h. TLC analysis (EtOAc) showed consumption of the starting material. The solution was concentrated to remove residuai POCI3. The residue was poured onto ice and basified with a saturated solution of NaHCO3 to pH ~ 8. The mixture was extracted with EtOAc (2 x 100.mL). The combined organic layers were dried over Na2SO4, fïltered, and concentrated. The residue was purified by flash chromatography (1:10 EtOAc/petroleum ether) to provide the title compound (15b) (21.9 g, 85% yield) as a light yellow solid. 1H NMR (400
MHz, CDCb) δ 7.79 (s, 1H), 4.50 (q, J = 7.2 Hz, 2H), 1.55 (s, 3H), 1.50-1.40 (m, 5H), 1.03 (q, J = 3.9 Hz, 2H); m/z (ESI+) for (C13Hi3CIN2O2), 264.9 (M+H)*.
Step 3: 4-chloro-6-(1-methylcyciopropyl)-2,3-dihydro-1H-pyrroio[3,4-c]pyridin-1-one (15c)
Cl 15c
To a solution of ethyl 2-chloro-3-cyano-6-(1-methylcyclopropyl)pyridine-4-carboxylate (15b) (2.5 g, 9.44 mmol) in EtOH (500 mL) was added Raney Ni (2.0 g 34.1 mmol). The black mixture was stirred at 30 °C under an atmosphère of H2 at 30 psi for 48 h. TLC analysis (1:10 EtOAc/petroleum ether) showed consumption of the starting material, The mixture was filtered through a pad of Celite®. The filter cake was washed with MeOH (250 mL). The combinée! fîltrate was concentrated to dryness. The residue was slurried in EtOAc (5 mL) for 20 min and the suspension was filtered, The filter cake was washed with EtOAc (2 mL) and dried under vacuum to provide the title compound (15c) (1.1 g, 52% yield) as a grey solid. 1H NMR (400 MHz, CDCb) δ 7,66 (br. s, 1H), 7.23 - 7.05 (m, 1H), 4.56-4.34 (m, 2H), 1.55 (br. s, 3H), 1.39-1.11 (m, 2H), 0.99 - 0.66 (m, 2H); m/z (ESI+) for (C11H11CIN2O), 222.8 (M+H)+.
Step 4: Intermedîate 15
A 40 mL vial was charged with 4-chloro-6-(1-methylcyclopropyl)-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-1-one (15c) (200 mg, 0,898 mmol), Cs2CO3 (644 mg, 1.98 mmol), N-(tertbutoxycarbonyl)-O-methylserine (394 mg, 1.80 mmol), NiCb glyme (39.5 mg, 0.18 mmol), pyridine-2-yl-A/-cyanoamidine (26.3 mg, 0.180 mmol), iridium(lll) bis[2-(2,4-difluorophenyî)-5methyipyridine]-4,40-dî-tert-butyl2,20-bipyridine hexafluorophosphate (18.2 mg, 0,018 mmol) and anhydrous DMF (27 mL), The mixture was sparged with N2 for 2 min and irradiated with 365 nM light at 15-25 °C for 18 h (fan speed 5200 r/min, stir rate 1200 r/min, 100% LED). The mixture was concentrated and purified by flash chromatography (SiO2, 10-20% [0% MeOH in EtOAc] in Petroleum ether) to provide a yellow solid. Purification by prep. HPLC (Column: YMC Trîart C18 150*25pm*5pm, water (0.05% ammonia hydroxide v/v)-CAN) provîded Intermedîate 15 as a white solid (315 mg, 32%). 4H NMR (400 MHz, CDCb) δ 7.65 (s, 1H), 6.77 (s, 1H), 5.66 (d, J = 8.0 Hz, 1 H), 4.94 (d, J = 6.3 Hz, 1 H), 4.63 - 4.48 (m, 2H), 3.77 (dd, J = 8.9, 5.0 Hz, 1 H), 3.58 3,44 (m, IH), 3.26 (s, 3H), 1.62 (s, 3H), 1.45 (s, 9H), 1.30 (q, J = 3.6 Hz, 2H), 0.88 (q, J = 3.4 Hz, 2H); m/z (ESI+) for (Ci9H27N3O4), 362.3 (M+H)+.
Examples:
The Exemples prepared herein hâve stereochemistry assigned based on use of intermediates with confirmed stereochemistry, e.g., Examples 1 and 2, or based on the use of intermediates prepared from stereospecifîc starting materials, e.g., Examples 3 and 4.
Exemple 1: 4-[(1R)-1-aminopropyl]-2~{6-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol·3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyΓrolidin-1-yl]-2,3-dihydro-1H-pyrΓolo[3,4c]pyridin-1-one
Step 1 : (S,S)-2-methyl-N-[(1 R)-1-(2-{6-[(5S)-5-methyl-6,7-dihydro-5H-pyrroîo[2,1-c][1,2,4]triazol3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yî]-1-oxo-2,3-dihydro-1/7-pyrrolo[3,4-c]pyridin-4yl)propy[]propane-2-sulfinamîde
A mixture of (S,S)-2-methyl-W-[(1R)-1-{6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro1 /-/-pyrrolo[3,4-c]pyridin-4-yl}propylJprûpane-2-suîfinamide (Intermediate 5) (63.0 mg, 0.17 mmol), (5S)-3-(6-bromopyridin-2-yl)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole (Intermediate 2) (147 mg, 0.528 mmol), K3PO4 (336 mg, 1.59 mmol), Pd2(dba)3 (30.4 mg, 0.0528 mmol) and XantPhos (61.1 mg, 0.106 mmol) in 1,4-dioxane (4.5 mL, c=0,1 M) was heated at 100 °C (block temp) in 40 mL vial (capped) for 18 h. The mixture was fîltered through Celite®, washed with DCM. The filtrate was concentrated in vacuo and the crude compound was purified by flash chromatography (SiO2, 0-10% MeOH/DCM) to provide the title compound as pale yellow color foam (194 mg, 64% yield). m/z (APCI+) for (C29H4oN302S), 577.3 (M+H)+.
Step 2: Example 1
A solution of 4 N HCl in 1,4-dioxane (1.01 mmol, 0.252 mL, 4 M) was added to a suspension of (S,S)-2-methyl-N-[(1R)-1-(2-{6-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrrofo[3,4-c]pyridin-4-yl)propyl]propane-2-sulfinamide (194 mg, 0.336 mmol) in MeOH (12 mL).
The resulting mixture was stirred at RT for 2 h. The volatiles were removed under reduced pressure. The crude product was purified by Chiral SFC (Phenomenex Lux Cellulose-1 4.6 x 100mm 3pm column 30% MeOH + 10 mM NH3 in CO2 @ 120 bar, 4 mL/min) to provide Example 1 (146 mg, 92% yield, >99% de) as pale yellow color solid. 1H NMR (600 MHz, DMSO-de) δ 8.48 (d, J=8.3 Hz, 1H), 8.01 (t, J = 8.0 Hz, 1H), 7.91 (d, J= 7.7 Hz, 1H), 6.67 (s, 1H), 5.22-5.03 (m, 3H), 4.33-4.21 (m, 2H), 3.60 - 3.50 (m, 1H), 3.41 - 3.32 (m, 1H), 3.06 - 2.98 (m, 1H), 2.97 2.89 (m, 1H), 2.88-2.76 (m, 1H), 2.37 - 2.27 (m, 1H), 2.09- 1.86 (m, 5H), 1.69-1.62 (m, 1H), 1.44 (d, J = 6.4 Hz, 3H), 1.15 (d, J = 6.2 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H); m/z (APCI+) for (C26H32N3O), 473.2 (M+H)+; [a]D22 = +37.0° (c=0.1 M, MeOH).
Table 4 provides single crystal X-ray diffraction data confirming the stereochemistry of Example 1. The single crystal X-ray diffraction studies were carried out on a Bruker Microstar APEX II CCD diffractometer equipped with Cu Ka radiation (λ =1.54178 A). Crystals of Example 1 were grown from acetonitrile/pentane. A 0.25 x 0.2 x 0.15 mm piece of a coîorless crystal was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using φ and en scans. Crystal-to-detector distance was 40 mm and exposure time was 2, or 10 seconds depending on the 2Θ range per frame using a scan width of 1.00°. Data collection was 99.4% complété to 67.679° in Θ. The data were integrated using the Bruker SAINT Software program and sealed using the SADABS software program. Solution by direct methods (SHELXT) produced a complété phasing model consistent with the proposed structure. Ail nonhydrogen atoms were refined anisotropically by fuil-matrix least-squares (SHELXL-2014). Ail carbon bonded hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the approprîate HFIX command in SHELXL-2014.
Table 4 | |
Empirical formula: | C31 H45 Ng O2 |
Molecular weight | 561.75 |
Température | 100.0 K |
Wavelength | 1.54178 A |
Crystal System | Orthorhombic |
Space group | P2,2i2i |
Unit cell dimensions: | a = 6.7104(13) A a= 90°. |
b = 15.482(3) A β= 90°. | |
C = 30.288(6) A y = 90° | |
Volume | 3146.6(11) A3 |
Z | 4 |
Density (calculated) | 1,186 Mg/m3 |
Absorption coefficient | 0.611 mm’1 |
F(000) | 1212 |
Crystal size
Thêta range for data collection Index ranges Reflections collected Indépendant reflections Completeness to thêta = 67.679° Absorption correction Max. and min. transmission Refinement method
Data / restreints / parameters Goodness-of-fit on F2 Final R indices [l>2sigma(l)J R indices (ail data)
Absolute structure parameter Largest diff. peak and hole
0.25 x 0.2 x 0.15 mm3
2.918 to 68.067°.
_7<=h<=7, -18<=k<=18, -36<=l<=36 27016
5698 [R(int) = 0.0296]
99.4 %
Semi-empirical from équivalents 0.5201 and 0.4162
Full-matrix least-squares on F2 5698 / 1 /389 1.067
R1 = 0.0726, wR2 = 0.2035
R1 = 0.0768, wR2 = 0.2088 -0.10(10)
0.630 and -0.318 e.A'3
Example 2: 4-[(1R)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-cl[1,2,4]triazol-3yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
H2N
Step 1: (S,S)-N-[(1R)-1-(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1I2,4]triazol-3-yl]pyridin2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)ethyl]-2methylpro pane-2-sulfinamide
To a mixture of (S,S)-2-methyl-N-[(1R)-1~{6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3dihydro-1/-/-pyrrolo[3,4-c]pyridin-4-yl}ethyl]propane-2-sulfinamide (Intermediate 4) (50 mg, 0.14 mmol), (5S)-3-(6-bromopyridin-2-yl)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1 -c][ 1,2,4]tnazole (Intermediate 3) (42.2 mg, 0.144 mmol), and K3PO4 (87.4 mg, 0.412 mmol) m 1,4-dioxane (3 mL) was added Pd2(dba)3 (12.6 mg, 0.014 mmol) and XantPhos (15.9 mg, 0.027 mmol) under Nz. After addition, the mixture was bubbled with N2 for 2 min. The resulting mixture was sealed and stirred at 85 °C for 18 h. The reaction mixture was concentrated in vacuo, and the residue was purified by flash chromatography (SiO2, 10% EtOAc/MeOH) to provide the title compound (60 mg, 76% yieid) as a yellow solid. ’H NMR (400 MHz, CDCI3) b 8.70 (d, J = 8.2 Hz, 1H), 8.18 (d, J = 7.4 Hz, 1H), 7.93 (t, J = 8.0 Hz, 1H), 6.76 (s, 1H), 5.11 -5.02 (m, 2H), 4.99 - 4.93 (m, 1H), 4.61 -4.49 (m, 2H), 4.34-4.27 (m, 1H), 3.67 - 3.57 (m, 1H), 3.46-3,35 (m, 1H), 3.11-3.01 (m, 3H), 2.65 (td, J= 3.7, 7.9 Hz, 1H), 2.19-2.08 (m, 3H), 2.07 (s, 1H), 1.86-1.79 (m, 1H), 1.79 (br. d, J = 2.3 Hz, 1H), 1.69 (d, J = 6.4 Hz, 3H), 1.31 - 1.28 (m, 3H), 1.22 (s, 9H), 1.02 (t, J = 7.5 Hz, 3H); m/z (ESI+) for (CaoH^NaCqS), 577.5 (M+H)+; [a] D22 = +85.3° (c=0.1 M, MeOH).
Step 2: Example 2
To a solution of(S,S)-N-[(1R)-1-(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro~1Hpyrrolo[3I4-c]pyridin-4-yl)ethyl]-2-methylpro pane-2-sulfinamide (60 mg, 0.10 mmol) in EtOAc (5mL) was added dropwise 4 M HCl in EtOAc (3 mL) at 0 “C. The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated in vacuo. To the residue was added EtOAc (10 mL) and water (10 mL). The aqueous layer was basified with saturated NaHCO3 and extracted with DCM (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was iyophilized for 16 h to provide Example 2 (47 mg, 95%) as pale yellow color solid. 1H NMR (400 MHz, DMSO-ds) δ 8.59 (d, J = 8.3 Hz, 1H), 8.09-8.02 (m, 1H), 8.02-7.97 (m, 1H), 6.58 (s, 1H), 5.33 (d, J = 17.1 Hz, 1H), 5.10 (d, J= 17.1 Hz, 1 H), 4.99 (br. t, J =6.1 Hz, 1 H), 4.29 - 4.19 (m, 1H), 4.12 (q, J = 6.9 Hz, 1H), 3.55 (br. t, J = 8.0 Hz, 1H), 3.04-2.85 (m, 3H), 2.58-2.55 (m, 1H), 2.11 - 1.96 (m, 4H), 1.79 - 1.66 (m, 2H), 1.36 (d, J = 6.5 Hz, 3H), 1.24 - 1.20 (m, 3H), 0,93 (t, J = 7.4 Hz, 3H); m/z (ESI+) for (C26H32N8O), 473.4 (M+H)+.
Example 3: 4-[(1S)-1-amînoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
Step 1: (S,R)-N-[(1S)-1-(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyndin2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)ethyl]-2methylpro pane-2-sulfinamide
To a suspension of (S,R)-2-methyl-A/-[(1S)-1-{6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3dihydro-1H-pyrrolo[3,4-c]pyrïdin-4-yl}ethyl]propane-2-sulfinamide (Intermedîate 14) (2000 mg, 5.487 mmol), (5S)-3-(6-bromopyndin-2-yl)-5-ethyl-6T7-dihydro-5H-pyrrolo[2,1-c|[1,2,4]triazole (Intermedîate 3) (1610 mg, 5.49 mmol) and K3PO4 (3490 mg, 16.5 mmol) in 1,4-dioxane (30 mL), Pd2(dba)3 (502 mg, 0.549 mmol) and XantPhos (635 mg, 1.10 mmol) were added under N2, After 10 addition, the mixture was bubbled with Argon for 2 min. The resulting mixture was sealed and allowed to stir at 85 °C for 18 h. TLC analysis showed consumption ofthe starting material. The mixture was diluted with H2O (100 mL) with stirring and the résultant suspension was filtered. The aqueous fîltrate was separated. The solid was washed with DCM (100 mL). The organic layer was dried over NasSCu, filtered and concentrated to provide a yellow residue (3 g) which was purified 15 by flash chromatography (SiO2, 0-10% MeOH in EtOAc) to provide a yellow solid. The solid was dissolved in DCM (50 mL) and silica-SH (4 g) was added. The yellow mixture was refluxed for 20 min. The mixture was filtered, and the filter cake was washed with DCM/MeOH (10:1). The fîltrate was concentrated. The treatment with silica-SH was repeated three additional times to provide the title compound (2,3 g, 72.7%) as a yellow solid. Ή NMR (400 MHz, CDCb) δ 8.71 (dd, J = 20 0.7, 8.4 Hz, 1H), 8.18 (dd, J = 0.7, 7.6 Hz, 1H), 7.97-7.87 (m, 1H), 6.76 (s, 1H), 5.19-5,11 (m,
1H), 5.03-4.94 (m, 2H), 4.65-4.57 (m, 1H), 4.57-4.51 (m, 1H), 4.24 (br t, J= 6.1 Hz, 1H), 3.66 - 3.56 (m, 1H), 3.48 - 3.39 (m, 1H), 3.13 - 2.98 (m, 3H), 2.71 - 2.59 (m, 1H), 2.21 - 2.03 (m, 4H), 1.87- 1.75 (m, 2H), 1.68 (d, J = 6.5 Hz, 4H), 1.30 (d, J =6.2 Hz, 3H), 1.24 (s, 9H), 1.02 (t, J = 7.5 Hz, 3H), m/z (ESI) for (C3oH4oN302S), 577.5 (M+H)+.
Step 2: Example 3
To a solution of (S,R)-N-[(1S)-1-(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2-methytpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-4-yl)ethyl]-2-methylpro pane-2-sulfinamide (2300 mg, 3.988 mmol) in EtOAc (10 mL) was added 4M HCl in EtOAc (20 mL) at 0 °C. After addition, the mixture was stirred at 15 30 °C for 1 h. The reaction was monitored by LCMS. The resulting yellow suspension was concentrated to provide a residue which was dissolved in H2O (30 mL) and extracted with EtOAc (25 mL). The aqueous layer was basified with a solution of saturated NaHCCh to pH ~ 8 and extracted with DCM (3 x 35 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to provide a solid to which DCM (50 mL) was added. The solution was filtered through glass microfiber filter GF/F (—0.7 pm) four times. The filtrate was concentrated to provide a yellow solid which was purified by prep. HPLC (Column: Agela DuraShell C18 150*40mm*5pm, water (0.05% ammonia hydroxide v/v)-CAN, Gradient Time 12 min, Flow Rate 25 mL/min). This provided Example 3 (1.5 g, 79.6%) as a yellow solid. 1H NMR (400 MHz, DMSO-de) δ 8.55 (d, J = 8.0 Hz, 1H), 8.08 - 7.90 (m, 2H), 6.51 (s, 1H), 5.26 (d, J = 16.8 Hz, 1H), 5.08-4.92 (m, 2H), 4.23 (br. t, J= 5.8 Hz, 1H), 4.09 (q, J= 6.5 Hz, 1H), 3.53 (br. t, J = 7.5 Hz, 1H), 3.30- 3.23 (m, 1H), 3.07-2.83 (m, 3H), 2.62-2.53 (m, 1H), 2.16- 1.85 (m, 6H), 1.77 - 1.64 (m, 2H), 1.33 (d, J = 6.5 Hz, 3H), 1.21 (d, J = 6.0 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H). m/z (ESI) for (C26H32NSO), 473.4 (M+H)+.
Example 4: 4-[(1R)-1-aminoethyl]~2-{6-[(5S)-5-ethyl-6,7-dihydro-5/-/-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
Step 1: (S,S)-N-[(1/:?)-1-(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin2-yl}-6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridîn-4-yl)ethyl]-2methylpropane -2-sulfinamide
A solution of (S,S)-2-methyi-N-[(1R)-1-{6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro1 H-pyrrolo[3,4-c]pyridin-4-yl}ethyl]propane-2-sulfinamide (Intermediate 13) (627 mg, 1.78 mmol), (5S)-3-(6-bromopyridin-2-yl)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole (Intermediate 3) (521 mg, 1.78 mmol), K3PO4 (1.13 g, 5.34 mmol), Pd2(dba)3 (102 mg, 0.178 mmol) and XantPhos (206 mg, 0.356 mmol) in 1,4-dioxane (17.8 mL, c=0.1 M) was heated at 100 °C in a 100 mL flask with condenser under N2 for 18 h. The mixture was cooled to RT, filtered and washed with DCM (20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (24 g, SiO2, 0-10% MeOH/DCM) to provide the title compound as a pale-yellow color solid (808 mg, 80%). m/z (APCI+) for (C^H^NgOjS), 565.3 (M+H)+.
Step 2: Example 4
A 4 N solution of HCI in 1,4-dioxane (1.07 mL, 4.29 mmol) was added to a solution of (S,S)N-[(1R)-1-(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)ethyl]-2methylpropane-2-$ulfinamide (808 mg, 1.43 mmol) in MeOH (14.3 mL, c=0.1 M). The mixture was stirred at RT for 2 hr. The volatile materials were removed under reduced pressure. The crude product was purified by Chiral SFC (Phenomenex Lux Cellulose-1 21 x 250 mm column, 30% MeOH + 10mM NH3 in CO2 held at 120 bar, 100 mL/mîn) to provide Example 4 (345 mg, 52% yield, >99% de, >99% pure) as pale yellow color solid. ήΗ NMR (400 MHz, DMSO-cfe) δ 8.56 (dd, J = 1.0, 8.1 Hz, 1H), 8.07-8.01 (m, 1H), 8.00-7.93 (m, 1H), 6.78 (s, 1H), 5.34 - 5.28 (m, IH), 5.17-5.10 (m, 1H), 5.02-4.95 (m, 1H), 4.89 (td, J = 6.7, 13.4 Hz, 1H), 4.18 (q, J = 6.7 Hz, 1H), 3.01 -2.94 (m, 2H), 2.93 (s, 3H), 2.62 - 2.54 (m, 2H), 2.09 - 1.97 (m, 1H), 1.84 - 1.72 (m, 1H), 1.41 (d, J = 6.6 Hz, 3H), 1.20 (d, J = 6.6 Hz, 6H), 0.92 (t, J = 7.5 Hz, 3H); m/z (APCI+) for (C25H32N8O), 461.3 (M+H)*. [a]D22 = +120.5° (c=0.1 M, MeOH).
Example 5: 4-[(1 R)-1-aminopropyi]-2-{3-[(5S)-5-methyl-6,7-dihydro-5/-/-pyrrolo[2,1c][1,2,4]triazol-3-yl]phenyl}-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1/7-pyrrolo[3,4-c]pyridin-1-
Step 1 : (S,S)-2-methyl-N-[(1R)-1-(2-{3-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol3-yl]phenyl}-6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrroio[3,4-c]pyridin-4yl)propyl]propane-2-sulfinamide
A mixture of (SJS)-2-methyl-/\/-(1-{6-[methyl(propan-2-yl)amino]-1-oxo-2I3-dfhydro-1Hpyrrolo[3,4-c]pyridin-4-yl}propyl)propane-2-sulfinamide (Intermediate 10) (63 mg, 0.17 mmol), (5S)-3-(3-bromophenyl)-5-methyl-6,7-dihydro-5H-pyrroîo[2,1-c][1,2,4]triazole (Intermediate 2) (48 mg, 0.172 mmol), K3PO4 (109 mg, 0.516 mmol), Pd2(dba)3 (9.88 mg, 0.0172 mmol) and XantPhos (19.9 mg, 0.0344 mmol) in 1,4-dioxane (4.5 mL, c=0.1 M) was heated at 100 °C in a 40 mL vial (capped) for 18 h. The volatiles were removed under reduced pressure. The residue was purified by flash chromatography (12 g, SiO2, 0-10% MeOH/DCM) to provide the title compound as a pale-yellow color foam (74.0 mg, 76%). m/z (APCI+) for (C29H4oN802S), 565.3 (M+H)+.
Step 2: Example 5
A 4 N solution of HCl in 1,4-dioxane (0.164 mL, 0.655 mmol) was added to a solution of (S,S)-2-methyl-/\/-[(1R)-1-(2-{3-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2I1-c][1,2,4]triazol-3yl]phenyl}-6-[methyl(propan-2-yi)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4yl)propyl]propane-2-sulfinamîde (74 mg, 0.13 mmol) in MeOH (5.0 mL, c=0.026 M). The mixture was stirred at RT for 2 h. The volatiles were removed under reduced pressure. The crude product was purified by Chiral SFC (Phenomenex Lux Cellulose-1 4.6 x 100mm 3pm column 5-60% MeOH + 10 mM NHs in CO2 ramping over 3.0 minutes @ 120 bar, 4 mL/min) to provide Example 5 (11.6 mg, 19% yield, >99% de, >95% pure) as pale yellow color solid. ’H NMR (600 MHz, DMSO-de) δ 8.54 (d, J = 8.3 Hz, 1H), 8.35 (br. s, 2H), 8.07 (t, J = 8.0 Hz, 1H), 8.00-7.90 (m, 1H), 6.91 (d, J = 0.9 Hz, 1H), 5.27-5.07 (m, 3H), 5.01 (br. s, 1H), 4.37 (br. s, 1H), 3.14-2.97 (m, 2H), 2.94 (d, J = 1.5 Hz, 3H), 2.92-2.85 (m, 1H), 2.42-2.35 (m, 1H), 2.06-1.91 (m, 2H), 1.50 (d, 4=6.1 Hz, 3H), 1.19 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H); m/z (APCI+) for (C25H32N8O), 461.3 (M+H)+. [a]D22 = +75.9° (c=0.2 M, MeOH).
Example 6: 4-[(^)-1-amino-2-methoxyethyl]-6-(1-methylcyclopropyl)-2-{6-[(5S)-5-methyl-6,7dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1F/-pynrolo[3,4-c]pyndin-1one Example 6(a) Example 6(b)
Stereochemistry of 6a and 6b is arbitrarily depicted with the understanding that the two isomers were separated (see description preceding intermediates section).
Step 1: tert-butyl {2-methoxy-1-[6-(1-methylcyclopropyl)-2-{6-[(5S)-5-methyl-6(7-dihydro-5/7pyrrolo[2I1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-1-oxo-2,3-dîhydro-1H-pyrroio[3,4-c]pyridin-4yl]ethyl}carbamate
A solution of tert-butyl {2-methoxy-1-[6-(1-methylcyclopropyl)-1-oxo-213-dihydro-1Hpyrrolo[3,4-c]pyridin-4-yl]ethyl}carbamate (Intermediate 15) (136 mg, 0,376 mmol), (5S)-3-(6bromopyfidin-2-yl)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole (Intermediate 2) (105 mg, 0.376 mmol), K3PO4 (240 mg, 1.13 mmol), and 1,4-dioxane (12 mL) was bubbled with nitrogen for 2 min, To this mixture was added Pd2(dba)3 (34.5 mg, 0.038 mmol) and XantPhos (43.5 mg, 0.075 mmol). The reaction was heated to 85 °C and was allowed to stir at this température for 18 h. The reaction was cooled and combined with an identical reaction run on a 43 mg scale (Intermediate 15). The combined mixture was concentrated and purified via flash chromatography (SiO2, 10:1 EtOAc/MeOH) followed by prep. TLC (SiO2, 10:1 EtOAc/MeOH) to provide the title compound as a yellow solid (170 mg, 61%). Ή NMR (400 MHz, CDCh) δ 8.67 (dd, J = 12.2, 8.3 Hz, 1H), 8.20
- 8.10 (m, 1H), 8.01 -7.84 (m, 1H), 5.66 (d, J = 8.0 Hz, 1H), 5.35 - 5.11 (m, 3H), 5.03 (d, J = .7 Hz, 1H), 3.60 - 3.46 (m, 2H), 3.27 (d, J = 8.5 Hz, 3H), 3.16 - 2.94 (m, 4H), 2.50 (d, J = 8,7 Hz, 2H), 2.39 (s, 2H), 1.71 (s, 3H), 1.43 (s, 9H), 1.33 (q, J- 2.3 Hz, 2H), 0.92 (t, J = 2.6 Hz, 2H). m/z (ESI) for (C30H37N7O4), 460.2 (M+H)+.
Step 2: Example 6
To a solution of ferf-butyl {2-methoxy-1-[6-(1-methylcyclopropyl)-2-{6-[(5S)-5-methyl-6,7dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-1-oxo-2,3-dihydro-1H-pyrrolo[3,4c]pyridin-4-yl]ethyl}carbamate (170 mg, 0.304 mmol) in DCM (5 mL) was added dropwise a 4 M solution of HCl in EtOAc (3 mL) at 0 °C. The reaction was stirred at 20 °C for 1 h and was then concentrated. The resulting residue was diluted with H2O (15 mL) and was basified to pH ~8 with a solution of saturated NaHCO3. The mixture was extracted with DCM (3x8 mL) and the combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to provide a yellow solid. The resulting solid was purified via prep. SFC (column: Daicel Chiralpak 250mm*30mm*10pm, 0.1% NH3*H2O EtOH) to provide:
The first-eluting isomer as Example 6a (30 mg, 21%). Ή NMR (400 MHz, DMSO-cfe) δ 8.56 (d, J = 7.9 Hz, 1H), 8.08 (t, J = 7.8 Hz, 1H), 7.99 (d, J = 7.8 Hz, IH), 7.57 (s, 1H), 5.48(d, J = 18.1 Hz, 1H), 5.30 (d, J= 18.1 Hz, 1H), 5.12 (br. t, J = 6.5 Hz, 1H), 4.30 (t, J= 6.3 Hz, 1H),3.65
-3.52 (m, 2H), 3.30-3.26 (m, 3H), 3.13-2.86 (m, 3H), 2.40 (br. dd, J = 8.4, 11.9 Hz, 3H),1.59
- 1.52 (m, 6H), 1.31-1.24 (m, 2H), 0.89 (d, J = 2.9 Hz, 2H). m/z (ESI) for (C25H29N7O), 560.3 (M+H)+. [a] D22 = +66.Γ (c=0.1 M, MeOH).
The second-elutîng isomer as Example 6b (33 mg, 23%). 1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 7.9 Hz, 1H), 8.07 (t, J = 7.9 Hz, 1H), 7.99 (d, J =7.3 Hz, 1H), 7.55 (s, 1H), 5.44 (d, J = 18.1 Hz, 1H), 5.31 (d, J = 18.1 Hz, 1H), 5.16 (br. t, J = 6.6 Hz, 1H), 4.29 (t, J = 6.4 Hz, 1H), 3.55 (d, J =6.4 Hz, 2H), 3.25 (s, 3H), 3.13-2.86 (m, 3H), 2.40(br. dd, 4=8.2, 11.6 Hz, 1H), 2.12 (br. s, 2H), 1.59 - 1.48 (m, 6H), 1.30 - 1.23 (m, 2H), 0.88 (d, J=3.1 Hz, 2H). m/z (ESI) for (C25H2SN7O)t 560.2 (M+H)+. [a] D22 = +41.5°.
Additional compounds of the invention were prepared by modifications of the methods exemplified herein and are presented in Tables 5, 6, and 7. Except where otherwise indicated, ail compounds having chiral carbons were prepared and/or isolated as a single enantiomer as depicted in the structure. Chirality is further indicated by the compound name which désignâtes spécifie stereochemistry as (R) or (S) for each chiral carbon. When ail chiral carbons are so designated as known stereochemistry, the stereochemîstry is based on the use of known chiral starting materials and/or confirmation of resolved enantiomers through X-ray crystallography. Some compounds were prepared from racemic intermediates and resolved into single enantiomers by an appropriate chiral préparative SFC method. Where stereochemistry is not known but enantiomers are separated, “or1, or “or2 is at the chiral carbon atom. In the name, the carbon with the resolved but not confirmed stereochemical center, is îdentified with the symbol “ξ.” The bond drawn at that carbon is a représentation ofthe stereochemistry; meaning, the carbon would hâve that bond configuration drawn (solid wedge) or the opposite configuration (hashed wedge). See, e.g., Examples 101 and 102. When obtained, the optical rotation (aD22 or aD20) is provided after the IUPAC name, provided simply as a.
100
Table 5
Ex # | Structure | IUPAC Name, and rotation | LRMS (m/z) (Nl+H)+ A | 1H NMR |
7 (F)* | , l JÛL rA P~\ J ' / N ^=/ J H2N | 4-[(1R)-1aminoethyl]-2{6-[(5R)~5ethyl-6,7dihydro-5Hpyrrolo[2,1C][1,2,4]triaZOl3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = -144.8° | 473.2 | 5H NMR (400 MHz, DMSO-A) δ 8.58 (dd, J = 0.9, 8.2 Hz, 1H), 8.078.01 (m, 1H), 8.00-7.96 (m, 1H), 6.55 (s, 1H), 5.30 (d, J= 16.9 Hz, 1H), 5.06 (d, J = 16.9 Hz, 1H), 5.00 (br. t, J =6.1 Hz, 1H), 4.23 (br. t, J =5.9 Hz, 1H), 4.11 (q, J = 6.6 Hz, 1H), 3.54 (br. dd, J = 7.5, 9.7 Hz, 1H), 3.02-2.89 (m, 3H), 2.57 (br. d, J= 11.4 Hz, 1H), 2.15-1.89 (m, 5H), 1.77-1.66 (m, 2H), 1.33 (d, J -6.7 Hz, 3H), 1.22 (d, J = 6.2 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). |
8 (F)* | / ^ΥΟ-γΧ ôyy Cb 2........ HjN | 4-[(1S)-1amînoethyl]-2- {6-[(5R)-5ethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol· 3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = -99.9° | 473.3 | 1H NMR (400 MHz, DMSO-d6) 6 8.58 (d, J = 7.5 Hz, 1H), 8.10-8.02 (m, 1H), 8.01 -7.95 (m, 1H), 6.57 (s, 1H), 5.31 (d, J= 17.1 Hz, 1H), 5.09 (d, J = 16.8 Hz, 1H), 4.98 (br. s, 1 H), 4.24 (br. t, J = 6.0 Hz, 1H), 4.11 (q, J = 6.7 Hz, 1H), 3.60-3.52 (m, 1 H). 3.03-2.86 (m, 3H), 2.57 (br. d, J= 11.5 Hz, 1H), 2.17-1.89 (m, 5H), 1.801.66 (m, 2H), 1.36 (d, J = 6.8 Hz, 3H), 1.21 (d, J = 6.3 Hz, 3H), 0.93 (t, J= 7.4 Hz, 3H). |
9 (F)* | , ι Γ1 04^0 Vf HaN | 4-[(1R)-1aminopropyl]2-{6-[(5R)-5methyl-6,7dihydro-5Hpyrrolo[2,1cHI^^Jtriazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one | 473.2 | Ή NMR (400 MHz, DMSO-de) δ 8.51 (dd, J = 07, 8.3 Hz, 1H), 8.087.96 (m, 1H), 7.93-7.84 (m, 1H), 6.53 (s, 1H), 5.35 - 5.00 (m, 3H), 4.18 (quin, J = 6.3 Hz, 1H), 3.93 (br. s, 1H), 3.49 (ddd, J = 2.4, 7.3, 9.8 Hz, 1H), 3.102.78 (m,4H), 2.37-2.30 (m, 1H), 2.04-1.87 (m, 3H), 1.74 (dt, J = 7.0, 13.8 Hz, 1H), 1.67-1.56 (m, 2H), 1.44 (d, J =6.4 Hz, |
101
a =-125.4° | 3H), 1.15 (d, J = 6.2 Hz, 3H), 0.84 (t, J =7.4 Hz, 3H). | |||
10 (F)* | , i jCl / TA AA A\^\ 9 / N N \ )......m' h2» | 4-[(1S)-1aminopropyi]2-{6-[(5ξ)-5methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazoi3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yi]-2,3dihydro-1/-/pyrrolo[3,4c]pyridin-1-one a = +28.8° | 473.2 | Ή NMR (600 MHz, DMSO-de) δ 8.52 - 8.43 (m, 1H), 8.04-7.97 (m, 1H), 7.90 (d, J= 7.7 Hz, 1H), 6.70-6.60 (m, 1H), 5.22 - 5.13 (m, 1H), 5.11 5.00 (m, 2H), 4.31 -4.19 (m, 2H), 3.57-3.51 (m, 2H), 3.09-2.89 (m, 2H), 2.87-2.74 (m, 1H), 2.382.21 (m, 1H), 2.11 - 1.87 (m, 5H), 1.73 - 1.61 (m, 1 H), 1.44 (d, J = 6.4 Hz, 3H), 1.20-1.11 (m, 3H), 0.86 (t, 4=1 A Hz, 3H). |
11 (F)* | , i II / A AA CAŒ Ύ/ N\ / or^v^ HjN | 4-[(1S)-1aminopropyl]2-{6-[(ξ)-5methy!-6,7dihydro-5Hpyrroio[2,1c][1,2,4jtriazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dthydro-1Hpyrroio[3,4c]pyndin-1-ûne a = -117.6° | 473.7 | 1H NMR (600 MHz, DMSO-de) Ô 8.47 (d, J = 8.3 Hz, 1H), 8.06-7.93 (m, 1H), 7.90-7.82 (m, 1H), 6.55 (s, 1H), 5.305.13 (m, 1H), 5.09-5.02 (m, 2H), 4.22 (br. s, 1H), 4.03-3.89 (m, 1H), 3.54 3.49 (m, 2H), 3.07-2.97 (m, 2H), 2.93 (qd, 7=8.8, 12.2 Hz, 2H), 2.83 (dd, 4 = 8.9, 15.1 Hz, 1H), 2.382.29 (m, 1H), 2.06-1.95 (m, 2H), 1.94 - 1.88 (m, 1H), 1.87- 1.79 (m, 1H), 1.74 (td, 7=6.7, 13.5 Hz, 1H), 1.65 (d, J= 2.2 Hz, 1H), 1.45 (d, 7= 6.4 Hz, 3H), 1.13 (d, 7= 6.2 Hz, 2H), 0.83 (t, 7 =7.3 Hz, 2H). |
12 (F)* | i n / JA AA A\^w, \ryj L/ / \=T MJ HSN | 4-[(1R)-1aminoethyl]-2- {6-[(5R)-5ethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6[methyl(propan -2-yl)amino]2,3-dihydro- 1 H-pyrroio[3,4c]pyridin-1-one | 461.2 | IH NMR (600 MHz, DMSO-d6) δ 8.74 (s, 1 H) 8.62 (d, 7= 8.25 Hz, 1 H) 8.10 (t, 4 = 8.17 Hz, 1 H) 8.01 (d, 4 = 7.70 Hz, 1 H) 6.71 (s, 1 H) 5.17 (s, 2 H) 4.49-4.61 (m, 4 H) 4.34 (br. s, 1 H) 3.61 -3.63 (m, 2 H) 2.55 (br. s, 1 H) 2.02 - 2.13 (m, 2 H) 1.95-2.02 (m, 1 H) 1.82 - 1.93 (m, 2 H) 1.64- 1.80 (m, 1 H) 1.52 (br. d, 7=6.05 Hz, 3 H) 1.29-1.40 (m, 1 H) |
102
a = -86.9° | 1.11-1.28 (m, 4 H) 0.880.98 (m, 3 H). | |||
13 (H* | l iX f / N N \ OA A N—\ / ^A h2n | 4-[(1 R)-V aminopropyl]2-{6-[(5ξ)-5ethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dfhydro-1/7pyrro1o[3,4c]pyridin-1-one a = +48.Γ | 487.2 | Ή NMR (400 MHz, DMSO-ds) δ 8.62 - 8.52 (m, 1H), 8.10-8.02 (m, 1H), 8.01 -7.89 (m, 1H), 6.63 (s, 1H), 5.29 (d, J = 16.6 Hz, 1H), 5.08 (d, J = 16.8 Hz, 1H), 5.04-4.89 (m, 1 H), 4.33-4.20 (m, 1H), 4.06-3.92 (m, 1H), 3.65-3.52 (m, 1H), 3.473.36 (m, 1H), 3.00-2.92 (m, 3H), 2.66-2.55(m, 1H), 2.17-2.07 (m, 2H), 2.04-1.94 (m,2H), 1.921.71 (m,4H), 1.26 (d, J = 6.1 Hz, 3H), 0.98-0.88 (m, 6H). |
14 (F)* | i jOl / A. OX /AO f / N N \ ÔhXa \.......H N--x / orf\^A m2n | 4-[(1R)-1aminopropyi]2-{6-[(5ξ)-5ethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol· 3-yl]pyridin-2- yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dîhydro-1Hpyrrolo[3,4c]pyridin-1-one a = -108.8° | 487.2 | Ή NMR (400 MHz, DMSO-de) δ 8.62 - 8.52 (m, 1H), 8.10-8.02 (m, 1H), 8.01 -7.89 (m, 1H), 6.63 (s, 1H), 5.29 (d, J = 16.6 Hz, 1H), 5.08 (d, J = 16.8 Hz, 1H), 5.04 — 4.89 (m, 1 H), 4.33 — 4.20 (m, 1H), 4.06-3.92 (m, 1H), 3.65-3.52 (m, 1H), 3.473.36 (m, IH), 3.00-2.92 (m, 3H), 2.66-2.55 (m, 1 H), 2.17 - 2.07 (m, 2H), 2.04-1.94 (m, 2H), 1.921,71 (m, 4H), 1.26 (d, J = 6.1 Hz, 3H), 0.98-0.88 (m, 6H). |
15 (F)* | , v ίΊ / /X XX a\ a> f / Ν h Ό \ \ /X * X / ori\A Y-mur h2m | 4-[(1S)-1aminopropyl]2-{6-[(5ξ)-5ethyl-6,7dihydro-SHpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrro!o[3,4c]pyfidin-1-one a = -139.5° | 487.2 | M NMR (600 MHz, DMSO-d6) δ 8.54 - 8.46 (m, 1H), 8.02-7.95 (m, 1H), 7.93-7.83 (m, 1H), 6.49 (s, 1H), 5.24-5.12 (m, 1H), 4.98 (d, J= 16.5 Hz, 1H), 4.88 (br. s, 1H), 4.18 (br. s, 1H), 3.48 (br. s, 1 H), 2.99-2.77 (m, 4H), 2.57-2.46 (m, 1H), 2.081.87 (m, 4H), 1.80-1.72 (m, 1H), 1.72-1.53 (m, 3H), 1.21 -1.11 (m, 4H), 0.90-0.78 (m,6H). |
103
16 (F)* | O 00 | O to. to ' / N^Z7 | 4-[(1S)-1aminopropyl]2-{6-[(5ξ)-5- ethyl-6,7- dihydro-5H- | 487.2 | 1H NMR (600 MHz, DMSO-de) δ 8.56 - 8.46 (m, 1H), 8.04-7.95 (m, 1H), 6.50 (S, 1H), 5.31 - 5.13 (m, IH), 4.93 (d, J = |
HjN | pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one | 15.4 Hz, 2H), 4.19 (br. s, 1H), 3.48 (br. s, 2H), 2.97 -2.78 (m, 4H), 2.50 (d, J = 11.0 Hz, 1H), 2.09-1.86 (m, 4H), 1.78-1.69 (m, 1H), 1.68- 1.50 (m, 3H), 1.17-1.10 (m, 4H), 0.86 (t, J =7.2 Hz, 3H), 0.81 (t, J = 6.4 Hz, 3H). | |||
a = +52.4° | |||||
17 (H) | O M HjN ' | Cl L/ llim*·—·£ J | 4-(2aminopropan2-yl)-2-{6- [(5S)-5-methy l6,7-dfhydro- 5H-pyrrolo[2,1c][1,2,4]triazû!3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidÎ n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one | 473.1 | Ή NMR (400 MHz, DMSO-ds ) δ 8.62 (d, J = 8.1 Hz, 1H), 8.41 (br. s, 3H), 8.14-8.07 (m, 1H), 8.07-8.02 (m, 1H), 6.76 (s, 1H), 5.45 (d, J = 16.3 Hz, 1H), 5.27-5.16(m, 2H), 4.39 (br. d, J = 2.0 Hz, 1H), 3.72-3.61 (m, 1H), 3.18-3.08 (m, 1H), 3.072.91 (m, 2H), 2.42 (br. d, J = 6.4 Hz, 1H), 2.13-1.98 (m, 3H), 1.76-1.67 (m, 7H), 1.53 (d, J =6.5 Hz, 3H), 1.20 (d, J=6.2 Hz, 3H); |
18 (J)* | o 00/ HaN | n to. ^^to. -N X T5^ \ ' Z N ^/7 ^0TT\^J | 4-[(1ξ)-1aminoethyl]-2{6-[(5R)-5(fluoromethyl)6,7-dihydro5H-pyrrolo[2,1- c][1,2,4]triazol3-yl]pyridin-2y!}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = +23.8° | 477.4 | 1H NMR (400 MHz, DMSO-de) δ 8.58 (d, J = 8.0 Hz, IH), 8.43-8.33 (m, 3H), 8.11 (t, J = 7.9 Hz, IH), 8.02 (d, J = 7.8 Hz, 1H), 6.73 (s, 1H), 5.425.31 (m, 1H), 5.24 (d, J = 16.5 Hz, 1H), 5.11 -4.99 (m, 2H), 4.92-4.86 (m, 1H), 4.63-4.55 (m, 1H), 4.40-4.33 (m, 1H), 3.663.60 (m, 1H), 3.11 -2,91 (m, 3H), 2.78 - 2.69 (m, 1H), 2.53-2.52 (m, 1H), 2.15-1.96 (m, 3H), 1.781.70 (m, 1H), 1.56 (d, J = 6.7 Hz, 3H), 1.22 (d, J = 6.1 Hz, 3H). |
104
19 (J)* | i jCï i A- W N ρΗ^Ο f L/ jj----/ Χζΐιιΐ'Ύ 1 orl).......... H2N | 4-[(1ξ)-1aminoethyl]-2{6-[(5R)-5(fluoromethyl)6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2/?)-2methylpyrroiidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one α = -3.1° | 477.0 | 1H NMR (400 MHz, DMSO-de) δ 8.63 (d, J = 8.0 Hz, IH), 8.56-8.43 (m, 3H), 8.15-8.04 (m, 2H), 6.73 (s, 1H), 5.535.36 (m, 1H), 5.08-5.00 (m, 2H), 4.97-4.88 (m, 1H), 4.69-4.61 (m, 1H), 4.37 (br. s, 1H), 3.673.62 (m, 1H), 3.45-3.37 (m, 1H), 3.13-2.95 (m, 3H), 2.79-2.72 (m, 1H), 2.14-1.96 (m, 3H), 1.791.70 (m, 1H), 1.56 (d, J = 6.5 Hz, 3H), 1.20 (d, J = 6.3 Hz, 3H). |
20 (J? | v jC1 / Ύ YY / / M hJ \ —\ z?—\ / 1 /N \-/ hû /'p / »=/ / ........\ J h2n | 4-[(1R)-1aminopropyl]2-{6-[(5R)-5( hydroxy methyl )-6,7-dihydro5H-pyrroio[2,1c][1,2,4]trrazol3-yl]pyridin-2- yl}-6- [methyl(propan -2-yl)aminoj2,3-dihydro- 1 H-pyrrolo[3,4c]pyridin-1-one | 477.2 | dH NMR (400 MHz, DMSO-d6) δ 8.57 (d, J = 7.9 Hz, 1H), 8.06 (t, J = 8.0 Hz, 1H), 7.98 (d, J =7 A Hz, 1H), 6.74 (s, 1H), 5.28 (d, J- 17.1 Hz, 1H), 5.07 (d, J = 17.1 Hz, 1H), 5.044.98 (m, 1H), 4.98-4.89 (m, 1H), 3.91 -3.83 (m, 3H), 3.02-2.82 (m, 6H), 2.77-2.69 (m, 1H), 1.77 (br. d, J = 7.2 Hz, 1H), 1.71 - 1.59 (m, 1H), 1.15 (d, J = 6.6 Hz, 6H), 0.89 (t, J =7.4 Hz, 3H). |
21 (F)* | ο ί| Z /ΥΛ· L> \y-J HjN | 4-[(1R)-1aminoethyl]-2- {6-[(5S)-5methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6- [methyi(propan -2-yl)amino]- 2,3-dihydro1H-pyrrolo[3,4c]pyridin-1-one | 446.6 | 1H NMR (600 MHz, DMSO-dg) δ 8.44 - 8.51 (m, 1H) 7.96 (t, J = 8.20 Hz, IH) 7.88 (br. d, J = 6.60 Hz, 1H) 6.64 (br. s, 1H) 5.28 (br. d, J= 16.69 Hz, 1H) 5.10 (br. d, J = 16.32 Hz, 1H) 5.04 (br. s, 1H) 4.84 (br. s, 2H) 2.97 3.04 (m, 2H) 2.87-2.95 (m, 2H) 2.80-2.83 (m, 3H) 2.27-2.37 (m, 2H) 1.42 - 1.56 (m, 3H) 1.261.42 (m, 3H) 1.09 (br. d, J = 4.77 Hz, 6H). |
22 (H) | z Il —-z Ώ g τ y----ùj z | 4-(2aminopropan2-yl)-6- (dimethylamino )-2-{6-[(5ξ)-5methy 1-6,7dihydro-5Hpyrroio[2,1c][1,2,4]triazol- | 433.2 | 1H NMR (600 MHz, DMSO-de) δ 8.50 (d, J = 8.4 Hz, 1H), 8.02-7.93 (m, 1H), 7.91 -7.83 (m, 1H), 6.68 (s, 1H), 5.47 — 5.24 (m, 2H), 5.12-5.01 (m, IH), 3.03 (s, 6H), 3.01 -2.96 (m, 1H), 2.95-2.86 (m, 1H), 2.85-2.78 (m, |
105
3-yl]pyridin-2yl}-2,3-dihydro1H-pyrrolo[3,4c]pyridin-1-one a = +80.7° | 1H), 2.31 (dd, J = 8.3, 12.3 Hz, 1H), 1.44 (d, 4=6.4 Hz, 3H), 1.42 (s, 3H), 1.40 (s, 3H). | |||
23 (H) | 1 O. / N \ \ /V j t / \/ y—1 p N^=\ h2n L | 4-(2aminopropan2-yl)-6- (di methyl amino )-2-{6-[(5ξ)-5methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-2,3-dihydro- 1 H-pyrrolo[3,4c]pyridin-1-one a = -64.6° | 433.2 | ’H NMR (600 MHz, DMSO-d6) δ 8.50 (d, 4 = 8.4 Hz, 1H), 8.02-7.94 (m, 1H), 7.90 (d, 4=7.7 Hz, 1 H), 6.69 (s, 1H), 5.49 -5.23(m,2H), 5.06 (quin, 4=6.5 Hz, 1H), 3.03 (s, 6H), 3.02-2.97 (m, 1H), 2.91 (qd, 4 = 8.8, 12.4 Hz, 1H), 2.85-2.79 (m, 1H), 2.31 (dd, 4 = 8.3, 11.9 Hz, 1H), 1.44 (d,4=6.4Hz, 3H), 1.43 (s, 3H), 1.41 (s, 3H). |
24 (F)* | , i XZ / ?V W yVa A-TU L/ M^=/ |Lh‘ié. 1 x or2\^^ oiy- H2N | 4-[(1ξ)-1aminoethyl]-2{6-[(5ξ)-5methy 1-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yÎ]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = 140.8° | 459.2 | ’H NMR (400 MHz, DMSO-Λ) δ 8.57 (dd, 4 = 0.7, 8.3 Hz, 1H), 8.108.03 (m, 1H), 7.97 (dd, 4 = 0.7, 7.6 Hz, 1H), 6.59 (s, 1H), 5.35 (d, 4= 17.1 Hz, 1H), 5.22-5.10 (m, 2H), 4.56 (s, 1H), 4.29-4.21 (m, 1H), 4.19-4.11 (m, 1H), 3.61 -3.50 (m, 1H), 3.16-2.81 (m, 4H), 2.442.31 (m, 2H), 2.11 -2.01 (m, 2H), 1.99- 1.93 (m, 1H), 1.74-1.67 (m, 1H), 1.53 (d, 4 = 6.6 Hz, 3H), 1.40 (br. d, 4 = 6.4 Hz, 3H), 1.25 - 1.18 (m, 3H). |
25 (F)* | , i iV / ,Y yY. <z\ .- « f / N \ r \ / C J ' / f \—T y—J «γ 14 \ orl)— H^N | 4-[(1ξ)-1aminoethyl]-2- {6-[(5ξ)-5methyl-6,7dihydro-5Hpyrrolo(2,1c][1,2,4]triazol· 3-yl]pyridin-2- yl}-6-[(2R)-2methylpyrrolidi n-1-yi]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = +46.6° | 459.2 | ’H NMR (400 MHz, DMSO-de) δ 8.56 (d, 4 = 7.9 Hz, 1H), 8.05 (t, 4 = 7.6 Hz, 1H), 7.97 (d, 4=7.1 Hz, 1H), 6.58 (s, 1H), 5.38 -5.29 (m, 1H), 5.22-5.07 (m, 2H), 4.55 (s, 1H), 4.29 -4.13 (m, 2H), 3.54 (br. d, 4 = 2.4 Hz, 2H), 3.13 — 2.79 (m, 4H), 2.43-2.30 (m, 1H), 2.11 -2.02 (m, 2H), 1.98-1.93 (m, 1H), 1.73-1.63 (m, 1H), 1.51 (d, 4=6.6 Hz, 3H), 1.39 (d, 4 = 6.6 Hz, 3H), 1.20 (d, 4 = 6.1 Hz, 3H). |
106
26 (F)* | , i ίύ / A-s A^yJ L/ ^-sZ \.-—-/ ΙΜΙ1·^ l QFp......Hl1 h2n | 4-[(1ξ)-1aminQethyl]-2{6-[(5ξ)-5methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin~2- yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1H* pyrrolo[3,4c]pyridin-1-one a = -94.9° | 459.2 | 1H NMR (400 MHz, DMSO-dg) δ 8.58 (dd, J = 0.7, 8.3 Hz, IH), 8.098.02 (m, 1H), 8.00-7.96 (m, 1H), 6.59 (s, 1H), 5.39 -5.30 (m, 1H), 5.23-5.11 (m, 2H), 4.56 (s, 1H), 4.24 (br. d, J= 5,4 Hz, 2H), 3.64 -3.50 (m, 1H), 3.14-2.84 (m, 4H), 2.43-2.28 (m, 2H), 2.13-2.03 (m, 2H), 1.97 (br. s, 1H), 1.71 (br. d, J = 2.2 Hz, 1H), 1.52 (d, J = 6,4 Hz, 3H), 1.39 (br. d, J = 6.4 Hz, 3H), 1.22 (d, J = 6.1 Hz, 3H). |
27 (F)* | chY ri ory.......... H/J | 4-[(1ξ)-1aminoethyl]-2{6-[(5ξ)-5methyl-6,7dihydro-5Hpyrrolo[2,1c](1,2,4]triazol· 3-yt]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = + 17.4° | 459.2 | 4H NMR (400 MHz, DMSO-Λ) ô 8.58 (d, J = 8.1 Hz, 1H), 8.09-8.03 (m, 1H), 7.99-7.95 (m, 1H), 6.57 (s, 1H), 5.375.29 (m, 1H), 5.23-5.10 (m, 2H), 4.56 (s, 1 H), 4.25 (br. s, 1H), 4.19-4.13 (m, IH), 3.56 (br. d, J=2.0 Hz, 1H), 3.15-2.84 (m, 4H), 2.42-2.30 (m, 2H), 2.122.01 (m, 2H), 1.96 (br. s, 1H), 1.74- 1.66 (m, 1H), 1.52 (d, J = 6.4 Hz, 3H), 1.37 (br. d, J =6.4 Hz, 3H), 1.21 (d, J= 6.1 Hz, 3H), |
28 (F)* | L jQ / M T5^ \ v/y γ / fj—/ n» y J h2n | 4J(1R)riaminopropyl]6(dimethylamino )-2-{6-[(5S)-5methyl-6,7dihydro-5Hpyrrolo[2,1- c][1,2,4]triazol3-yl]pyridin-2yl}-2,3-dihydro1 H-pyrroiû[3,4c]pyrîdin-1-one a = +99.9° | 433.3 | Ή NMR (600 MHz, DMSO-Λ) δ 8.47 (d, J = 8.3 Hz, 1H), 8.05-7.97 (m, 1H), 7.92 (d, J= 7.5 Hz, 1H), 6.82 (s, 1H), 5.19 -5.02 (m,3H), 4.21 (br. t, J =6.2 Hz, 1H), 3.10 (s, 6H), 3.07-2.93 (m, 3H), 2,90-2.80 (m, 1H), 2.41 2.30 (m, 1H), 2.01 - 1.82 (m, 2H), 1,46 (d, J= 6,4 Hz, 3H), 0.87 (t, J =7,4 Hz, 3H). |
29 (J? | i jd / X XK “MfyJ . M / n=/^ , .........\ J HiN | 4-[(lR)-1aminoethyl]-2{6-[(5R)-5(f lu orom ethyl) 6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2- | 465.2 | 1H NMR (400 MHz, DMSO-ds) δ 8.58 (d, J = 8.19 Hz, 1H), 8.07-8,13 (m, 1H), 8.00-8.06 (m, 1H), 6.92 (s, 1H), 5.29 — 5.38(m, 1H), 5,18-5.26 (m, 1 H), 4.96-5.05 (m, 3H), 4.85-4.90 (m, 1H), |
107
yl}-6- [methyl(propan -2-yl)amino]2,3-dihydro1 H-pyrrolo[3,4- clpyridin-Lone | 4.48-4.60 (m, 1H), 3.003.07 (m, 2H), 2.93-2.96 (m, 3H), 2.69-2.81 (m, 3H), 2.20-2.34 (m, 1H), 1.55 (d, J = 6.72 Hz, 3H), 1.15-1.19(m, 6H). | |||
30 (J)* | , i jQ f / N N r5^ a CMV a H N=/ xm>.....< j HjN | 4-[(1R)-1aminoethyl]-2{6-[(5R)-5(hydroxymethyl )-6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2- yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dîhydro-1 Hpyrrolo[3,4c]pyridîn-1-one a = +50.8° | 475.2 | Ή NMR (600 MHz, DMSO-ds) δ 8.55 (d, J = 8.3 Hz, 1H), 8.08-8.01 (m, 1 H), 7.99-7.95 (m, 1H), 6.57 (s, 1H), 5.27 (d, J = 16.9 Hz, 1H), 5.09 (d, J = 16.9 Hz, 1H), 5.04 — 4.99 (m, 1H),4.29-4.21 (m, 1 H), 4.18 (q, J = 6.3 Hz, 1H), 3.89-3.81 (m, 2H), 3.57-3.52 (m, 1H), 3.052.81 (m, 4H), 2.71 (br. dd, J = 9.4, 11.5 Hz, 1H), 2.55 -2.51 (m, 1H), 2.13-2.01 (m, 2H), 2.00-1.92 (m, 1H), 1.70 (br. dd, J = 2.4, 5.0 Hz, 1H), 1.38 (d, J = 6.6 Hz, 3H), 1.21 (d, J = 6.2 Hz, 3H). |
31 (J)* | , i jQ f / N N 1| \ Γ\—/ yJ m, N-~y \=ζ~ \.........(Jl H2M | 4-[(1R)-1aminopropyl]2-{6-[(5R)-5(hydroxymethyl )-6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one | 489.4 | Ή NMR (400 MHz, DMSO-de) δ 8.67 - 8.59 (m, 1H), 8.42 (br. s, 3H), 8.17 - 8.10 (m, 1H), 8.04 (dd, J = 0.8, 7.6 Hz, 1H), 6.74 (s, 1H), 5.25-5.10 (m, 3H), 4.42 (br. d, J =5.8 Hz, 1H), 4.33 (br. s, 1H), 3.93 (br. d, J = 2.8 Hz, 1H), 3.91 (br. d, J=2.5 Hz, 1H), 3.63-3.57 (m, 1H), 3.43 (br. d, J-9.0 Hz, 1H), 3.18 -3.06 (m, 1H), 3.03-2.91 (m, 2H), 2.82-2.72 (m, 1H), 2.14-1.92 (m, 5H), 1.74 (br. d, J=6.6 Hz, 1H), 1.22 (d, J = 6.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H); |
32 (J)* | , k/Cu. r\_xyJ . 1/ N=Z / .........\ 1 KnM | 4-[(1R)-1aminopropylj2-{6-[(5R)-5(fluoromethyl)6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-6-[(2R)-2methylpyrrolidi n-1-yl]-2,3dihydro-1H- | 491.2 | Ή NMR (400 MHz, DMSO-de) δ 8.57 (d, J = 8.31 Hz, 1H), 8.05-8.14 (m, 1H), 7.97 - 8.04 (m, 1H), 6.71 (s, 1H), 5.335.39 (m, 1H), 5.26-5.33 (m, 1H), 5.14-5.23 (m, 1H), 5.03-5.12 (m, 1H), 4.96-5.04 (m, 1 H), 4.834.92 (m, 1H), 4.29 (br. d, J = 5.87 Hz, 2H), 3.60 (br. t, J = 7.83 Hz, 1H), 3.36- |
108
pyrroio[3,4cjpyndin-1-one | 3.46 (m, 2H), 2.89-3.10 (m, 3H), 2.67-2.77 (m, 1H), 1.85-2.17 (m, 5H), 1.72 (br. s, IH), 1.21 (br. d, J = 6.11 Hz, 3H), 0.91 (br. t, J =7.27 Hz, 3H). | |||
33 (J)* | i n -x fl t N=z / 1111.....\ J HjN | 4-[(1R)-1aminopropyl]6- (dimethylamino )-2-{6-[(5R)-5(fluoromethyl)6,7-dihydro5H-pyrroio[2,1c][1,2,4]triazol· 3-yl]pyridin-2yl}-2,3-dihydrO' 1 H-pyrro!o[3,4c]pyridin-1-one a = +58.7° | 451.3 | 1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 8,3 Hz, 1H), 8.16-8.06 (m, 1H), 8,04-7.97 (m, 1H), 6,90 (s, 1H), 5,44 — 5,27 (m, 1H), 5.24-5.07 (m, 2H), 5,05-4.96 (m, 1H), 4.94-4.82 (m, 1H), 4.33-4.19 (m, 1H), 3.16 (s, 6H), 3.13-2.93 (m, 3H), 2.79 -2.62 (m, 1H), 2.07-1.79 (m, 2H), 0.90 (br. t, J =7.3 Hz, 3H). |
34 (J? | 1 JÛL / A^ \_XAJ F L/ / \=/ / ^U1......\ J HaH | 4-[(1R)-1aminopropyl]2-{6-[(5R)-5(fluoromethyl)6,7-dihydro5H-pyrroio[2,1c][1,2,4]triazol3-yl]pyridin-2y!}-6[methyl(propan “2-yl)amino]2,3-dihydro- 1 H-pyrrolo[3,4c]pyridin-1-one | 479.4 | Ή NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 8.0 Hz, 1H), 8.43 (br. s, 3H), 8.15-8.08 (m, 1H), 8.03 (d, J = 7.5 Hz, 1H), 6.93 (s, 1H), 5.44-5.28 (m, 1H), 5.21 -5.06 (m, 2H), 5.05-4.93 (m, 2H), 4.93-4.83 (m, 1H), 4.35 (br. d, J= 6.3 Hz, 1H), 3.13 -2.96 (m, 3H), 2.94 (s, 3H), 2.77-2.70 (m, 1H), 2.05-1.91 (m, 2H), 1.17 (dd, J =6.7, 15.4 Hz, 6H), 0.90 (t, J =7.4 Hz, 3H). |
35 (Jf | i £Ù A-. / N N X \ Yl Λ----Λ ί 1 , « <L/YJ , ,~γ / Ν=ζ χ.........\ J 0Γ/™\ h2n ο---- | 4-[(1ξ)-1amino-2methoxyethyl]2-{6-[(5R)-5(fluoromethyl)6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2y 1)-6-(1methylcyclopro pyl)-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = +91.2° | 478.1 | 1H NMR (400 MHz, CDCh) δ 8.70 (dd, J =0.7, 8.4 Hz, 1H), 8.20 (dd, J = 0.7, 7.6 Hz, 1H), 8.01 -7.90(m, 1H), 7.71 (s, 1H), 5.32 — 5.16 (m, 2H), 5.16-5.05 (m, 1H), 5.02-4.73 (m, 2H), 4.34 (t, J =6.5 Hz, 1H), 3.69-3.58 (m, 2H), 3.43-3.35 (m, 3H), 3.223.03 (m, 3H), 2.96-2.86 (m, 1H), 1.61 (s, 3H), 1.41 - 1.31 (m, 2H), 0.91 (q, J = 3.1 Hz, 2H). |
109
36 (F)* | kXAa z—ί\ / i /N h- / \=/ ^ιΐί......\ J or^ | 4-[(1ξ)-1aminopropyl]2-{6-[(5R)-5(hydroxymethyl )-6,7-dihydro5H-pyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2y 1)-6-(1methylcyclopro pyi)-2,3- dihydro-1 Hpyrrolo[3,4c]pyridin-1-one a = +152.9° | [M+Na] *482.1 | Ή NMR (400 MHz, DMSO-cfe) 6 8.59 -8.52 (m, 1H), 8.10-8.03 (m, 1H), 8.01 -7.96 (m, 1H), 7.53 (s, 1H), 5.39 (d, J = 18.0 Hz, 1H), 5.18 (d, J = 18.0 Hz, 1H), 5.06-4.97 (m, 1H), 4.00 (t, 4= 6.6 Hz, 1H), 3.87 (d, 4=3.6 Hz, 2H), 3.07-2.81 (m, 3H), 2.77-2.69 (m, 1H), 1.85 1.73 (m, 1H), 1.71 - 1.61 (m, 1H), 1.56 (s, 3H), 1.31 - 1.22 (m, 2H), 0.92-0.81 (m, 5H). |
37 (F)* | Z Τ·Γ \ —ri J i , n 5AA A / N=z ..........\ J ΟΓ7^\ HjN | 4-[(1ξ)-1aminopropyl]6-(1- methylcyclopro pyl)-2-{6-[(5S)5-methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol3-yl]pyridin-2yl}-2,3-dihydro1 H-pyrrolo[3,4c]pyridin-1-one a = +92.8° | 444.1 | 1H NMR (400 MHz, DMSO-cfe) δ 8.56 (d, 4 = 8.3 Hz, 1H), 8.10-8.02 (m, 1H), 8.00-7.94 (m, 1H), 7.52 (s, 1H), 5.46 (d, 4= 18.1 Hz, 1H), 5.26 (d, J = 18.1 Hz, 1H), 5.12 (quin, 4 = 6.4 Hz, 1H), 3.98 (t, 4 = 6.5 Hz, 1H), 3.14-2.84 (m, 3H), 2.40 (br. dd, 4 = 8.4, 11.7 Hz, 1H), 1.80 (quind, 4 = 6.9, 13.9 Hz, 1H), 1.72-1.61 (m, 1H), 1.59- 1.47 (m, 6H), 1.301.21 (m, 2H), 0.93-0.81 (m, 5H). |
38 (F)* | v Γ1 Z 'N N \ Al z7’—ri J 1 A /—\ /λ / n=Z ^111......\ J ory— H2N 0---- | 4-[(1ξ)-1amino-2methoxyethyl]2-{6-[(5R)-5(hydroxymethyl )-6,7-dihydro5H-pyrrofo[2,1c][1,2,4]triazol3-yl]pyrîdin-2yi}-6-(1methylcyclopro pyi)-2,3- dihydro-1 Hpyrrolo[3,4c]pyridin-1-one a = +82.7° | 476.3 | Ή NMR (600 MHz, DMSO-cfe) 6 8.60-8.51 (m, 1H), 8.13-8.05 (m, 1H), 8.00 (d, 4 = 7.5 Hz, 1H), 7.56 (s, 1H), 5.39 (br. d, 4= 17.8 Hz, 1H), 5.22 (br. d, 4= 17.8 Hz, 1H), 5.03 (br. d, 4 = 3.1 Hz, 1H), 4.35-4.21 (m, 1H), 3.943.82 (m, 2H), 3.66-3.52 (m, 2H), 3.28 (br. s, 3H), 3.04-2.89 (m, 2H), 2.85 (dd, J = 9.2, 14.1 Hz, 1H), 2.74-2.67 (m, 1H), 1.57 (s, 3H), 1.28-1.23 (m, 3H), 0.91 — Q.86(m, 2H). |
*Letter within parenthèses is the Method by which Example was prepared.
Λ[Μ+Η]* unless otherwise indîcated.
Example 100: 4-(2-aminopropan-2-yi)-2~[6-(4-ethyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl]-6-[(2R)-2methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
A mixture of 4-(2-aminopropan-2-yl)-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H5 pyrrolo[3,4-c]pyridin-1-one (Intermediate 6) (63.0 mg, 0.23 mmol), 2-bromo-6-(4-ethyl-4H-1,2,4triazoL3-yi)pyridine (Intermediate 1) (58.1 mg, 0.230 mmol), K2CO3 (69.8 mg, 0.505 mmol), Cu! (10.9 mg, 0.058 mmol), and N,N-dimethylethylenediamine (0.115 mmol, 0.0125 mL) in CH3CN (3.0 mL) was heated at 120 °C with microwave irradiation for 30 min. The volatile material was removed, and the residue was purified by flash chromatography (SiO2, 0-10% MeOH/DCM). The 10 product was further purified by HPLC (Phenemonex Gemini NX C18 column, 150 x 21.2mm, 5pm.
Mobile A: Water + 10mM Ammonium Acetate, Mobile B: Acetonitriie) to provide Example 100 as a pale yellow solid (49.3 mg, 49% yield). Ή NMR (600 MHz, DMSO-d6) δ 8.74 (s, 1 H), 8.62 (d, J = 8.4 Hz, 1H), 8.11 -8.04 (m, 1H), 8.03-7.90 (m, 1H), 6.55 (s, 1H), 5.40 (s, 2H), 4.65 (q, 4=7.2 Hz, 2H), 4.24 - 4.19 (m, 1H), 3.29 - 3.33 (m, 2H, assumed; partially obscured by water peak), 15 2.16-2.03 (m, 2H), 1.98- 1.89 (m, 1H), 1.71 - 1.69 (m, 1H), 1.50 (t, 4= 7.1 Hz, 3H), 1.47 (d, J = 5.9 Hz, 6H), 1.22 (d, J = 6.2 Hz, 3H); m/z (APC1+) for (C24H30NeO), 447.3 (M+H)*
Table 6
Ex. # | Structure, séparation method | IUPAC Name, rotation | LRMS (m/z) (M+H)+ A | ήΗ NMR |
101 (E)* | ργΥ Y Y ) HjN Peak 1 (separated by SFC on Phenomenex Lux Cell-1,40% methanol with 10 mM NH3) | 4-[(1ξ)-1aminoethyl]-6- [(2R)-2methylpyrrolid in-1-yl]-2-[6(4-propyl-4H1,2,4-triazol3-yl)pyrîdin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one | 447.2 | 1H NMR (600 MHz, DMSO-ds) δ 8.72 (s, 1H), 8.60 (td, 4 = 2.3, 8.3 Hz, 1H), 8.09-8.02 (m, 1H), 7.99 (br. d, 4 = 7.7 Hz, 1H), 6.57 (s, 1H), 5.17 (br. s, 2H), 4.59-4.53 (m, 3H), 4.29-4.18 (m, 2H), 3.223.18(m, 1H), 2.10-2.01 (m, 2H), 1.96 (br. s, 1H), 1.91 -1.82 (m, 2H), 1.70 (br. s, 1H), 1.39 (br. d, 4 = 4.2 Hz, 3H), 1.35-1.31 (m, 1H), 1.21 (br. d,4=5.7 Hz, 4H), 0.94 (br. t, 4=7.2 Hz, 3H). |
111
102 (E)* | / /A f / N \ Ύ z if 1 l , N r «— N \ ) θΓν·ΙΜ h2n Peak 2 (separated by SFC on Phenomenex Lux CelL1, 40% methanol with 10 mM NH3) | 4-[(1ξ)-1aminoethyl]-6[(2R)-2methylpyrrolid in-1-yl]-2-[6(4*propyL4H1,2,4-triazol· 3-yl)pyridin-2yO-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one | 447.2 | Ή NMR (600 MHz, DMSO-ds) δ 8.74 (s, 1H), 8.62 (d, J=8.3 Hz, 1H), 8.12-8.07 (m, 1H), 8.00 (d, J = 7.7 Hz, 1H), 6.70 (s, 1H), 5.16 (s, 2H), 4.584.52 (m, 4H), 4.33 (br. s, 1 H), 3.64-3.60 (m, 2H), 2.12-2.02 (m, 2H), 1.98 (br. d, J = 4.2 Hz, 1H), 1.90 - 1.83 (m, 2H), 1.75-1.70 (m, 1H), 1.52 (br. d, J = 6.1 Hz, 3H), 1.23-1.18 (m, 4H), 0.93 (t, J =7.4 Hz, 3H). |
103 (A)* | i A / N N \ <ι/ν Pc ^“C 0 ory-^ h2n | 4-[(1ξ)-1aminoethyl]-2[6-(4cyclobutyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-(1methylcyclopr opy[)-2,3 dihydro-1 Hpyrroio[3,4c]pyridin-1one a = +8.4° | 430.1 | Ή NMR (400 MHz, CDCI3) 6 8.75 (d, J =8.3 Hz, 1H), 8.50 (s, 1H), 8.14-8.07 (m, 1H), 8.02-7.91 (m, 1H), 7.71 (s, 1H), 5.78 (quin, J =8.4 Hz, 1H), 5.28 (d, J =2.8 Hz, 2H), 4.33 (q, J = 6.6 Hz, 1H), 2.73 — 2.58 (m, 2H), 2.52-2.35 (m, 2H), 2.10 - 1.98 (m, 1H), 1.97 - 1.84 (m, 1H), 1.62 (s, 3H), 1.49 (d, J = 6.8 Hz, 3H), 1.37 (br. d, J = 3.5 Hz, 2H), 0.91 (d, J = 2.8 Hz, 2H). |
104 (A)* | 0 || K. ^^x / N N \ <LAyJ A □ ory.......... HjN | 4-[(1ξ)-1aminoethyl]-2(6-(4- cyclobutyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-(1methyicyclopr opyl)-2,3dihydrO’1 Hpyrrolo[3,4c]pyridin-1 one a = +1.5° | 430.1 | Ή NMR (400 MHz, CDCI3) δ 8.75 (d, J =8.5 Hz, 1H), 8.50 (s, 1H), 8.10 (d,J = 7.8 Hz, 1H), 8.01 -7.91 (m, 1H), 7.71 (s, 1H), 5.78 (quin, J = 8.5 Hz, 1H), 5.28 (d, J =2.8 Hz, 2H), 4.33 (q, J = 6.6 Hz, 1H), 2.722.60 (m, 2H), 2.51 -2.36 (m, 2H), 2.11 - 1.98 (m, 1H), 1.97- 1.86 (m, 1H), 1.62 (s, 3H), 1.49 (d, J = 6.5 Hz, 3H), 1.41 - 1.33 (m, 2H), 0.91 (d, J= 2.8 Hz, 2H). |
105 (A)* | O f| A. L+p T/ ^--0/ □ orl/ h3n | 4-[(1ξ)-1aminopropyl]- 2-[6-(4cyclobutyl-4H1,2,4-triazol· 3-yl)pyridin-2yl]-6-(1methylcyclopr o py 1)-2,3dihydro-1H- | 444.1 | Ή NMR (400 MHz, CDCI3) 6 8.75 (d, J = 8.3 Hz, 1H), 8.50 (s, 1H), 8.10 (d, J = 7.5 Hz, 1H), 8.02-7.92 (m, 1H), 7.71 (s, 1H), 5.78 (quin, J= 8.4 Hz, 1H), 5.33 -5.18(m, 2H), 4.06 (t, J = 6.7 Hz, 1H), 2.73-2.59 (m, 2H), 2.43 (quin, J = 10.4 Hz, 2H), 2.04 (q, J = |
112
pyrrolo[3,4c]pyridin-1“ one a = -1,9° | 9.6 Hz, 1H), 1.97-1.84 (m, 2H), 1.84- 1.74 (m, 1H), 1.62 (s, 3H), 1.37 (q, J = 3.2 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H), 0.91 (q, J = 3.4 Hz, 2H). | |||
106 (A)* | i îCl Ato AA. -sAA. an ory.........z | 4-[(1ξ)-1aminopropyl]2-(6-(4cyclobutyl-4H1,2,4-triazol3-yi)pyridin-2yl]-6-(1methylcyclopr opyl)-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one a = +22.4° | 441.1 | 1H NMR (400 MHz, CDCb) δ 8.75 (d, J = 8.5 Hz, 1H), 8.50 (s, 1H), 8.10 (d, J = 7.5 Hz, 1H), 8.02-7.92 (m, 1 H), 7.71 (s, 1H), 5.78 (quin, J= 8.5 Hz, 1H), 5.34 -5.18 (m, 2H), 4.06 (t, J = 6.7 Hz, 1H), 2.72-2.59 (m, 2H), 2.52-2.35 (m, 2H), 2.04 (q, J = 10.0 Hz, 1H), 1.98-1.85 (m, 2H), 1.78 (dd, J = 7.0, 14.1 Hz, 1H), 1.62 (s, 3H), 1.37 (q, J =3.1 Hz, 2H), 0.95 (t, J = 7.5 Hz, 3H), 0.91 (q, J = 3.3 Hz, 2H). |
107 (G)* | , ι Λ / «M /X f / ^EU γΛ \ O _AvJ L/ n ς ' ory ΗΝ\ | 2-[6-(4-ethyl5-methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-4-[(W-1(methyiamino) ethyl]-6-[(2R)2mefhylpyrrolid in-1-yl]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one α = +2.1° | 461.1 | ήΗ NMR (400 MHz, CDCb) δ 8.74 (d, J= 8.5 Hz, 1H), 8.14 (d, J= 7.5 Hz, 1H), 7.93 (t, J = 8.0 Hz, IH), 6.72 (s, 1H), 5.11 (d, J = 2.0 Hz, 2H), 4.61 (q, J = 7.3 Hz, 2H), 4.29 (br. t, J = 6.0 Hz, 1H), 3.79 (q, J = 6.6 Hz, 1H), 3.66-3.60 (m, 1H), 3.45-3.38 (m, 1H), 2.60 (s, 3H), 2.37 (s, 3H), 2.21 -2.00 (m, 3H), 1.55 (t, J = 7.2 Hz, 3H), 1.43 (d, J = 6.8 Hz, 3H), 1.28 (d, J= 6.3 Hz, 3H). |
108 (G)* | 1 JLÙ z A- z z\ m a x< f / N N \ ôf M ory......... HN\ | 2-[6-(4-ethyl5-methyî-4H1,2,4-triazol3-yl)pyridin-2yi]-4-[(U)-i(methylamino) ethyl]-6-[(2R)- 2- methylpyrrolid in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -80.5° | 461.2 | 1H NMR (400 MHz, CDCb) δ 8.73 (d, J = 8.5 Hz, IH), 8.13 (d, J = 7.5 Hz, 1H), 7.93 (t, J = 8.0 Hz, 1 H), 6.72 (s, 1H), 5.10 (s, 2H), 4.61 (q, J- 7.1 Hz, 2H), 4.30-4.22 (m, IH), 3.76 (q, J = 6.7 Hz, 1H), 3.62 (br. t, J= 7.3 Hz, 1H), 3.47 -3.38 (m, 1H), 2.59 (s, 3H), 2.37 (s, 3H), 2.202.01 (m, 3H), 1.55 (t, J = 7.2 Hz, 3H), 1.44 (d, J = 6.8 Hz, 3H), 1.29 (br. d, J = 6.3 Hz, 3H). |
113
109 (E)* | . i Al / A^ -A f ___/ » N A ri q^Aj orp.......... HM | 2-[6-(4-ethyl4H-1,2,4triazol-3yl)pyridin-2γΙ]-4-[(1ξ)-1(methylamino) ethyl]-6-[(2R)2methylpyrrolid in-1-yl]-2,3dihydro-1 Hpyrrolo[3,4c]pyncftn-1one a = -1.5° | 447.1 | Ή NMR (400 MHz, CDCI3) 6 8.67 (d, 4=8.4 Hz, 1H), 8.20 (s, 1H), 8.08 (d, 4 = 7.3 Hz, 1H), 7.86 (t, 4 = 8.0 Hz, 1H), 6.64 (s, 1H), 5.02 (d, 4= 1.6 Hz, 2H), 4.63 (q, 4 = 7.2 Hz, 2H), 4.23 4.16 (m, 1H), 3.71 (q, 4 = 6.8 Hz, 1H), 3.57-3.50 (m, 1H), 3.42-3.29 (m, 1 H), 2.29 (s, 3H), 2.071.92 (m, 3H), 1.69 (br. d, J = 3.0 Hz, 1H), 1.55-1.50 (m, 3H), 1.35 (d, 4=6.8 Hz, 3H), 1.19 (d, 4= 6.3 Hz, 3H). |
110 (E)* | , i jCl CriA Ά □rlAMN\ | 2-[6-(4-ethyl4H-1,2,4- triazol-3yl)pyridin-2ΥΙ]-4-[(1ξ)-1(methylamino) ethyl]-6-[(2R)2- methylpyrrolid in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one a = -88.2° | 447.1 | 1H NMR (400 MHz, CDCI3) 6 8.66 (d, 4 = 8.5 Hz, 1H), 8.19 (s, 1H), 8.08 (d, 4 = 7.6 Hz, 1H), 7.86 (t, 4 = 8.1 Hz, 1H), 6.63 (s, 1H), 5.05 -4.97 (m, 2H), 4.62 (q, 4 = 7.2 Hz, 2H), 4.22-4,13 (m, 1H), 3.68 (q, 4= 6.5 Hz, 1H), 3.58-3.47 (m, 1H), 3.38-3.28 (m, 1H), 2.28 (s, 3H), 2.08 - 1.92 (m, 3H), 1.74- 1.69 (m, 1H), 1.53 (t, 4 = 7.3 Hz, 3H), 1.35 (d. 4 = 6.6 Hz, 3H), 1.20 (d, 4 = 6.3 Hz, 3H). |
111 (A)* | i Λ / Μ N ri zri ri—ri ( /N γ # HM^ | 2-[6-(4-ethyl4H-1,2,4triazol-3yl)pyridin-2yl]-4-[(1R)-1(methylamino) ethyl]-6-(1methylcyclopr opyl)-2,3dihydro-1Hpyrrolo[3,4c]pyridîn-1one a = +16.2° | 418.2 | 1H NMR (500 MHz, DMSO-d6) 6 8.77 (s, 1H), 8.63 (dd, J = 0.7, 8.3 Hz, 1H), 8.11 (t, J = 7.9 Hz, 1 H), 8.03 (d, J = 7.5 Hz, 1 H), 7.57 (s, 1H), 5.32 (s, 2H), 4.71 -4.61 (m, 2H), 4.05-3.87 (m, 1H), 2.27 (s, 3H), 1.57 (s, 3H), 1.53 (t, J = 7.2 Hz, 3H), 1.36 (d, J = 6.6 Hz, 3H), 1.32 1.23 (m, 2H), 0.92-0.85 (m, 2H). |
112 (A)* | ï Λ A- AA A\^a y1 /5 ri ί I n AJ j/ \h— / N ( Y-.»11111 HN\ | 2-[6-(4-ethyl4H-1,2,4triazol-3yi)pyridin-2y!]-4-[(1 S)-1(methylamino) ethyl]-6-(1methylcyclopr | 418.2 | 1H NMR (500 MHz, DMSO-cfe) 6 8.77 (s, 1H), 8.63 (d, 4=8.0 Hz, 1H), 8.11 (t, 4 = 8.0 Hz, 1H), 8.03 (d, 4=7.4 Hz, 1H), 7.59 (s, 1H), 5.32 (s, 2H), 4.65 (quind, 4 = 6.7, 13.6 Hz, 2H), 4.14-3.94 (m, |
114
opyl)-2,3dihydro-1 Hpyrrolo[3,4c]pyndin-1one a = -19.7° | 1 H), 2.37-2.26 (m, 3H), 1.57 (s, 3H), 1.52 (t, 4 = 7.2 Hz, 3H), 1.38 (br. d, 4 = 6.7 Hz, 3H), 1.34-1.25 (m, 2H), 0.89 (d, 4 = 2.7 Hz, 2H). | |||
113 (A)* | kXX- / N \ <l^Xj HN\ | 4-((1 S)-1(methylamino) ethyl]-6-(1methylcyclopr o pyl)-2-(6-(4propyl-4H1,2,4-triazoî3-y!)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyrrdin-1 one 0 = -18.3° | 432.2 | 1H NMR (400 MHz, DMSO-ds) δ 8.75 (s, 1H), 8.63 (d, 4= 8.3 Hz, 1H), 8.10 (t, 4 = 7.9 Hz, 1H), 8.02 (d, 4= 7.5 Hz, 1H), 7.55 (s, IH), 5.29 (s, 2H), 4.65-4.54 (m, 2H), 3.873.85 (m, 1H), 2.21 (s, 3H), 1.95-1.83 (m, 2H), 1.56 (s, 3H), 1.32 (br. d, 4 = 6.8 Hz, 3H), 1.28- 1.22 (m, 2H), 0.93 (1,4=7.3 Hz, 3H), 0.88 (s, 2H). |
114 (C)* | l iù Z Yr ν' \ .-1 Λ--K I | N * 14=^=/ h2n | 4-(2- aminopropan2-yl)-2-[6-(4ethyl-4H- 1,2,4-triazol3-yl)pyridin-2yl}-6-(1methylcyclopr opyl)-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one | 418.2 | Ή NMR (600 MHz, DMSO-ds) δ 8.71 -8.80 (m, 1H), 8.61 (d, 4 = 8.3 Hz, 1H), 8.07-8.17 (m, 1H), 7.93-8.05 (m, 1H), 7.57 (s, 1H), 5.48 (s, 2H), 4.64 (q, J = 7.1 Hz, 2H), 1.56 (s, 3H), 1.47-1.54 (m, 9H), 1.32 (br. s, 2H), 0.86 - 0.95 (m,2H). |
115 (A)* | l iù / N N \ ΥΊ Z----V. I l , N /7 'Y—-J ' N=^=Z H2N | 4-[(1R)-1aminoethyl]-2[6-(4-ethyl4H-1,2,4triazol-3yl)pyridin-2yl]-6-(1methylcyclopr opyl)-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one o = +10. Γ | 404.3 | 4H NMR (400 MHz, DMSO-de) δ 8.69 (s, 1H), 8.55 (d, 4 = 8.3 Hz, 1H), 8.05-7.99 (m, 1 H), 7.997.93 (m, 1H), 7.46 (s, 1H), 5.36-5.24 (m,2H), 4.57 (q, 4 = 7.1 Hz, 2H), 4.15 (q, 4 = 6.6 Hz, 1H), 1.49 (s, 3H), 1.45 (t, 4 = 7.1 Hz, 3H), 1.28 (d, 4 = 6.8 Hz, 3H), 1.24-1.18(m, 2H), 0.80 (d, 4 = 3.1 Hz, 2H). |
115
116 | l>b | +r+X 1 7N | 4-((1 S)-1aminoethyI]-2- [6-(4-ethyl- | 404.3 | 4H NMR (400 MHz, DMSO-A) δ 8.76 (s, 1H), 8.61 (d, J = 8.3 Hz, 1H), |
(A)* | ' N==< HjN | -Ν'-/ | 4H-1.2.4triazol-Syl)py ridin-2yl]-6-(1methylcyclopr □pyl)-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one a = -10.4° | 8.12-8.05 (m, 1H), 8.058.00 (m, 1H), 7.52 (s, 1H), 5.37 (d, J = 4.5 Hz, 2H), 4.64 (q, J = 7.3 Hz, 2H), 4.22 (d, J = 6.8 Hz, 1H), 1.55 (s, 3H), 1.52 (t, J = 7.2 Hz, 3H), 1.35 (d, J = 6.8 Hz, 3H), 1.28-1.23 (m, 2H), 0.87 (d, J = 3.0 Hz, 2H). | |
117 (A)* | v jO ory-™ / h2n | k N l N N | 4-[(1ξ)-1aminoethyl]-6(1methylcyclopr opyl)-2-[6-(4propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1□ne a = +4.6° | 418.2 | Ή NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.63 (d, J = 7.8 Hz, 1H), 8.10 (t, J= 7.4 Hz, 1H), 8.03 (d, J =7.4 Hz, 1H), 7.54 (s, 1H), 5,34 (s, 2H), 4.58 (br. t, J =7.2 Hz, 2H), 4.21 (d, J = 6.7 Hz, 1H), 1.96-1.83 (m, 2H), 1.56 (s, 3H), 1.34 (d, J= 6.6 Hz, 3H), 1.30 - 1.25 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H), 0.87 (d, J = 3.2 Hz, 2H). |
118 (A)* | % 9 Jl JL +Û+ Yz^0 . b | x. N ! .N | 4-[(1ξ)-1aminoethyl]-6(1- methylcyclopr opyl)-2-[6-(4propyl-4H1,2,4-triazol3-yl)pyridin-2yi]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = +3.5° | 418.2 | 1H NMR (400 MHz, DMSO-ds) δ 8.75 (s, 1H), 8.63 (d, J = 7.9 Hz, 1H), 8.10 (t, J = 7.7 Hz, 1H), 8.02 (d, J = 7A Hz, 1H), 7.54 (s, 1H), 5.41 -5.28 (m,2H), 4.65-4.52 (m, 2H), 4.21 (q, J = 6.6 Hz, 1H), 1.99 - 1.82 (m, 2H), 1.56 (s, 3H), 1.34 (d, J = 6.7 Hz, 3H), 1.30-1.22 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H), 0.87 (d, J = 3.1 Hz, 2H). |
119 (A)* | T'A î 0 II J bT x^-so b | 1 N + | 4-[(1ξ)-1aminopropyl]2-[6-(4-ethyl- 4H-1,2,4triazol-3yl)pyridin-2yl]-6-(1methylcyclopr opyl)-2,3dihydro-1H- | 418.2 | 4H NMR (400 MHz, DMSO-ds) δ 8.76 (s, 1H), 8.62 (d, J = 8.3 Hz, 1H), 8.11 (t, J = 8.0 Hz, 1 H), 8.02 (d, J = 7.6 Hz, 1H), 7.55 (s, 1H), 5.39-5.28 (m, 2H), 4.64 (dq, J = 2.6, 7.0 Hz, 2H), 3.99 (t, J = 6.5 Hz, 1H), 1.85 - 1.72 (m, 1H), 1.66 (td, J = 7.1, 13.8 |
116
pyrrolo[3,4c]pyridin-1one a = -1.6° | Hz, 1H), 1.31 -1.23 (m, 2H), 0.92-0.82 (m, 5H). | |||
120 (A)* | V jO / Η τΎ^ \ υΊ /----\ I I N Kr y ory........,z | 4-[(1ξ)-1aminopropyl]2-[6-(4-ethyl4H-1,2,4triazol-3yl)pyridin-2yl]-6-(1methylcyclopr o py 1)-2,3dihydro-1Hpyrrolo[3,4c]py ridin-1 one a = -2.4° | 418.2 | ήΗ NMR (400 MHz, DMSO-ds) δ 8.76 (s, 1H), 8.62 (d, J = 8.2 Hz, 1H), 8.10 (t, J = 8,0 Hz, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 5.39-5.28 (m,2H), 4.64 (dq, J = 2.1, 7.0 Hz, 2H), 3.97 (t, J = 6.5 Hz, 1H), 2.31 - 1,89 (m, 2H), 1.84-1.73 (m, 1H), 1.70- 1.60 (m, 1H), 1.56 (s, 3H), 1.52 (t, J = 7,1 Hz, 3H), 1.31 - 1.23 (m, 2H), 0.90-0.82 (m, 5H). |
121 (A)* | v n A- Y^\ 7 N N Y^ \ γ^Ί /—A / 1 zN XJ fl z / \ orÿ * / HjN | 4-[(1ξ)-1aminopropyl]6-(1methylcyclopr opy 1)-2-(6-(4propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = +7,9° | 432.1 | 1H NMR (400 MHz, DMSO-ds) δ 8.75 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.12-8.06 (m, 1H), 8.068.01 (m, 1H), 7.54 (s, 1H), 5.30 (s, 2H), 4.58 (q, J = 6.8 Hz, 2H), 3.97 (t, J = 6.7 Hz, 1H), 1.96-1.83 (m, 2H), 1.83- 1.72 (m, 1H), 1.70- 1.60 (m, 1H), 1.56 (s, 3H), 1.32-1.21 (m, 2H), 0,95 (t, J = 7.3 Hz, 3H), 0.91 -0.83 (m, 5H). |
122 (A)* | z O X YZ | 4-[(1ξ)-1aminopropyl]6-(1methylcyclopr opyl)-2-[6-(4propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one a = -101.4“ | 432.1 | 4H NMR (400 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.64 (d,J=8.5 Hz, 1H), 8.12 (t, J= 7.7 Hz, 1H), 8.03 (d, J = 7.5 Hz, 1H), 7.61 (s, 1H), 5.36-5.25 (m, 2H), 4.64-4.52 (m, 2H), 4.17 (br. t, J =6.4 Hz, 1H), 1.94-1.81 (m, 3H), 1.79-1.70 (m, IH), 1,58 (s, 3H), 1,41 -1.27 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H), 0.90 (br. d, J = 2.5 Hz, 2H), 0.89 — 0.84 (m, 3H). |
117
123 (D)* | v O. \ _/qJ Lx 7 A ' HjN ' | 4-(2aminopropan2-yl)-6[ethyl(methyl) amino]-2-[6(4-ethyl-5methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one | 435.3 | Ή NMR (600 MHz, DMSO-dg) ô 8.53 (d, J = 8.25 Hz, 1H), 7.93-8.04 (m, 1H), 7.90 (d, J = 7.70 Hz, 1H), 6.65 (s, 1H), 5.31 (s, 2H), 4.48 (q, 7 = 6.97 Hz, 2H), 3.54-3.58 (m, 2H), 2.98 (s, 3H), 2.42 (s, 3H), 1.35- 1.43 (m, 9H), 1.03 (t, J = 6.97 Hz, 3H). |
124 (C)* | v jn / JM .aM <îA\ -N / / N N \ \ rt J '7 / f H2N ' | 4-(2- aminopropan2-yl)-6[ethyl(methyl) aminoj-2-[6- (4-ethyl-4H- 1,2,4-triazol- 3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 - one | 421.3 | Ή NMR (400 MHz, DMSO-ds) δ 8.74 (s, 1H), 8.63 (dd, J = 8.19, 0.86 Hz, 1H), 8.05-8.18 (m, 1H), 7.98-8.04 (m, 1H), 6.73 (S, 1H), 5.41 (s, 2H), 4.65 (q, J = 7.09 Hz, 2H), 3.64 (q, J = 6.97 Hz, 2H), 3.06 (s, 3H), 1.51 (t, J = 7.15 Hz, 3H), 1.46 (s, 6H), 1.11 (t, J = 6.97 Hz, 3H). |
125 (A)* | i Λ JM. / \ / \ .ai /—a 1 1 /N MJ 77 XV——J ' N==\ \ ory.......... / HjN | 4-[(1ξ)-1aminoethyl]-6(1methylcyclopr opyl)-2-{6-[4- (pentan-3-yl)4H-1,2,4triazol-3yl]pyridin-2yi}-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -7.9° | 446.3 | Ή NMR (400 MHz, DMSO-d6) δ 8.92 (s, 1H), 8.64 (d, 7= 8.4 Hz, 1H), 8.11 (t, J =8.0 Hz, 1H), 7.96 (d, 7= 7.6 Hz, 1H), 7.54 (s, 1H), 5.50-5.27 (m, 3H), 4.20 (br. d, 7= 6.4 Hz, 1H), 1.97-1.84 (m, 4H), 1.56 (s, 3H), 1.34 (d, 7 = 6.8 Hz, 3H), 1.31 1.23 (m, 2H), 0.87 (br. d, 7 = 2.9 Hz, 2H), 0.84-0.73 (m, 6H). |
126 (A)* | cj ZΟ^χ .A. 1 II ° * | 4-[(1ξ)-1aminoethyI]-6(1methylcyclopr opyl)-2-{6-[4(pentan-3-yl)4H-1,2,4triazol-3yï]pyridin-2yl}-2,3dihydro-1Hpyrrolo[3,4- | 446.3 | Ή NMR (400 MHz, DMSO-d6) ô 8.93 (s, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.12 (t, 7 = 8.0 Hz, 1H), 7.96 (d, 7 = 7.0 Hz, 1H), 7.55 (s, 1H), 5.46-5.28 (m, 3H), 4.23 (q, 7 = 6.4 Hz, 1H), 1.99-1.82 (m, 4H), 1.56 (s, 3H), 1.35 (d, 7 = 6.8 Hz, 3H), 1.31 1.25 (m, 2H), 0.87 (d, 7 = |
118
c]pyridin-1 one a = +0.32° | 2.8 Hz, 2H), 0.82-0.75 (m, 6H). | |||
127 (G)* | i IX / \ AÎ. J ' / Z yx ^/nA orV-^ h2n | 4-[(1 ξ)-1aminoethytJ-6[ethy!(methyl) amino]-2-[6(4-ethyl-5methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -18.6° | 421.4 | 1H NMR (400 MHz, Methanol-d4) δ 8.66 (br. d, J= 8.2 Hz, 1H), 8.057.89 (m, 2H), 6.84-6.73 (m, 1H), 5.12 (br. s, 2H), 4.65 (q, J = 7.1 Hz, 2H), 4.14 (q, J = 6.4 Hz, 1H), 3.71 (br. d, J = 6.7 Hz, 2H), 3.16-3.07 (m, 3H), 2.60 (s, 3H), 1.56 (t, J = 7.1 Hz, 3H), 1.49 (d, J =6.6 Hz, 3H), 1.20 (t, J= 7.0 Hz, 3H). |
128 (G)* | v jQ / \ ZX J ' / \/ y-J /N λ z X \ x orl/.......... h2n | 4-[(1ξ)-1aminoethyl]-6[ethyl(methyl) amino]-2~[6(4-ethyf-5methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrro!o[3,4c]pyridin-1one a = +24.1° | 421.2 | 1H NMR (400 MHz, Methanol-d4) δ 8.73 - 8.59 (m, 1H), 8.06-7.86 (m, 2H), 6.86 - 6.69 (m, 1H), 5.12 (br. s, 2H), 4.65 (q, J = 7.0 Hz, 2H), 4.13 (br. d, J = 6.6 Hz, 1H), 3.71 (br. d, J = 6.7 Hz, 2H), 3.11 (br. d, J = 1.6 Hz, 3H), 2.60 (s, 3H), 1.56 (t, J =7 Λ Hz, 3H), 1.49 (d, J =6.7 Hz, 3H), 1.20 (t, J =6.9 Hz, 3H). |
129 (E)* | i iX / K. /k. / / >r A \ \ 7\ J ' 7 ' /7 A V / N^=/ ory— HjN | 4-ί(1ξ)-1aminoethyl]-6[ethyl(methyl) amino]-2-[6(4-ethyl-4H1,2,4-triazo I3-yl)pyridin-2yl]-2,3dihydro-1 Hpyrrolo[3,4clpyndin-1one a = +8.4° | 407.3 | Ή NMR (400 MHz, DMSO-ds) δ 8.74 (s, 1H), 8.61 (dd, J = 0.9, 8.3 Hz, 1H), 8.13-8.05 (m, 1H), 8.03-7.97 (m, 1H), 6.73 (s, 1H), 5.32-5.17 (m, 2H), 4.63 (q, J = 7.1 Hz, 2H), 4.10 (q, J = 6.7 Hz, 1H), 3.64 (q, J =7.0 Hz, 2H), 3.05 (s, 3H), 2.11 (br. s, 2H), 1.50 (t, 4=7.2 Hz, 3H), 1.35 (d, J = 6.7 Hz, 3H), 1.10 (t, J =7.0 Hz, 3H). |
119
130 (E)* | i ra / / N \ \ rxJ ' / \—f y-J z-z / \=Λ ory.......... Ύ | 4-[(1ξ)-1aminoethyl]-6[ethyl(methyl) amino]-2-[6(4-ethyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -16.0° | 407.2 | 1H NMR (400 MHz, DMSO-ds) δ 8.76 (s, 1H), 8.62 (dd, J = 0.7, 8.3 Hz, 1H), 8.32 (br. s, 2H), 8.15 -8.08 (m, 1H), 8.00 (dd, J = 0.7, 7.6 Hz, 1 H), 6.89 (s, 1H), 5.26-5.13 (m, 2H), 4.69-4.56 (m, 3H), 3.71 (sxt, J = 7.3 Hz, 2H), 3.12 (s, 3H), 1.55 (d, J= 6.8 Hz, 3H), 1.48 (t, J =7.2 Hz, 3H), 1.12 (t, J= 7.0 Hz, 3H). |
131 (C)* | l iù IL ^X< / N \ \ /—\ i 1 /N \-/ y-J N----\ \ h2n ' | 4-(2aminopropan2-yl)-6(dimethylamin o)-2-[6-(4propyl-4H1,2,4-triazol· 3-yl)pyridin-2yl]-2,3dihydrû-1 Hpyrrolo[3,4c]pyridin-1one | 421.2 | 1H NMR (600 MHz, DMSO-ds) δ 8.73 (s, 1H), 8.63 (dd, J= 0.9, 8.3 Hz, 1H), 8.15-8.05 (m, 1H), 8.02-7.95 (m, 1H), 6.78 (s, 1H), 5.39 (s, 2H), 4.59 (t, J = 7.0 Hz, 2H), 3.11 (s, 6H), 1.93 - 1.83 (m, 2H), 1,47 (s, 6H), 0.90 (t, J = 7.4 Hz, 3H). |
132 (cr | v jd / N γΧ \ \ fi-----ù / 1 ?W \-/ \d / HzN ' | 4-(2aminopropan2-yl)-6(dimethylamin o)-2-[6-(4ethyl-4H- 1,2,4-triazo!3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one | 407.3 | Ή NMR (600 MHz, DMSO-dg) δ 8.67 (s, 1H), 8.54 (d, J= 8.2 Hz, 1H), 8.04-7.96 (m, 1H), 7.957.85 (m, 1H), 6.67 (s, 1H), 5.33 (s, 2H), 4.57 (q, J = 7,1 Hz, 2H), 3.02 (s, 6H), 1.43 (t, J = 7.2 Hz, 3H), 1,39 (s, 6H), |
133 (I)* | , ι IÂ 7 A- xY 6 Y γ H2N ' | 4-(2aminopropan2-yl)-2-[6-(5methyl-4propyl-4H- 1,2,4-triazol3-yl)pyridin-2yl]-6-[(2R)-2methyÎpyrrolid in-1-ylJ-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one | 475.3 | 1H NMR (600 MHz, DMSO-de) ô 8.60 (d, J = 8.4 Hz, 1H), 8.05 (t, J= 8.0 Hz, 1H), 7.94 (dd, J=0.8, 7.6 Hz, 1H), 6.56 (s, 1H), 5.51 -5.26 (m, 2H), 4.50 (t, J = 7.2 Hz, 2H), 4,22 (t, J = 5.8 Hz, 1H), 3.303.32 (m, 2H assumed; partiaily obscured by water peak) 2.48 (s, 3H), 2.152.02 (m, 2H), 1.97 (br. s, 1H), 1.77 (qd, J = 7.4, 14.6 Hz, 2H), 1.69-1.71 (m, 1H) 1.47 (s, 3H), 1.46 (s, |
120
3H), 1.22 (d, 4 = 6.2 Hz, 3H), 0.92-0.85 (m, 3H). | ||||
134 | o Y > 7 Z | 4-(2aminopropan2-yl)-2-[6-(4- | 461.3 | ’H NMR (400 MHz, DMSO-Λ) δ 8.55 (dd, J = 0.9, 8.3 Hz, 1H), 8.09- |
(I)* | UK Y -u h2n ' | ethyl-5methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-[(2R)-2methylpyrrolid in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one | 7.96 (m, 1H), 7.93-7.80 (m, 1H), 6.49 (s, 1H), 5.33 (s, 2H), 4.49 (q, 4=7.1 Hz, 2H), 4.19-4.08 (m, 1H), 3.58-3.42 (m, 1H), 3.233.25 (m, 1H, assumed; partially obscured by water peak), 2.42 (br. s, 3H), 2.09- 1.85 (m, 3H), 1.651.55 (m, 1H), 1.44-1.36 (m, 9H), 1.15 (d, 4=6.2 Hz, 3H). | |
135 | 1 id 1 Y A 9 Z N N \ | 4-[(1ξ)-1aminoethyl]-2- [6-(5-methyl- | 461.8 | ’H NMR (400 MHz, DMSO-Λ) δ 8.63 (d, 4 = 8.3 Hz, 1H), 8.07 (t, 4 = 7.9 |
(I)* | Op Y cry-™ / Peak 2 (separated using a Phenomenex Lux Cellulose1,21 x 250 mm, 5um column at 35°C, Eluted with 20% MeOH + 10mM ammonium acetate in CO2. Pressure held at 120 bar with flow rate of 100 mL/min.) | 4-propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-[(2R)-2methylpyrrolid in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one | Hz, 1H), 7.98-7.90 (m, 1H), 6.58 (s, IH), 5.20 (s, 2H), 4.53-4.41 (m, 2H), 4.31 -4.22 (m, 1H), 4.104.06 (m, 2H), 3.59-3.54 (m, 1H), 2.50-2.49 (m, 3H), 2.11 -2.03 (m, 2H), 1.99-1.91 (m, 1H), 1.861.78 (m, 2H), 1.73-1.69 (m, 1H), 1.35 (d, 4=6.6 Hz, 3H), 1.22 (d, 4 = 6.2 Hz, 3H), 0.96 (t, 4=7.5 Hz, 3H). | |
136 | i jd / /Y f / Ά N \ r-A 4--( i 7 | 4-[(1ξ>1aminoethyl]-2- [6-(5-methyl- | 461.8 | ’H NMR (400 MHz, DMSO-Λ) δ 8.61 (d, 4 = 8.3 Hz, 1H), 8.06 (t, 4=7.9 |
(cr | V \p V zW ory.......... / HjW Peak 1 (separated using a Phenomenex Lux Cellulose1,21 x 250 mm, 5um column at 35°C, Eluted with 20% MeOH + 10mM ammonium acetate in CO2. Pressure held at 120 bar with flow rate of 100 mL/min.) | 4-propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-[(2R)-2m ethyl pyrrolid in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one | Hz, 1H), 7.96 (d, 4= 7.6 Hz, 1H), 6.57 (s, 1H), 5.19 (s, 2H), 4.53-4.43 (m, 2H), 4.29-4.18 (m, 1H), 4.13-4.03 (m, 1H), 3.623.52 (m, 1H), 2.49 (br. s, 3H), 2.09-2.03 (m, 2H), 1.96 (br. d, 4 =2.9 Hz, 1H), 1.84-1.77 (m, 2H), 1.70 (br. d, 4= 2.7 Hz, 1H), 1.34 (br. d, 4=6.1 Hz, 3H), 1.22 (d, 4=6.4 Hz, 3H), 0.95 (t, 4 = 7.3 Hz, 3H), 0.900.89 (m, 1H). |
121
137 (C)* | kXX / N N \ \ z—X ί i ?N \ i N=i \ )........ >z HaN | 4-[(1 S)-1aminoethyl]-6(dimethylamin o)-2-[6-(4* propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -4.5° | 406.2 | 1H NMR (600 MHz, DMSO-Λ) δ 8.72 (d, J = 2.0 Hz, IH), 8.63-8.56 (m, 1H), 8.10-8.02 (m, 1H), 8,01 -7.97 (m, 1H), 6.85-6.61 (m, 1H), 5,18 (br. s, 2H), 4.56 (br. t, J = 7.2 Hz, 2H), 4.10 (br. s, IH), 3.09 (d,J= 3,1 Hz, 6H), 1.97-1.84 (m, 2H), 1.34 (br. d, J =5.9 Hz, 3H), 1.00-0.85 (m, 3H). |
138 (C)* | l id IL MX Z 'n' n \ L --------< J | N \—/ d r-J f Η2Ν | 4-[(1R)-1aminoeihyl]-6(dimethylamin o)-2-[6-(4propyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1 one a = +4.9° | 406.2 | Ή NMR (600 MHz, DMSO-cfe) ô 8.72 (s, 1H), 8.59 (br. d, J = 7.9 Hz, IH), 8.07-8.01 (m, 1H), 7.98 (d, J = 7.3 Hz, 1H), 6.71 (s, 1H), 5.17 (br. d, J= 2.2 Hz, 2H), 4.64-4.49 (m, 2H), 4.09 (br. d, J =4.8 Hz, 1H), 3.08 (s, 6H), 1.95-1.84 (m, 2H), 1,34 (br. d, J = 6.6 Hz, 3H), 0.94 (br. t, J =7.2 Hz, 3H). |
139 (D* | i n d zkj 'd \_Z yX zM / \=T ( \ H2N ' | 4-(2aminopropan2-yl)-6[methyl(propa n-2-yl)amino]2-[6-(5methyi-4propyl-4H1,2,4-triazol3-yl)pyridîn-2yi]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one | 463.5 | ’H NMR (400 MHz, DMSO-Λ) δ 8.72 (d, J = 8.3 Hz, 1H), 8.59 (br. s, 3H), 8.19 (t, J= 8.0 Hz, 1 H), 7.98 (d, J =7.5 Hz, 1H), 6.93 (s, 1H), 5.26 (s, 2H), 4.97 (br. s, 1H), 4.60 (br. t, J =7.3 Hz, 2H), 2.94 (s, 3H), 2.70 (s, 3H), 1.92 -1.78 (m, 2H), 1.72 (s, 6H), 1.17 (d, J = 6.5 Hz, 6H), 0.91 (t, J = 7.3 Hz, 3H). |
140 (E)* | l Jd / /K ^YK <Xm 7 / in n ' Ύ \ A_dJ d7 N=\ / HSN | 4-[(1R)-1aminopropyl]2-[6-(4-ethyl4H-1,2,4triazol-3yl)pyridin-2yl]-6-[(2R)-2methylpyrrolîd in-1-yl)-2,3dihydro-1Hpyrrolo[3,4- | 447.2 | Ή NMR (600 MHz, DMSO-Λ) δ 8.73 - 8.62 (m, 1H), 8.55 (d, J = 8.3 Hz, 1H), 8.08-7.98 (m, 1H), 7.93 (d, J =7.6 Hz, 1H), 6.50 (s, 1H), 5.14 (d, J= 1.7 Hz, 2H), 4.57 (dq, J = 3.4, 7.0 Hz, 2H), 4.224.08 (m, 1H), 3.77 (br. t, J = 6.1 Hz, 1H), 3.55-3.41 (m, 1H), 3.30-3.25 (m, 1 H, assumed; partially |
122
c]pyridin-1 one | obscured by water peak), 2.00 (d, J= 5.3 Hz, 1H), 1.92- 1.87 (m, 1H), 1.761.51 (m, 4H), 1.44 (t, J = 7.2 Hz, 3H), 1.15 (d, J = 6.2 Hz, 3H), 0.82 (t, J =7.4 Hz, 3H). | |||
141 (E)* | HZN | 4-[(1S)-1aminopropyl]2-[6-(4-ethyl- 4H-1,2,4trîazol-3yl)py ridin-2yl]-6-[(2R)-2methyîpyrrolid in-1-yi]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one | 447.2 | Ή NMR (400 MHz, DMSO-ds) δ 8.67 (s, 1H), 8.55 (dd, J = 0.7, 8.4 Hz, 1H), 8.11 -7.99 (m, 1H), 7.93 (dd, J =0.7, 7.6 Hz, 1H), 6.52 (s, 1H), 5.12 (s, 2H), 4.66-4.50 (m, 2H), 4.26-4.07 (m, 1H), 3.873.71 (m, IH), 3.56-3.45 (m, 1H), 3.27-3.29 (m 1H, assumed; partially obscured by water peak, ) 2.05-1.95 (m, 2H), 1.931.86 (m, 1H), 1.79-1.68 (m, 1H), 1.65-1.51 (m, 2H), 1.44 (t, J= 7.2 Hz, 3H), 1.14 (d, J = 6.2 Hz, 3H), 0.82 (t, J =7.4 Hz, 3H). |
142 (E)* | ï Λ Z N \ \ /7 < f l Ή \—/ yZ ,A Z A / f oh)—'7 / HjN | 4-((1 ξ)-1aminopropyl]- 6- (dimethylamin 0)-2-(6-(4propyl-4H~ 1,2,4-triazol- 3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -3.8° | 421.2 | Ή NMR (600 MHz, DMSO-de) δ 8.75 (s, 1H), 8.62 (d, J = 8.3 Hz, 1H), 8.10 (t, J= 8.0 Hz, 1H), 8.01 (d, J = 7.5 Hz, 1H), 6.92 (d, J= 2.0 Hz, IH), 5.24-5.05 (m, 2H), 4.68 4.57 (m, 1H), 4.56-4.46 (m, 1H), 4.34 (br. s, 1H), 3.17 (s, 6H), 2.07-1.81 (m, 4H), 0.92 (td, J =7.3, 15.0 Hz, 6H). |
143 (E)* | v O / N N \ \ ΓΛ J 1 / N^=/ / \ orV.........' / h2n | 4-[(1ξ)-1aminopropyl]6- (dimethyiamin o)-2-[6-(4propyl-4l- 1,2,4-triazol3-yl)pyndin-2yl]-2,3dihydro-1Ipyrrolo[3,4c]pyridin-1 one | 421.2 | 1H NMR (600 MHz, DMSO-ds) δ 8.65 (s, 1H), 8.52 (dd, J = 2.9, 8.3 Hz, IH), 7.98 (dt, J = 2.1, 7.8 Hz, 1H), 7.92 (d,J=7.5 Hz, 1H), 6.66 (d, J = 3.7 Hz, 1H), 5.08 (br. s, 2H), 4.60-4.41 (m, 2H), 3.873.67 (m, 1H), 3.02 (s, 6H), 1.81 (sxt, J = 7.0 Hz, 2H), 1.75-1.65 (m, 1H), 1.57 (br. s, 1H), 0.88 (t, J = 7.3 Hz, 3H), 0.82 (t, J = 6.3 Hz, 3H). |
123
a = +5.6° | ||||
144 (E)* | z 0 H ii Ato A2 | 4-[(1 R)-1aminopropyl]6-[(2R)-2methylpyrrolid in-1-yl]-2-[6(4-propyl-4H1,2,4-triazol3-yl)pyridin-2- yll-2,3- dihydro-1Hpyrrolo[3,4c]pyridin-1one | 461.2 | 1H NMR (400 MHz, DMSO-ds) δ 8.66 (s, 1H), 8.56 (dd, J = 0.7, 8.3 Hz, 1H), 8.07-7.98 (m, 1H), 7.96-7.84 (m, 1H), 6.50 (s, 1H), 5.11 (s, 2H), 4.62 -4.41 (m, 2H), 4.15 (t, J = 5.7 Hz, 1H), 3.77 (br. s, 1H), 3.56-3.42 (m, 1H), 3.30-3.27 (m, 1H, assumed; partially obscured by water peak), 2.08-1.92 (m, 3H), 1.861.76 (m, 2H), 1.75-1.46 (m, 3H), 1.15 (d, J= 6.2 Hz, 3H), 0.88 (t, J =7.4 Hz, 3H), 0.82 (t, J=7.3 Hz, 3H). |
145 (E)* | , ι fù f Λα aa. AxCj Jm N=S / / h2n | 4-((1 S)-1aminopropyl]6-[(2R)-2methylpyrrolid in-1-yl]-246(4-propyl-4H- 1,2,4-triazol3-yl)pyridin-2ylb2,3dihydro-1Hpyrrolo(3,4c]pyridin-1one | 461.2 | 1H NMR (600 MHz, DMSO-cfe) δ 8.66 (s, 1H), 8.56 (d, J = 8.3 Hz, 1 H), 8.10-7.98 (m, 1H), 7.967.88 (m, 1H), 6.52 (s, 1H), 5.17-5.00 (m, 2H), 4.62 4.39 (m, 2H), 4.27-4.06 (m, 1H), 3.87-3.71 (m, 1H), 3.56-3.43 (m, 1H), 3.30-3.29 (m 1H, assumed; partiaily obscured by water peak) 2.07-1.95 (m, 2H), 1.921.70 (m, 4H), 1.66-1.51 (m, 2H), 1.14 (d, J = 6.1 Hz, 3H), 0.88 (t, J= 7.4 Hz, 3H), 0.81 (t, J = 7.3 Hz, 3H). |
146 (E)* | 1ΓΎ / ru ru aa‘ \ \ /—\ l I N -+X c ory * h2n | 4-[(1ξ)-1aminopropyl]6- (dimethylamin o)-2-[6-(4ethyl-4H1,2,4-triazol3-yl)pyrîdin-2- yl]-2,3- dihydro-1 Hpyrrolo[3,4c]pyridin-1one a = +1.2° | 407.2 | 1H NMR (600 MHz, DMSO-dg) δ 8.71 (s, 1H), 8.54 (d, J =8.3 Hz, 1H), 8.50-8.40 (m, 2H), 8.04 (t, J= 8.0 Hz, 1H), 7.93 (d, J = 7.3 Hz, 1H), 6.85 (s, 1H), 5.29-4.99 (m, 2H), 4,70-4.49 (m, 2H), 4.394.24 (m, 1H), 3.10 (s, 6H), 2.07-1.82 (m, 2H), 1.42 (t, J = 7.2 Hz, 3H), 0.82 (t, J = 7.4 Hz, 3H). |
124
147 (E)* | ιίχ / N N \ \ z?—1 1 /N \ / yY X / \=T / orV.........7 HgN | 4-[(1ξ)-1aminopropyl]6- (dimethylamin o)-2-[6-(4ethyl-4H- 1,2,4-triazol3-yl)pyridin-2y!]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -0.4° | 407.2 | 1H NMR (600 MHz, DMSO-cfe) 5 8.69 (s, 1H), 8.53 (d, J= 8.3 Hz, 1H), 8.18 (br. s, 2H), 8.02 (t, J = 8.0 Hz, IH), 7.95-7.85 (m, 1H), 6.91 -6.76 (m, 1H), 5.22-4.97 (m, 2H), 4,70-4.47 (m, 2H), 4.454.27 (m, 1H), 3.10 (s, 6H), 2.04- 1.75 (m, 2H), 1.42 (t, J = 7Λ Hz, 3H), 0.84 (t, J = 7.4 Hz, 3H). |
148 (G)* | i Γ1 / A- AA X\X\ u/yj Ju /Λ< b HjN | 4-((1 ξ)-1aminoethyl]-6[methyl(propa n-2-yl)amino]2-(6-(5methyl-4propyl-4H- 1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = +3.8° | 449.3 | Ή NMR (400 MHz, DMSO-C/e) δ 8.58 (d, J = 8.3 Hz, 1H), 8.02 (t, J= 7.5 Hz, 1H), 7.94 (d, J- 8.0 Hz, 1H), 6.71 (s, 1H), 5.15 (s,2H), 4.96-4.85 (m, 1H), 4.45(br. dd, J = 6.3, 8.8 Hz, 2H), 4.07 (d, J = 6.8 Hz, 1H), 2.86 (s, 3H), 2.48-2.43 (m, 3H), 1.88 1.76 (m, 2H), 1.33 (d, J = 6.5 Hz, 3H), 1.15 (d, J = 6.5 Hz, 6H), 0.94 (t, J =7.3 Hz, 3H). |
149 (G)* | 1 iù / A^ / x / fl N N \ xy / \=X i \ ory.......1 fl HZN | 4-[(1ξ)-1aminoethyl]-6[methyl(propa n-2-yl)amino]~ 2-(6-(5methyl-4propyl-4H1,2,4-triazol3-yi)pyridin-2yi]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -10.6° | 449.3 | 1H NMR (400 MHz, DMSO-de) δ 8.62 (d, J = 8.3 Hz, 1H), 8.06 (t, J =8.0 Hz, 1H), 7.96 (d, J =7.5 Hz, 1H), 6.75 (s, 1H), 5.19 (S, 2H), 4.93 (s, 1H), 4.47 (br. dd, J = 6.0, 8.5 Hz, 2H), 4.11 (d, J = 6.5 Hz, 1H), 2.89 (s, 3H), 2.502.48 (m, 3H), 1.90-1.76 (m, 2H), 1.35 (d,/=6.8 Hz, 3H), 1.17 (d, J= 6.8 Hz, 6H), 0.96 (t, J = 7.4 Hz, 3H). |
150 (E)* | 1 iA / A- A. oxP b ory......... H/J | 4-((1 ξ)-1aminoethyl]-2(6-(4-ethyi4H-1,2,4triazol-3y[)pyridin-2yl]-6-[(2R)-2methylpyrrolid | 433.1 | Ή NMR (400 MHz, DMSO-de) δ 8.73 (s, 1H), 8.59 (d, J =8.3 Hz, 1H), 8.09-8.04 (m, 1H), 7.99 (d, J = 7.5 Hz, 1H), 6.56 (s, 1H), 5.21 (br. s, 2H), 4.63 (q, J= 7.2 Hz, 2H), 4.55 (s, 1H),4.23(br. s, 2H), 3.51 |
125
in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a =-29.3° | (br. s, 3H), 2.09-2.02 (m, 2H), 1.96 (br. d, 4 = 2.4 Hz, IH), 1.70 (br. dd, J= 2.4, 4.8 Hz, 1H), 1.50 (t, 4=7.2 Hz, 3H), 1.39 (br. d, 4 = 6.4 Hz, 3H), 1.23 - 1.18 (m, 3H). | |||
151 (E)‘ | v Al z x AA A\ ΑΦ A ory h3n | 4-((1 ξ)-1aminoethyl]-2[6-(4-ethyl4H-1,2,4triazol-3yl)pyridin-2yl]-6-[(2R)-2methylpyrrolîd in-1-yl]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one a = -49.4° | 433.1 | Ή NMR (400 MHz, DMSO-cfe) δ 8.76 (s, 1H), 8.59 (d, 4= 8,3 Hz, IH), 8.36-8.32 (m, 2H), 8.12 8.05 (m, 1H), 7.98 (d, 4 = 7.5 Hz, 1H), 6.70 (s, 1H), 5.16 (br. d, 4 = 2.8 Hz, 2H), 4.67-4.55 (m, 3H), 4.394.31 (m, 1H), 3.68-3.54 (m, 2H), 2.07 (br. s, 2H), 2.01 - 1.94 (m, 1H), 1.761.67 (m, 1H), 1.56 (d, 4 = 6.6 Hz, 3H), 1.48 (t, 4=7.2 Hz, 3H), 1.19 (d, 4 = 6.2 Hz, 3H). |
152 (E)* | l il IL /X. A\ / N \ /-A q ÛFl?.......... h3n | 4-[(1ξ)-1aminoethyl]-6(dimethylamin 0)-2-(6-(4ethyl-4H1,2,4-triazol3-yl)pyridin-2yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = +13.7° | 393.3 | dH NMR (600 MHz, DMSO-cfe) δ 8.73 (s, 1H), 8.62-8.56 (m, 1H), 8.108.01 (m, 1H), 7.98 (br. d, J = 7.7 Hz, 1H), 6.75 (s, 1H), 5.32-5.13 (m, 2H), 4.62 (q, 4 = 7.0 Hz, 2H), 4.274.06 (m, 1H), 3.12-3.03 (m, 6H), 1.49 (br. t, 4 = 7.1 Hz, 3H), 1.41 - 1.19 (m, 3H). |
153 (E)* | z z ^^7 λν Z'--- Λ. 1 F °£ 1¾. z | 4-[(1ξ)-1aminoethyl]-6(dimethylamin o)-2-[6-(4ethyl-4H1,2,4-triazol3-yl)pyridin-2- yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -10.94 | 393.3 | 1H NMR (600 MHz, DMSO-cfe) δ 8.76 (s, 1H), 8.60 (d, 4 = 8.3 Hz, 1H), 8.09 (t, 4 = 8.1 Hz, 1H), 7.99 (d, 4 = 7.5 Hz, 1H), 6.90 (d, 4 = 2.2 Hz, 1H), 5.24-5.08 (m, 2H), 4.734.54 (m, 3H), 3.16 (d, 4 = 1.8 Hz, 6H), 1.54 (d, 4 = 6.8 Hz, 3H), 1.47 (t, 4=7.2 Hz, 3H). |
126
154 (G)* | Y ory | cy Y | 4-[(1ξ)-1aminoethyl]-2[6-(4-ethyl-5methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-[(2R)-2methylpyrrolid in-1 -yi]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1one a = -48.5° | 447.2 | 1H NMR (400 MHz, DMSO-ds) δ 8.62 - 8.57 (m, 1H), 8.31 (br. s, 2H), 8.08 (t, J =8.0 Hz, 1H), 7.95 (d, J = 7.7 Hz, 1H), 6.73-6.70 (m, 1H), 5.18 (br. s, 2H), 4.60-4.47 (m, 3H), 4.39-4.31 (m, 1H), 3.67-3.58 (m, 1H), 3.363.35 (m, 1H), 2.50 (s, 3H), 2.11 -2.03 (m, 2H), 2.001.96 (m, 1H), 1.76-1.71 (m, 1H), 1.56 (d, J= 6.8 Hz, 3H), 1.43 (t, J = 7.1 Hz, 3H), 1.19 (d, 4=6.2 Hz, 3H). |
155 (G)* | o f / N--\ 7^^ ory.......... | z . Y / rx \ z | 4-[(1ξ)-1aminoethyl]-2[6-(4-ethyl-5methyl-4H1,2,4-triazol3-yl)pyridin-2yl]-6-[(2R)-2methylpyrrolid in-1-yl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1one a = -35.6° | 447.2 | 1H NMR (400 MHz, DMSO-d6) δ 8.58 (br. d, 4 = 8.3 Hz, 1H), 8.04 (t, 4 = 7.9 Hz, 1H), 7.95 (br. d, 4 = 7.7 Hz, 1H), 6.53 (s, IH), 5.22 (br. d, 4 = 8.8 Hz, 2H), 4.60-4.48 (m, 3H), 4.21 (br. s, IH), 3.58-3.50 (m, 3H), 3.17 (br. s, 1H), 2.49 — 2.47(m, 3H), 2.08-2.00 (m, 2H), 1.95 (br. s, 1H), 1.69 (br. d, 4= 2.2 Hz, 1H), 1.45 (br. t, 4 = 6.5 Hz, 3H), 1.43-1.29 (m, 3H), 1.20 (br. d, 4=5.5 Hz, 3H). |
*Letter within parenthèses is the Method by which Exampie was prepared.
Λ[Μ+Η]+ unless otherwise indicated.
Example 200: 2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1 -c][ 1,2,4]triazol-3-yi]pyridin-2-yl}-4
[(methylamino)methyl]-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
Step 1 : tert-butyl [(2-{6-[(5S)-5-ethyi-6,7-dihydro-5/7-pyΓrolo[2,1-c][1,2,4]triazol·3-yl]pyridin-2-yl}6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1/7-pyrrolo[3,4-c]pyridin-4yl)methyl]methylcarbamate
127
A mixture of tert-butyl methyl({6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-4-yl}methyl)carbamate (Intermediate 8) (752 mg, 2.09 mmol), (5S)-3-(6bromopyridin-2-yl)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole (Intermediate 3) (612 mg, 2.09 mmol), K3PO4 (1.33 g, 6.26 mmol), Pd2(dba)3 (120 mg, 0.209 mmol), and XantPhos (241 mg, 0.417 mmol) in 1,4-dioxane (20.9 mL, c=0.1 M) was heated at 100 °C in 100 mL flask with condenser under N2 for 18 h. The mixture was cooled to RT, filtered and washed with DCM (20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (24 g, SiO2, 0-10% MeOH/DCM) to provide the title compound as a pale-yellow solid (1.13 g, 85%). m/z (APCl+) for (C31H40N8O3), 573.30 (M+H)+.
Step 2: Example 200
A 4 N solution of HCI in 1,4-dioxane (4.42 mL, 17.7 mmol) was added to a solution of tertbutyl [(2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2methy1pyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)methyl]methylcarbamate (1.01 g, 1.77 mmol) in DCM (22.1 mL, c=0.08 M). The mixture was stirred at RT for 2 h. The volatile material was removed under reduced pressure. The crude product was purified by SFC (ZymorSPHER HADP column with methanol and 10 mM NH3) to provide Example 200 as a paleyellow solid (640 mg, 77%). Ή NMR (400 MHz, DMSO-c/6) δ 8.97 (br. s, 1H), 8.60 (dd, J = 0.9, 8.3 Hz, 1H), 8.17-8.06 (m, 1H), 8.04-7.95 (m, 1H), 6.76 (s, 1H), 5.28 (d, J = 16.6 Hz, 1H), 5.09 — 4.91 (m, 2H), 4.45-4.19 (m, 3H), 3.73-3.61 (m, 1H), 3.49-3.37 (m, 1H), 3.09-2.87 (m, 3H), 2.76 (s, 3H), 2.61 -2.54 (m, 1H), 2.15-1.96 (m, 4H), 1.80- 1.64 (m, 2H), 1.21 (d, J= 6.2 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). m/z (APCI+) for (C26H32N3O), 473.3 (M+H)+. [a]D22 = +76.0° (c=0.1 M, MeOH).
Example 201: 2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-4[(methylamino)methyl]-6-[methyl(propan-2-yi)amino]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
128
Step 1 : tert-butyl [(2-{6-[(5S)-5-ethyl-6,7-dihydFO-5H-pyrrolo[2,1-c][1I2,4]triazol·3-yl]pyridin-2-y]}6-[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3t4-c]pyridin-4yl)methyl]methylcarbamate
To a screw-cap flask equipped with a magnetic stir bar was added tert-butyl methyl({6[methyl(propan-2-yl)amino]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl}methyl)carbamate (Intermediate 9) (294 mg, 0.84 mmol), (5S)-3-(6-bromopyridin-2-yl)-5-ethyl-6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]triazole (Intermediate 3) (260 mg, 0.88 mmol), K3PO4 (537 mg, 2.53 mmol), Pd2(dba)3 (78.0 mg, 0.084 mmol), XantPhos (97.6 mg, 0.17 mmol), and 1,4-dioxane (16.9 mL, 0.05 M). The mixture was bubbled with N2 for 5 minutes before sealing the flask and heating to 85 eC for 22 h. LCMS analysis showed consumption of the starting material. The reaction mixture was concentrated, and the residue was purified by flash chromatography (SiO2, 100% heptane to 1:10 MeOH/EtOAc) to provide the title compound (344 mg, 73% yield) as a yellow solid. Ή NMR (400 MHz, CDCh) δ = 8.72 - 8.65 (m, IH), 8.13 (d, J = 7.5 Hz, 1H), 7.91 (t, J = 7.9 Hz, IH), 6.89 (s, 1H), 5.13-4.85 (m, 4H), 4.25-4.08 (m, 1H), 3.10-2.96 (m, 6H), 2.96-2.93 (m, 3H), 2.66 -2.58 (m, 1H), 2.07 - 1.94 (m, 1H), 1.87- 1.74 (m, 1H), 1.53 (s, 1H), 1.50 - 1.35 (m, 9H), 1.23 (dd, 7=2.8, 6.6 Hz, 6H), 1.00-0.87 (m, 3H); LCMS m/z (APCI) for (C30H40NBO3), 561.3 (M+H)+
Step 2: Example 201
To a flask equipped with a magnetic stir bar and containing tert-butyl [(2-{6-[(5S)-5-ethyl6,7-dihydro~5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[methyl(propan-2-yl)amino]-1-oxo2,3-dihydro-1 H-pyrrolo[3,4-G]pyridin-4-yl)methyl]methylcarbamate (344 mg, 0.62 mmol) and CH2CI2 (12.3 mL, 0.05 M) was added HCl (4 M in 1,4-dioxane, 1.53 mL, 6.2 mmol). After stirring at RT for 20 h, LCMS analysis showed consumption of starting material. Toluene (5 mL) was added to the reaction flask and the reaction mixture was concentrated. The crude residue was passed over a strong ion exchange (SCX) column to remove residual HCl and concentrated to provide Example 201 (278 mg, 98% yield) as a yellow solid. Ή NMR (400 MHz, CDCI3) δ = 8.59 (d, J = 7.8 Hz, 1H), 8.11 - 8.03 (m, 1H), 8.00 - 7.96 (m, 1H), 6.77 (s, 1H), 5.76 (s, 1H), 5.25 (s, 1H), 5.08 (s, 3H), 3.84 (s, 2H), 3.01 -2.88 (m, 6H), 2.61 -2.54 (m, 1H), 2.39 (s, 3H), 2.05-1.93 (m, 1H), 1.80 - 1.67 (m, 1 H), 1.16 (d, 7 = 6.7 Hz, 6H), 0.92 (t, 7= 7.4 Hz, 3H); LCMS m/z (APCI) for (C25H32NsO), 461.3 (M+H)+.
129
Example 202: 2-{6-[(5R)-5-(fluoromethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]tnazol-3-yl]pyndin2-yl}-4-[(methylamino)methyl]-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4c]pyridin-1-one
HN \
Step 1 : tert-butyl [(2-{6-[(5R)-5-(fluoromethyl)-6,7-dihydro-5H-pynOio[2,1-c][1,2,4]triazol-3yl]pyridin-2-yi}-6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4yl)methyl]methylcarbamate
8oc-N \
To a mixture of tert-butyl methyl({6-[(2R)-2-methylpyrroiidin-1-yl]-1-oxo-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-4-yl}methyi)carbamate (Intermediate 8) (90 mg, 0.25 mmol), (58)-3-(6bromopyridin-2-yi)-5~ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole (intermediate 7) (74.2 mg, 0.250 mmol), and K3PO4 (159 mg, 0.749 mmol) in 1,4-dioxane (8 mL) was added Pd2(dba)3 (22.9 mg, 0.025 mmol) and XantPhos (28.9 mg, 0.0499 mmol) under N2. After addition, the mixture was bubbled with N2 for 2 min. The resulting mixture was sealed and stirred at 85 “C for 18 h. To the reaction mixture was added brine (30 mL). The mixture was extracted with EtOAc (20 mL x 2). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to provide a brown solid (250 mg). The material was purified by flash chromatography (SiO2, DCM/EtOAc = 1:1) to provide the title compound (120 mg, 83%) as a yellow solid. ’H NMR (400 MHz, CDCI3) δ 8.69 (d, 4 = 8.3 Hz, 1 H), 8.16 (d, J = 7.6 Hz, 1H), 7.96-7.86 (m, 1 H), 6.72 (s, 1H), 5.40 (d, 4 = 30.1 Hz, 1 H), 5.01 (dd, J = 48.3, 16.6 Hz, 4H), 4.71 (d, 4=14.5 Hz, 1 H), 4.26 - 4.05 (m, 1 H), 3.59 (t, J = 8.7 Hz, 1 H), 3.39 (q, J = 9.0, 8.4 Hz, 1 H), 3.22 - 3.05 (m, 3H), 3.02 (s, 3H), 2.92 -2.82 (m, 1H), 2.19-1.96 (m, 4H), 1.77-1.71 (m, 1H), 1.43 (s, 9H), 1.26 (d, 4 = 6.3 Hz, 3H). LCMS m/z (ESI) for (C3oH37FN803), 577.2 (M+H)
Step 2: Example 202
To a suspension of tert-butyl [(2-{6-[(5R)-5-(fluoromethyl)-6,7-dihydro-5H-pyrrolo[2,1c]t1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo~2,3-dihydro-1Hpyrrolo[3,4-c]pyndin-4-yl)methyl]methylcarbamate (120 mg, 0.208 mmol) in DCM (8 mL) was
130 added HCl in EtOAc (4 mL, 4 M) dropwise at 0 °C. The mixture was stirred at RT for 2 h and was monitored by LCMS. The reaction mixture was then cooled to 0 °C and HCl in EtOAc (5.0 mL, 4 M) was added. The mixture was stirred at RT for 30 min. The mixture was concentrated in vacuo to provide a yellow solid (100 mg). To the residue was added water (10 mL) and washed with 5 EtOAc (10 mL). The aqueous layer was lyophilized for 16 h to provide Example 202 (94 mg, 88%,
HCl sait) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 9.21 - 9.00 (m, 2H), 8.61 (d, J = 8.3 Hz, 1H), 8.14-8.08 (m, IH), 8.06-8.02 (m, 1H), 6.75 (s, 1H), 5.43 -5.29 (m, 1H), 5.23 (d, J = 16.6 Hz, 1H), 5.09-4.91 (m, 3H), 4.40-4.29 (m, 3H), 3.70 - 3.59 (m, 1H), 3.13-2.92 (m, 3H), 2.79-2.71 (m, 4H), 2.15-1.96 (m, 3H), 1.77-1.70 (m, 1H), 1.21 (d, J= 6.3 Hz, 3H). LCMS m/z 10 (ESI) for (C25H29FN8O), 477.4 (M+H)+.
131
Table Ί
Ex. # | Structure | IUPAC Name, rotation | LRMS (m/z) (M+H)+ Λ | Ή NMR |
203 (B)* | i fù t V -Ύ oR-1 CJ Hhl\ | 2-{6-[(5R)-5ethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol-3yl]pyridin~2-yl}-4[(methyiamino)m ethyl)-6-[(2R)-2methylpyrrolidin1-y[]-2,3-dihydro1 H-pyrrolo[3,4c]pyridin-1-one a = -155.8’ | 473.3 | M NMR (400 MHz, CDCb) δ 8.59 (d, J = 7.8 Hz, 1H), 8.11 -8.03 (m, 1H), 8.00-7.96 (m, 1H), 6.77 (s, 1H), 5.76 (s, 1H), 5.25 (s, 1H), 5.08 (s, 3H), 3.84 (s, 2H), 3.01 -2.88 (m, 6H), 2.61 — 2.54(m, 1 H), 2.39 (s, 3H), 2.051.93 (m, 1H), 1.801.67 (m, 1H), 1.16 (d, J = 6.7 Hz, 6H), 0.92 (t, J = 7.4 Hz, 3H). |
204 (Bf | ï ib / Av / Z N N \ “-TV \ M / \=A HN | 2-{6-[(5R)-5ethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol-3yl]pyridin-2-yl}-4[(methylamino)m ethyl]-6[methyl(propan2-νΙ)3ηβίηο]-2,3dihydro-1Hpyrrolo[3,4c]pyndin-1-one a = +210.0° | 461.1 | Ή NMR (400 MHz, CDCb) δ 8.70 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 7.3 Hz, 1H), 7.91 (t, J = 8.0 Hz, 1 H). 6.88 (s, 1H), 5.14 — 5.03 (m, 2H),4.98-4.91 (m. 2H), 3.94-3.85 (m, 2H), 3.09-2.98 (m, 3H), 2.95 (s, 3H), 2.642.58 (m, 1H), 2.56 (s, 3H), 2.10 (ddd, J= 3.4, 7.5, 13.7 Hz, 1H), 1.78 - 1.74 (m, 1H), 1.23 (d, J =6.7 Hz, 6H), 1.01 (t, J= 7.5 Hz, 3H). |
205 (K)* | i jO \ / C J 1 / \—/ y-1 f / \|--/ \|IU-/ J HN | 2-{6-[(5R)-5(fluoromethyl)6,7-dihydro-5Hpyrroto[2,1c][1,2,4]tnazol-3yl]pyridin-2-yl}-4[(methylamino)m ethyl]-6[methyl(propan2-yl)amrno]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1-one | 465.4 | M NMR (400 MHz, DMSO-ds) δ 9.26 (br. s, 2H), 8.59 (d, J= 8.3 Hz, 1H), 8.10 (t, J= 7.9 Hz, 1H), 8.03 (d, J = 7.8 Hz, 1H), 6.91 (s, 1H), 5.42 (br. d, J=8.0 Hz, 1H), 5.25 (d, J= 16.6 Hz, 1H), 5.09 - 4.93 (m, 4H), 4.40 - 4.27 (m. 2H), 3.12-2.95 (m, 3H), 2.93 (s, 3H), 2.772.70 (m, 4H), 1.17 (d, J = 6.5 Hz, 6H). |
132
206 (B)* | v jd / 'N Ν \ \ λ—X j ,Ν \—/yX , /Χ / \=/ .........\ y ΗΝ\ | 6(dimethylamino)2-{6-[(5S)-5ethyl-6,7dihydrû-5Hpyrrolo[2,1c][1,2,4]triazol-3yllpyridin-2-yl}-4[(methylamino)m ethyl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = +70.7° | 433.2 | Ή NMR (400 MHz, DMSO-cfe) δ 8.58 (d, J = 8.3 Hz, 1H), 8.10-8.03 (m, 1H), 7.99 (d, J= 7.6 Hz, 1H), 6.84 (s, 1H), 5.27 (d, J= 17.1 Hz, 1H), 5.08-4.94 (m, 2H), 4.06-3,94 (m, 2H), 3.15 (br. s, 6H), 3.05-2.87 (m, 4H), 2.81 (s, 1H), 2.49-2.47 (m, 3H), 2.04- 1.89 (m, 1H), 1.79-1.67 (m, 1H), 0.91 (t, J =7.3 Hz, 3H). |
207 (B)* | ι id jl ^ΧΚ XX / 'Ν' Χ^ \ \ r~\ J I / / y-J s / ι ΗΝ | 6- (dimethylamino)2-{6-[(5R)-5ethyl-6,7dihydrci-5Hpyrrolo[2,1c][1,2,4]triazol-3yl]pyridin-2-y[}-4[(methylamino)m ethyl]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = -71.8° | 433.2 | NMR (400 MHz, DMSO-cfe) δ 8.58 (d, J = 8.1 Hz, 1H), 8.09-8.01 (m, 1H), 8.00-7.95 (m, 1H), 6.80 (s, 1H), 5.27 (d, J= 17.1 Hz, 1H), 5.10-4.95 (m,2H), 3.85 (br. s, 2H), 3.11 (s, 6H), 3.03-2.87 (m, 4H), 2.81 (s, 1H), 2.38 (s, 3H), 2.06- 1.92 (m, 1H), 1.74 (br. d, J= 8.1 Hz, 1H), 0.91 (t, J= 7.3 Hz, 3H). |
208 (B)* | κΧΧ \rj 7d / \j—/ μ........y J HN\ | 6(dimethylamino)4- [(methylamino)m ethyl]-2-{6-[(5S)5-methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol-3yl]pyridin-2-yl}2,3-dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = +58.5° | 419.2 | 4H NMR (400 MHz, DMSO-cfe) ô 8.58 (dd, J = 3.2, 8.1 Hz, 1H), 8,09 -8.03 (m, 1H), 7.97 (dd, J = 5.3, 7.0 Hz, 1H), 6.81 (d,J=2.2 Hz, 1H), 5.34-5.23 (m, 1H), 5.19-4.96 (m, 2H), 3.90 (br. d, J= 8.6 Hz, 2H), 3.28-3.26 (m, 3H), 3.14-3.08 (m, 6H), 3.08-2.86 (m, 4H), 2.85-2.79 (m, 1H), 2.45-2.36 (m, 3H). |
209 (B)* | i id X^ /Y. / Υ tM \ \^<J H /\-T — HN\ | 6- (dimethylamino)4„ [(methylamino)m ethyl]-2-{6-((5R)5-methyl-6,7dihydro-5Hpyrrolo[2,1- ^[1,2,4^13201-3yl]pyridin-2-yl}- | 419,2 | 1H NMR (400 MHz, DMSO-cfe) δ 8.58 (ddd, J= 0.7, 3.2, 8.3 Hz, 1H), 8.11 -8.00 (m, 1H), 8.01-7.93 (m, 1H), 6.79 (d, J= 1.7 Hz, 1H), 5.34-5.24 (m, 1H), 5.20-4.95 (m, 2H), 3.93-3.73 (m, 2H), 3.28-3.25 (m, 3H), |
133
2,3-dihydro-1Hpyrrolo[3,4c]pyridin-1-one a = -91.8° | 3.13-3.08 (m, 6H), 3.06-2.77 (m, 4H), 2.70-2.62 (m, 1 H), 2.41 -2.35 (m, 3H). | |||
210 (B)* | i iX / A^ Y \/“Ο γ / fl--*/ J NH\ | 4- [(methylamino)m ethyl]-2-{6-[(5S)5-methyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol-3yl]pyridin-2-yl}-6[methy[(propan2-yl)amino]-2,3dihydro-1 Hpyrrolo[3,4c]pyridin-1-one | 447.4 | 1H NMR (400 MHz, DMSO-ds) δ 8.57 (d, J = 8.1 Hz, 1H), 8.05 (t, J = 8.0 Hz, 1H), 7.96 (d, J = 7.4 Hz, 1H), 6.75 (s, 1H), 5.31 -5.21 (m, 1H), 5.20-5.07 (m, 2H), 4.95 (td, J= 6.8, 13.4 Hz, IH), 3.923.79 (m, 2H), 3.172.89 (m, 4H), 2.88 (s, 3H), 2.41 -2.39(m, 3H), 1.52 (br. d, J = 6.4 Hz, 3H), 1.15 (d, J = 6.8 Hz, 6H). |
211 (L)* | Z f ΛΆ 1 ·*· - /X zz TT 1 | 2-{6-[(5S,7S)- 5,7-dimethyl-6,7dihydro-5Hpyrrolo[2,1c][1,2,4]triazol-3yl]pyridin-2-yl}-4[(methylamino)m ethyl]-6[methyl(propan2-yl)amino]-2,3dihydro-1 Hpyrrolo[3,4c]pyridîn-1-one | 461.3 | dH NMR (400 MHz, DMSO-de) δ 8.58 (d, J = 7.7 Hz, 1H), 8.10-8.05 (m, 1H), 8.01 -7.97 (m, 1H), 7.48 (d, J= 8.1 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.85 (s, 1H), 5.305.22 (m, 1 H), 5.15 5.04 (m, 2H), 5.02 4.95 (m, IH), 4.11 (br. s, 2H), 3.50 (s, 1H), 2.91 (s, 3H), 2.64-2.56 (m, 4H), 2.29 (s, 1H), 1.53 (d, J = 6.5 Hz, 3H), 1.38 (d, J =6.8 Hz, 3H), 1.16 (d, J = 6.7 Hz, 6H). |
212 (L)* | ï ΓΧ / V XrtfX \ vry γ Y Y ..........TJ-X HN^ | 2-{6-[(5S,7R)5,7-dimethyl-6,7dihydro-5Hpyrrolo[2,1- c][1,2,4]triazol-3yl]pyridin-2-yl}-4[(methyiamino)m ethylJ-6[methyl(propan2-yl)amino]-2,3dihydro-1Hpyrrolo[3,4c]pyridin-1-one | 461.2 | 1H NMR (400 MHz, DMSO-c/s) δ 8.57 (d, J = 8.3 Hz, 1H), 8.07 (t, J = 8.0 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.50-7.44 (m, 1H), 7.10 (d, J= 7.9 Hz, 1H), 6.84 (s, 1H), 5.21 (s, 1H), 5.11 -4.93 (m, 3H), 4.11 (br. s, 1H), 2.90 (s, 3H), 2.57 (br. s, 2H), 2.29 (s, 1H), 2.102.03 (m, 1H), 1.55 (d, J = 6.4 Hz, 3H), 1.43 (d, J = 6.8 Hz, 3H), 1.16 (d, J = 6.6 Hz, 6H). There are 4 protons missing, ail believed to be under the water or DMSO peaks. |
134 *Letter within parenthèses is the Method by which Example was prepared.
Λ[Μ+Η]+ unless otherwise indîcated.
Example 300: 6-(dimethy)amino)-4-[(methylamino)methyl]-2-[6-(4-propyl-4H-1,2,4-tnazol-3yl)pyridin-2-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one
Step 1 : tert-butyl ({6-(dimethylamino)-1-oxo-2-[6-(4-propyl-4H-1,2,4-triazol·3-yl)pyridin-2-yl]-2,3dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl}methyl)methylcarbamate
A mixture of tert-butyl {[6-(dimethylamino)-1-oxo-2,3-dihydro-1/-/-pyrrolo[3,4-c]pyridin-4yi]methyl}methylcarbamate (Intermediate 11) (1.33 g, 4.15 mmol), 2-brom0-6-(4-propyl-4H-1,2,4triazol-3-yl)pyhdine (Intermediate 12) (1.16 g, 4,36 mmol), Pd2(dba)3 (380 mg, 0.415 mmol), XantPhos (480 g, 0.830 mmol), and K3PO4 (2.64 g, 12.5 mmoL) in 1,4-dioxane (46 mL) was degassed with N2 for 5 min and then stirred at 85 °C for 16 h. The reaction was anaîyzed by LCMS, which showed consumption ofthe starting material. The mixturewas cooled to RT, filtered through a pad of Celite®, and concentrated under vacuum. The residue was slurried with EtOAc (15 mL) for 10 min and the solids were collected by filtration. The filter cake was washed with EtOAc (4x) and then dried under vacuum. The residue was purified by flash chromatography (40 g SiO2, ΟΙ 00% EtOAc/heptane then 10% MeOH/EtOAc) to provide a light-yellow solid. The material was dissolved in 1:9 EtOH/DCM and treated with Ultra-pure Si-Thio SiO2 (1.59 g). The mixture was stirred for 2 h and the filtered. The filter cake was washed with 1:9 EtOH/DCM and the combined filtrate was concentrated under vacuum. The residue was dissolved in 1:9 EtOH/DCM and treated with Ultra-pure Si-Thio SiO2 (1.32 g). The mixture was stirred for 3 h and then filtered. The filter cake was washed with 1:9 EtOH/DCM and the combined filtrate was concentrated. The residue was dissolved in 1:9 EtOH and treated with Ultra-pure Si-Thio SiO2 (1.22 g). The mixture was stirred for 16 h and then filtered. The filter cake was washed with 1:9 EtOH/DCM. The combined filtrate was concentrated to dryness provide the title compound (2.08 g, 95% yield) as a light21055
135 yellow solid. Ή NMR (400 MHz, DMSO-d6) δ 8.74 (s, 1H), 8.61 (d, J = 8.4 Hz, 1H), 8.09 (t, J = 8.0 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 6.82 (s, 1H), 5.05 (d, J= 11.7 Hz, 2H), 4.56 (s, 2H), 4.52 4.46 (m, 2H), 3.09 (s, 6H), 2.92 (s, 3H), 1.88 - 1.76 (m, 2H), 1.40 - 1.19 (m, 9H), 0.87 (t, J = 7 A Hz, 3H); LCMS m/z (ESI+) for (C26H34NaO3), 507.4 (M+H)+.
Step 2: Example 300
To a suspension of tert-butyl ({6-(dimethylamino)-1-oxo-2-[6~(4-propyl-4H-1,2,4-trïazol-3yl)pyhdin-2-yl]-2T3-dihydro-1/-/-pyrrolo[3,4-c]pyridin-4-yl}methyl)methylcarbamate (1.96 g, 3.87 mmol) in MeOH (20 mL) was added a solution of HCl (4.0 M in 1,4-dioxane, 19.3 mL, 77.4 mmol) slowly at 0 °C. The mixture was stirred for 3 h at 0 °C and then allow to warm slowly to RT. The mixture was stirred at RT for 16 h. The reaction was concentrated to dryness. The solids were dissolved in 1:9 MeOH/DCM (80 mL), cooled to 0 °C, and then stirred with a saturated solution of Na2CO3 (25 mL) for 20 min. The mixture was separated. The aqueous layer was extracted with 1:19 MeOH/DCM (3x50 mL). The combined organic layers were washed with H2O (2x30 mL), dried over Na2SO4, filtered, and concentrated. The solids were slurried in EtOAc at 40 °C for 40 min. The solids were collected by filtration. The filter cake was washed with EtOAc and then dried for 16 h in a vacuum oven at 30 °C to provide Example 300 (1.42 g, 90% yield) as a yellow solid. Ή NMR (400 MHz, DMSO-rte) δ 8.73 (s, 1H), 8.62 (dd, J= 8.4, 1.0 Hz, 1H), 8.11 -8.04 (m, 1H), 8.00 (dd, J = 7.7, 1.0 Hz, 1H), 6.78 (s, 1H), 5.14 (s, 2H), 4.57 (dd, J = 7.9, 6.5 Hz, 2H), 3.80 (s, 2H), 3.09 (s, 6H), 2.35 (s, 3H), 1.88 (h, J = 7.4 Hz, 2H), 0.93 (t, J= 7A Hz, 3H); LCMS m/z (ESI+) for (C2iH26N8O), 407.3 (M+H)+.
Bioloqical Assavs and Data
HPK1 biochemical enzyme assay
HPK1 enzyme inhibition was measured by using the fluorescence-based chelationenhanced fluorescence (CHEF) method (1), and by using a proprietary fluorescent peptide substrate, in which a cysteine residue is alkylated with a sulfonamido-oxine-based dérivative to afford an amino acid termed C-Sox (CSx). The reactions were conducted in 50 pL volumes in 96well plates, and contained 0.5 nM human full-length autophosphorylated recombinant HPK1 (see below for production method), 3 μΜ phosphoacceptor peptide substrate (Ac-[CSx]HSLPRFNRamide peptide substrate, also known as AQT0178, AssayQuant Technologies Inc., Hopkinton, MA), test compound (11-dose 3-fold serial dilutions, 2% DMSO final) or DMSO only, 0.002% Tween-20, 1 mM DTT and 2.5 mM MgCI2 in 50 mM MOPS (3-(N-morpholino)propanesulfonic acid) buffer, pH 7.8, and were initiated by the addition of 45 μΜ ATP, foîlowing a 20-min preincubation. Initial reaction velocities were determined by foîlowing the peptide fluorescence (Àex = 360 nm, λβηι= 500 nm) at 30 °C for 15 min in a Tecan M1000 plate reader (Tecan Group Ltd., Mannedorf, Zürich, Switzerland). The inhibition constant (Kî) values were calculated by fitting initial
136 reaction velocities to the Morrison équation (2) for tight-binding compétitive inhibition by using a non-linear régression method and an experimentally measured apparent ATP Km (19 μΜ). The inhibitors were shown to be ATP-competitive from kinetic and crystallographic studies.
137
Production of autophosphorylated full-length recombinant HPK1
The DNA sequence encoding full-length human HPK1 (Genbank NM_001042600.2) was synthesized at GenScript and contained a limited number of silent base changes to eliminate certain restriction endonuclease enzyme récognition sites, and fused to a DNA sequence encoding a Tobacco Etch Virus (TEV)-cleavable N-terminai polyhistidine purification tag. A recombinant baculovirus was prepared by using the Bac-to-Bac method (InVitrogen) and was used to infect 9 L of S/21 insect cells. Ail purification steps were carried out at 4 °C. Cells containing recombinant HPK1 were lysed in 50 mM HEPES-NaOH, pH 7.5, 250 mM NaCI, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 10 μΜ leupeptin (Sigma), 10 μΜ E-64 (Sigma), and one ‘EDTA-free’ protease inhibitor tabiet (Roche) per 75 mL buffer, centrifuged at 15,000xgfor 1 h and the supernatant passed over 5 mL of ProBond IMAC resin (InVitrogen). After washing, HPK1 was eluted with 12.5 mL of 50 mM HEPES-NaOH, pH 7.5, 400 mM NaCI, 250 mM imidazole-HCI pH 7.5, 1 mM TCEP, 2 μΜ leupeptin, and 2 μΜ E-64. The eluted HPK1 was dialyzed ovemight against 0.8 L of 50 mM HEPES-NaOH, pH 7.5, 400 mM NaCI, 20 mM imidazole-HCI pH 7.5, 1 mM TCEP, 2 uM leupeptin, 2 uM E-64, 2 mM ATP-NaOH pH 7.3, 5 mM MgCk and 1 mg TEV (this step simultaneously allows for réduction of the imidazole concentration in préparation for the subséquent reverse IMAC chromatography step, removal ofthe polyhistidine purification tag by TEV protease, and autophosphorylation of HPK1 in the presence of MgATP). The de-tagged and autophosphorylated HPK1 was adjusted to 40 mM imidazole-HCI, pH 7.5, and passed through a 10 mL column of ProBond resin similarly equilibrated. The de-tagged HPK1 that passed through the column was concentrated to approximately 7 mL and purified further by gel filtration over a Superdex 26/60 size exclusion column (GE Healthcare) equilibrated and processed in 41.7 mM HEPES-NaOH buffer. pH 7.5, containing 417 mM NaCI, and 0.417 mM TCEP. The peak fractions containing HPK1 were pooled and concentrated to approximately 2.5 mL by using a centrifugal concentrator (Miltipore). The concentrated HPK1 was adjusted to 20% (v/v) glycerol by the addition of 50% (v/v) glycerol, resulting in a final formulation of 25 mM HEPESNaOH pH 7.5, 250 mM NaCI, 0.25 mM TCEP and 20% (v/v) glycerol. The final protein concentration was approximately 1 mg/mL as determined by the the Bradford assay (Pierce reagent) and using bovine sérum albumin (Pierce 2 mg/mL standard) as protein standard. Mass spectrogram analysis indicated the autophosphorylated HPK1 to contain an average of 15 phosphates per monomer. Aliquots ofthe enzyme were flash frozen in liquid nitrogen and stored at -80 °C, The final product contains a glycine-serine extension at the N-terminus of the full-length protein, as a resuit ofthe cloning strategy.
The final DNA sequence of N-terminaily tagged full-length HPK1 (SEQ ID NO. 1) comprised the sequence following the solidus after removal of the purification tag (underlined) which codes for full-length HPK1 with an additional 5’-GGATCC BamH I cloning site sequence (SEQ ID NO. 3):
138
ATGGCGTCGCATCACCATCACCATCACGATTACGATGGTGCTACGACCGAAAACCTGTATT TTCAG/
This provides (SEQ ID NO. 1):
GGATCCATGGACGTCGTGGACCCTGACATTTTCAATAGAGACCCCCGGGACCACTATGAC CTG CTACAG CGG CTG G GTGG CGG CACGTATGGG GAAGTCTTTAAG G CTCGCG ACAAGGT GTC AGG GGACCTGGTG G CACTGAAGATGGTGAAGATG G AG CCTG ATG ATGATGTCTCCAC C CTTCAG AAG G AAATCCTCATATTGAAAACTTG CCGG C ACGCCAAC ATCGTG G CCTACCAC GGGAGTTATCTCTGGTTGCAGAAACTCTGGATCTGCATGGAGTTCTGTGGGGCTGGTTCTC TCCAGGACATCTACCAAGTGACAGGCTCCCTGTCAGAGCTCCAGATTAGCTATGTCTGCCG GGAAGTGCTCCAGGGACTGGCCTATTTGCACTCACAGAAGAAGATACACAGGGACATCAA G GG AG CTAACATCCTC ATCAATG ATG CTGGGG AGGTC AG ATTG G CTGACTTTGGCATCTCG G CCC AG ATTG G G G CTACACTG G CCAGACGCCTCTCTTTC ATTGG G ACACCCTACTG G ATG GCTCCGGAAGTGGCAGCTGTGGCCCTGAAGGGAGGATACAATGAGCTGTGTGACATCTGG TCCCTGGGCATCACGGCCATCGAACTGGCCGAGCTACAGCCACCGCTCTTTGATGTGCAC CCTCTCAGAGTTCTCTTCCTCATGACCAAGAGTGGCTACCAGCCTCCCCGACTGAAGGAAA AAGGCAAATGGTCGGCTGCCTTCCACAACTTCATCAAAGTCACTCTGACTAAGAGTCCCAA GAAACGACCCAGCGCCACCAAGATGCTCAGTCATCAACTGGTATCCCAGCCTGGGCTGAA TCG AGG CCTG ATCCTGG ATCTTCTTGACAAACTG AAG AATCCCGG GAAAGG AC CCTCCATT GGGGACATTGAGGATGAGGAGCCCGAGCTACCCCCTGCTATCCCTCGGCGGATCAGATCC ACCCACCGCTCCAGCTCTCTGGGCATCCCAGATGCAGACTGCTGTCGGCGGCACATGGAG TTCAG GAAG CTCCG AGG AATG GAGACCAG ACCCCCAGCCAAC ACC G CTCGC CTACAG CCT CCCCG AGAC CTCAGGAGCAGCAGCCCCAGGAAG CAACTGTCAG AGTCGTCTG ACG ATG AC TATGACGACGTGGACATCCCCAGCCCTGCAGAGGACACACCTCCTCCACTTCCCCCCAAG CCCAAGTTCCGTTCTCCATCAGACGAGGGTCCTGGGAGCATGGGGGATGATGGGCAGCTG AGCCCGGGGGTGCTGGTCCGGTGTGCCAGTGGGCCCCCACCAAACAGCCCCCGTCCTGG GCCTCCCCCATCCAC CAG CAG CC CCCACCTCACCGCCCATTCAG AACCCTCACTCTGG AA CCCACCCTCCCGGGAGCTTGACAAGCCCCCACTTCTGCCCCCCAAGAAGGAAAAGATGAA GAGAAAGGGATGTGCCCTTCTCGTAAAGTTGTTCAATGGCTGCCCCCTCCGCATCCACAGC ACGGCCGCCTGGACACATCCCTCCACCAAGGACCAGCACCTGCTCCTGGGGGCAGAGGA AGG CATCTTCATCCTG AACCGG AATGACCAGG AG G CCACG CTG GAAATG CTCTTTCCTAG C CGGACTACGTGGGTGTACTCCATCAACAACGTTCTCATGTCTCTCTCAGGAAAGACCCCCC ACCTGTATTCTCATAGCATCCTTGGCCTGCTGGAACGGAAAGAGACCAGAGCAGGAAACCC CATCGCTCACATTAGCCCCCACCGCCTACTGGCAAGGAAGAACATGGTTTCCACCAAGATC CAGGACACCAAAGGCTGCCGGGCGTGCTGTGTGGCGGAGGGTGCGAGCTCTGGGGGCC CGTTCCTGTG CGGTGCATTGG AG ACGTCCGTTGTCCTG CTTCAG TG G TACCAGCCCATG AA CAAATTCCTGCTTGTCCGGCAGGTGCTGTTCCCACTGCCGACGCCTCTGTCCGTGTTCGC GCTGCTGACCGGGCCAGGCTCTGAGCTGCCCGCTGTGTGCATCGGCGTGAGCCCCGGGC
139
GGCCGGGGAAGTCGGTGCTCTTCCACACGGTGCGCTTTGGCGCGCTCTCTTGCTGGCTG GGCGAGATGAGCACCGAGCACAGGGGACCCGTGCAGGTGACCCAGGTAGAGGAAGATAT GGTGATGGTGTTGATGGATGGCTCTGTGAAGCTGGTGACCCCGGAGGGGTCCCCAGTCC GGGGACTTCGCACACCTGAGATCCCCATGACCGAAGCGGTGGAGGCCGTGGCTATGGTT 5 GGAGGTCAGCTTCAGGCCTTCTGGAAGCATGGAGTGCAGGTGTGGGCTCTAGGCTCGGAT
CAGCTGCTACAGGAGCTGAGAGACCCTACCCTCACTTTCCGTCTGCTTGGCTCCCCCAGG CCTGTAGTGGTGGAGACACGCCCAGTGGATGATCCTACTGCTCCCAGCAACCTCTACATCC AGGAATGA
The final protein sequence of N-terminally tagged full-length HPK1 (SEQ ID NO. 2) 10 comprised the sequence following the solidus after removal of the purification tag (underlined) with an additional N-terminal GlySer sequence encoded from the BamH I cloning site (SEQ ID NO. 4):
MASHHHHHHDYDGATTENLYFQ/
Thisgives (SEQ ID NO. 2):
GSMDVVDPDIFNRDPRDHYDLLQRLGGGTYGEVFKARDKVSGDLVALKMVKMEPDDDVSTLQ KEILILKTCRHANIVAYHGSYLWLQKLW1CMEFCGAGSLQDIYQVTGSLSELQISYVCREVLQGL AYLHSQKKIHRDIKGANILINDAGEVRLADFGISAQIGATLARRLSFIGTPYWMAPEVAAVALKGG YNELCDIWSLGITAIELAELQPPLFDVHPLRVLFLMTKSGYQPPRLKEKGKWSAAFHNFIKVTLTK SPKKRPSATKMLSHQLVSQPGLNRGLILDLLDKLKNPGKGPSIGDIEDEEPELPPAIPRRIRSTHR
SSSLGIPDADCCRRHMEFRKLRGMETRPPANTARLQPPRDLRSSSPRKQLSESSDDDYDDVDI PTPAEDTPPPLPPKPKFRSPSDEGPGSMGDDGQLSPGVLVRCASGPPPNSPRPGPPPSTSSP HLTAHSEPSLWNPPSRELDKPPLLPPKKEKMKRKGCALLVKLFNGCPLRIHSTAAWTHPSTKD QHLLLGAEEGIFILNRNDQEATLEMLFPSRTTWVYSINNVLMSLSGKTPHLYSHSILGLLERKETR AGNPÎAHISPHRLLARKNMVSTKIQDTKGCRACCVAEGASSGGPFLCGALETSVVLLQWYQPM
NKFLLVRQVLFPLPTPLSVFALLTGPGSELPAVCIGVSPGRPGKSVLFHTVRFGALSCWLGEMS TEHRGPVQVTQVEEDMVMVLMDGSVKLVTPEGSPVRGLRTPEIPMTEAVEAVAMVGGQLQAF WKHGVQVWALGSDQLLQELRDPTLTFRLLGSPRPVWETRPVDDPTAPSNLYIQE
Cell Based Assays
Phospho-SLP-76 (Ser376) Homogeneous Time Resolved Fluorescence (HTRF) Assay
Jurkat cells were seeded at 90,000 cells/well in 90uL of RPMI1640 growth medium containing 10% FBS and incubated at 37°C with 5% CO2 overnight. The following day, compounds were serially diluted from a 10mM top dose for an 11-point 3-fold dilution curve in DMSO. Compounds were intermediately diluted 1:100 into growth media prior to diluting 1:10 on cells for final concentration 10μΜ to 0.1nM in 0.1% DMSO. After 30 min pre-treatment with
140 compounds, the cells were stimulated using 200pg/mL of F(ab)2 complexed anti-CD3 (clone UCTH1) for 15 min at 37°C with 5% CO2. Stimulation was stopped with ice cold PBS and cells were harvested by centrifugation before lysis in Cisbio lysis buffer (Cisbio, Bedford, MA). Lysâtes were transferred to white, iow-volume plates containing anti-phospho-SLP-76-Cryptate plus antiphospho-SLP-76-d2 HTRF antibodies and incubated ovemight at room température protected from light according to the manufacturées protocol (Cisbio, Bedford, MA). HTRF was measured on a Perkin Elmer Envision and IC50 values were calculated by concentration-response curve fitting utilizing four-parameter nonlinear régression analyses.
Biological activity data for compounds is provîded in Table 8. The dataforthe HPK1 CHEF are provîded in Table 8, with column heading HPK1 Ki (μΜ). The data for the cellular PhosphoSLP-76 (Ser376) Homogeneous Time Resolved Fluorescence (HTRF) assays are provîded in Table 8, with column heading pSLP76 ICso (pM). For each of these two assays, the respective adjacent column provides the number of times the compound was tested in the assay.
Biochemical Selectivity Kinase Assay.
PRKD2 (PKD2) and RPS6KA2 (RSK3) kinase assays were performed with Km-levels of ATP at the Thermo Fisher Scientific, Inc. (Madison, Wl), using their lnvitrogen™SelectScreen™ fluorescence résonance energy transfer (FRET) Z’-LYTE™ technology, based on the differential sensitivity of phosphorylated and nonphosphorylated peptides to proteolytic cleavage. Human recombinant full-length GST-tagged PRKD2 (PKD2) and RPS6KA2 (RSK3) were produced by Thermo Fisher Scientific, Inc. (Madison, Wi). The kinase assays were conducted in 10-pL reactions. PRKD2 (PKD2) reactions contained 0.64 - 5.84 ng enzyme, 25 μΜ ATP (-Km), 2 μΜ of Ser/Thr 17 (Z’-LYTE™ peptide substrate), 10 mM MgCI2, 0.01% BRU-35, 1 mM EGTA in 50 mM HEPES, pH 7.5. RPS6KA2 (RSK3) reactions were conducted similarly, and contained 0.5 - 9 ng enzyme, or 10 μΜ ATP (-Km) and 2 μΜ Ser/Thr 06 peptide. After the 1-hour kinase reaction incubation, 5 pL of a 1:256 and 1:4096 dilution of Z’-LYTE™ Development Reagent A was added to the PRKD2 (PKD2) and RPS6KA2 (RSK3) reactions, respectively. The extent of kinase reactions, resulting in a change of FRET signal of the peptide substrate, was measured, and inhibition for each kinase was measured with respect to DMSO control and reported as an average of duplicate measurements. Each 50% inhibitory concentration (ICso) détermination was based on 10-dose duplicate measurements, fitted to a standard four-parameter ICso équation using XLfit software from IDBS (Guildford, United Kingdom). The dose response curve was curve fit to model number 205 (sigmoidal dose-response mode!). A ratio of the PRKD2 ICso to the HPK1 Ki and a ratio of the RSK3 IC50 to the HPK1 Ki, is provîded in the respective columns adjacent to the columns for PRKD2 IC50 and RSK3 ICso.
Alpha branched amine analogs, where at least one of R3a and R3b is other than hydrogen, greatly improved selectivity for HPK1 relative to other kinases (including PRKD2 and RSK3) relative to non-alpha branched amine compounds, e.g., Example 300. Cyclic, fused triazoles,
141
e.g., compounds of Formula l-B, where R4 is (R4-ii), provided improvement in biochemical and cellular potency relative to non-cyclic compounds, e.g., Example 300.
Table 8.
Ex. # | HPK1 Ki (μΜ) | # of Runs HPK1 Ki | pSLP76 ICso (μΜ) | # of Runs -pSLP76 | PRKD2 IC50 (nM) | PRKD2 IC50/ HPK1 Ki | RSK3 IC50 (nM) | RSK3 ICM/ HPK1 Ki |
1 | <0.00005 | 8 | 0.017 | 6 | 155 | >3100 | 47.0 | >940 |
2 | <0.00005 | 3 | 0.03 | 3 | 116 | >2320 | 21.3 | >420 |
3 | <0.00005 | 2 | 0.034 | 1 | 6.54 | >130 | 3.33 | >66 |
4 | <0.00005 | 2 | 0.036 | 1 | 217 | >4304 | 25.8 | >520 |
5 | <0.00005 | 2 | 0.031 | 1 | 251 | >5020 | 53.5 | >1080 |
6a | 0.00019 | 1 | 0.069 | 2 | 942 | 4958 | 48.6 | 256 |
6b | 0.0061 | 1 | 0.641 | 1 | ||||
7 | 0.0028 | 1 | ||||||
8 | 0.0056 | 2 | ||||||
9 | 0.00049 | 2 | 0.115 | 1 | ||||
10 | 0.00013 | 1 | 0.147 | 1 | ||||
11 | 0.00972 | 1 | ||||||
12 | 0.00198 | 1 | ||||||
13 | <0.00007 | 3 | 0.036 | 2 | ||||
14 | 0.00093 | 3 | 0.34 | 1 | ||||
15 | 0.00847 | 1 | ||||||
16 | 0.000093 | 1 | 0.487 | 1 | ||||
17 | <0.00005 | 1 | 0.023 | 2 | ||||
18 | <0.00005 | 2 | 0.042 | 3 | ||||
19 | 0.00015 | 1 | ||||||
20 | <0.00005 | 2 | 0.023 | 2 | ||||
21 | 0.000064 | 1 | 0.046 | 1 | ||||
22 | 0.00008 | 2 | 0.133 | 2 | ||||
23 | 0.005 | 3 | 0.329 | 2 | ||||
24 | 0.00176 | 1 | ||||||
25 | <0.00005 | 2 | 0.053 | 5 | ||||
26 | 0.00072 | 1 | 0.133 | 1 | ||||
27 | <0.00005 | 2 | 0.056 | 2 | ||||
28 | <0.000045 | 2 | 0.064 | 1 |
142
29 | 0.0002 | 3 | 0.072 | 2 | ||||
30 | <0.00005 | 1 | 0.062 | 2 | ||||
31 | <0.00005 | 1 | 0.042 | 1 | ||||
32 | 0.00006 | 1 | 0.046 | 1 | ||||
33 | 0.00021 | 1 | 0.179 | 1 | ||||
34 | 0.00015 | 1 | 0.026 | 2 | ||||
35 | 0.0003 | 1 | 0.181 | 2 | ||||
36 | 0.000074 | 1 | 0.110 | 2 | ||||
37 | <0.00005 | 1 | 0.049 | 1 | ||||
38 | 0.00018 | 1 | 0.197 | 2 | ||||
100 | <0.00005 | 4 | 0.039 | 4 | 51.2 | >1020 | 15.5 | >320 |
101 | 0.00017 | 3 | 0.118 | 1 | ||||
102 | 0.00011 | 3 | 0.107 | 1 | ||||
103 | 0.00138 | 2 | ||||||
104 | 0.00236 | 2 | ||||||
105 | 0.00201 | 2 | ||||||
106 | 0.0105 | 1 | ||||||
107 | 0.00102 | 2 | 0.140 | 1 | ||||
108 | 0.00061 | 2 | 0.084 | 1 | ||||
109 | 0.00031 | 1 | 0.061 | 1 | ||||
110 | 0.00009 | 2 | 0.042 | 2 | ||||
111 | 0.00342 | 1 | 0.470 | 1 | ||||
112 | 0.00077 | 1 | 0.421 | 1 | ||||
113 | 0.00067 | 1 | 0.133 | 2 | ||||
114 | 0.00041 | 2 | 0.148 | 3 | ||||
115 | 0.00056 | 2 | 0.216 | 4 | ||||
116 | 0.00064 | 1 | 0.214 | 1 | ||||
117 | 0.00102 | 1 | 0.270 | 1 | ||||
118 | 0.00150 | 1 | 0.324 | 1 | ||||
119 | 0.00090 | 1 | 0.165 | 2 | ||||
120 | 0.00297 | 1 | 0.531 | 1 | ||||
121 | 0.00412 | 2 | 0.553 | 2 | ||||
122 | 0.00078 | 1 | 0.354 | 1 | ||||
123 | 0.00097 | 1 | 0.243 | 1 | ||||
124 | 0.00037 | 2 | 0.098 | 2 | ||||
125 | 0.00142 | 1 |
143
126 | 0.00178 | 1 | ||||||
127 | 0.00141 | 1 | ||||||
128 | 0.00103 | 1 | 0.194 | 1 | ||||
129 | 0.00028 | 1 | 0.097 | 2 | ||||
130 | 0.0004 | 1 | 0.077 | 2 | ||||
131 | 0.00102 | 3 | 0.094 | 1 | ||||
132 | 0.00038 | 1 | 0.148 | 1 | ||||
133 | 0.00012 | 1 | 0.095 | 2 | ||||
134 | 0.00022 | 2 | 0.106 | 2 | ||||
135 | 0.00037 | 1 | 0.143 | 2 | ||||
136 | 0.00022 | 1 | 0.09 | 2 | ||||
137 | 0.00075 | 1 | 0.189 | 2 | ||||
138 | 0.00096 | 1 | 0.332 | 1 | ||||
139 | 0.00027 | 1 | 0.104 | 2 | ||||
140 | <0.00007 | 3 | 0.053 | 3 | ||||
141 | 0.00044 | 1 | ||||||
142 | 0.00154 | 1 | ||||||
143 | 0.00373 | 1 | ||||||
144 | 0.00011 | 1 | 0.090 | 3 | ||||
145 | 0.00046 | 1 | ||||||
146 | 0.00314 | 1 | ||||||
147 | 0.001 | 1 | ||||||
148 | 0.0004 | 1 | 0.096 | 2 | ||||
149 | 0.0006 | 1 | 0.171 | 2 | ||||
150 | 0.00011 | 1 | 0.059 | 1 | ||||
151 | 0.00012 | 1 | 0.033 | 1 | ||||
152 | 0.00153 | 1 | 0.191 | 1 | ||||
153 | 0.00125 | 1 | ||||||
154 | 0.00025 | 1 | 0.120 | 1 | ||||
155 | 0.00024 | 1 | 0.113 | 2 | ||||
200 | <0.00005 | 2 | 0.016 | 4 | 7.97 | >160 | 10.1 | >200 |
201 | <0.00005 | 1 | 0.037 | 1 | 5.43 | >108 | 6.73 | >134 |
202 | 0.00006 | 1 | 0.025 | 2 | 6.54 | 108 | 40.1 | 667 |
203 | 0.00104 | 1 | 0.182 | 3 | ||||
204 | 0.00129 | 1 | ||||||
205 | <0.00005 | 2 | 0.052 | 2 |
144
206 | 0.00012 | 1 | 0.078 | 2 | ||||
207 | 0.00268 | 1 | ||||||
208 | 0.0006 | 2 | 0.085 | 2 | ||||
209 | 0.00211 | 1 | ||||||
210 | <0.00005 | 2 | 0.047 | 3 | ||||
211 | <0.00005 | 1 | 0.078 | 2 | ||||
212 | 0.00032 | 1 | 0.159 | 1 | ||||
300 | 0.00014 | 1 | 0.094 | 4 | 1.93 | 14 | 6.26 | 23 |
An empty box in Table 8 means data was not obtained.
Ail publications and patent applications cited in the spécification are herein incorporated by reference in their entîrety. It will be apparent to those of ordinary skill in the art that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended daims.
Claims (24)
1. A compound of Formula I:
or a pharmaceutically acceptable sait thereof, wherein:
R1 is (Ci-Cs)alkyl, halo(Ci-C6)alkyl, (CrC5)alkoxy, halo(Ci-Ce)a!koxy, -N(R5)(R6), or (C3C3)cycloalkyl, wherein said (Ci-Cejalkyl, halo(Ci-Ce)alkyl, and (C3-C6)cycloalkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, (Ci-Cs)alkyl, or (Ci-Ce)alkoxy, wherein:
R5 and R6 are each independently hydrogen or (Ci-Cs)alkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (Ci~C6)alkoxy, cyano, and hydroxy, or
R5 and R6 taken together with the nitrogen to which they are attached form a (4- to 8-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, (Ci-C6)alkyl, halo(CiCg)alkyl, (Ci-Csjalkoxy, and halo(Ci-Ce)alkoxy;
R2 is N(R7)(R8), wherein:
R7 and R8 are each independently hydrogen or (Ci-C6)alkyl that is substituted with 0, or 1 substituent that is halogen, (Ci-Cejalkoxy, cyano, or hydroxy; or
R7 is hydrogen or (Ci-C0)alkyl that is substituted with 0, or 1 substituent that is halogen, (Ci-Cejalkoxy, cyano, or hydroxy; and R® taken together with the nitrogen to which it is attached and taken together with R3a and the carbon to which it is attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0,1, or 2 substituents independently selected from halogen, hydroxy, (Ci-C3)alkyl, halo(Ci-C3)alkyl, (CiC3)alkoxy, and halo(Ci-Cs)alkoxy; or
R7 and R® taken together with the nitrogen to which they are attached form a (4- to 6-membered)heterocycloalkyl that is substituted with 0, 1, or 2 substituents independently selected from halogen, hydroxy, (Ci-C6)alkyl, halo(Ci-Ce)alkyl, (CiCs)alkoxy, and halo(Ci-C3)alkoxy;
R®a is hydrogen, or (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is hydroxy, or (Ci-C3)alkoxy;
R3b is hydrogen, or (Ci-Cs)alkyl, provîded that R3a and R3b are not both H when R4 is (R421055
146
R4 is (R4-i) or (R4-ii):
wherein:
R4N is (Ci-Ce)alkyl, halo(Ci-C6)alkyl, or (C3-CB)cycloalkyl, wherein said (Ci-Ce)aikyl is substituted with 0 or 1 substituent that is hydroxy;
R4C is hydrogen, (Ci-C6)alkyl, halo(Ci-C6)alkyl, (Ci-C6)alkoxy, halo(CrC6)alkoxy, or (C3CB)cycîoalkyl, wherein said (Ci-CB)alkyl and halo(C-i-C6)a1kyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (C-i-C6)alkoxy;
R4D is hydrogen, (Ci-Ce)alkyI, halo(Ci-C6)alkyl, (Ci-Cs)alkoxy, halo(CrCB)alkoxy, or (C3C6)cycloalkyl, wherein said (Ci-C6)alkyl and halo(Ci-C6)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-Cs)alkoxy;
R4E is hydrogen, halogen, cyano, hydroxy, or (Ci-Cs)alkyl; and
R4F is hydrogen, halogen, cyano, hydroxy, (Ci-CB)alkyl, halo(Ci-C6)alkyl, (Ci-CB)alkoxy, halofCrCejalkoxy, or (C3-CB)cycloalkyl, wherein said (Ci-Ce)alkyl and halo(Ci-CB)alkyl are substituted with 0 or 1 substituent that is hydroxy, cyano, or (Ci-CB)alkoxy.
2. The compound of claim 1, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4i);
R4N is (Ci-Ce)alkyl, or (C3-Cs)cycloalkyl; and
R4C is hydrogen, or (Ci-C3)alkyl.
3. The compound of claims 1 or 2 , or a pharmaceutically acceptable sait thereof, wherein R1 is -N(R5)(Re), or (C3-Cs)cycloalkyl, wherein said (C3-Cs)cycloalkyl is cyclopropyl and is substituted with 0 or 1 substituent that is (Ci-C6)alkyl, wherein said (Ci-Cs)alkyl is methyl;
R5 and R6 are each independently hydrogen or (Ci-C3)alkyl, or
147
R5 and R6 taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is (Ci-Ce)alkyl;
R2 is N(R7)(R3), wherein R7 and R® are each independently hydrogen or (Ci-Ce)alkyl that is methyl;
R3a îs (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (Ci-C3) alkoxy; and R3b is hydrogen, or (Ci-C3)alkyl.
4. The compound of claim 1, or a pharmaceutically acceptable sait thereof, wherein R4 is (R4ü);
R4D is hydrogen, (Ci-C6)alkyl, or halo(Ci-Cs)alkyl, wherein said (Ci-C6)alkyl is substituted with 0 or 1 substituent that is hydroxy;
R4E is hydrogen; and
R4F is hydrogen, (Ci-C6)alkyl, or halo(Ci-C6)alkyl, wherein said (Ci-Cs)alkyl is substituted with 0 or 1 substituent that is hydroxy.
5. The compound of claim 1 or claim 4, or a pharmaceutically acceptable sait thereof, wherein R1 is -N(R5)(R6), or (C3-Cs)cycloalkyl, wherein said (C3-C6)cycloalkyl is cyclopropyl and is substituted with 0 or 1 substituent that is (Ci-Cs)alkyl, wherein said (Ci-Ce)alkyl is methyl;
R5 and R6 are each independently hydrogen or (Ci-C3)alkyl, or
R5 and R5 taken together with the nitrogen to which they are attached form a (5membered)heterocycloalkyl that is substituted with 0, or 1 substituent that is (Ci-Cs)alkyl;
R2 is N(R7)(R8), wherein R7 and R3 are each independently hydrogen or (Ci-C6)alkyl that is methyl;
R3a is hydrogen, or (Ci-C3)alkyl that is substituted with 0 or 1 substituent that is (C1C3)alkoxy; and
R3b is hydrogen, or (Ci-C3)alkyl.
6. The compound of any of daims 1 to 5, or a pharmaceutically acceptable sait thereof, wherein R1 îs 2-methyl-pyrrolidin-1 -yl, or 2(R)-methyl-pyrrolidin-1-yl.
7. The compound any of daims 1 to 6, or a pharmaceutically acceptable sait thereof, wherein R7 and R3 are each hydrogen.
8. The compound any of daims 1 to 6, or a pharmaceutically acceptable sait thereof, wherein R7 is hydrogen; and and R3 is (Ci-C3)alkyl.
9. The compound according to any one of daims 1 to 8, or a pharmaceutically acceptable sait thereof, wherein R3b is hydrogen, and wherein orientation of R2, R3a, and R3b provide a compound of Formula l(R) or Formula l(S):
10. The compound of any of claims 1 and 4 to 9, or a pharmaceutically acceptable sait thereof, wherein R4 îs 5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl, (5R)-5-methyl-6,7-dihydro5 5H-pyrrolo[2,1-c][1 T2,4]tnazol~3-yl, (5S)-5-methyl-6,7-dîhydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl,
5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl, (5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl, or (5R)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yi, wherein said methyl is substituted with 0 or 1 substituent that is F or OH.
11. The compound of claim 10, or a pharmaceutically acceptable sait thereof, wherein R4 is 10 (5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1 -c][1,2,4]triazol-3-yl, or (5S)-5-ethyl-6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]triazol-3-yl, wherein said methyl is substituted with 0 or 1 substituent that is F or OH.
12. A compound that is 4-[1-aminopropyl]-2-{6-[5-methyl-6,7-dihydro-5H~pyrrolo[2,115 c][1,2,4]triazoF3-yl]pyridin“2-yl}-6-[2-methylpyrrolfdin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1- one;
4-[1-aminoethyl]-2-{6-5-ethyl·6,7-dihydro-5H-pyrΓOlo[2,1-c][1,2,4]tπazol-3-yl]pyΓίdfn-2-yl}6-[2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[1-aminoethyl]-2-{6-[5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1s,2,4ltriazol“3-yl]pyridin-220 yl}-6-[2-methylpyrrolidin-1-yl]-2,3-dihydro-1/7-pyrrolo[3,4-c]pyridin-1-one;
4-[1-aminoethyl]-2-{6-[5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl}pyridin-2-yl}6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrroio[3,4-c]pyridin-1-one;
441-aminopropyl]-2-{3-[5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]phenyl}6-[methyl(propan-2-yl)amino]-2,3-dihydro-1/7-pyrrolo[3,4-c]pyridin-1-one; or
25 4-[1-amino-2-methoxyethyl]-6-(1-methylcyclopropyl)-2-{6-[5-methyl-6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one; or a pharmaceutically acceptable sait thereof.
13. The compound of claim 12, wherein the compound is 4-[(1R)-1-aminopropyl]-2-{6-[(5S)-5methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yi}-6-[(2R)-2'methylpyrrolidin-130 yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one,
149
4-[(1R)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1 H-pyrrolo[3,4-c]pyridin-1-one;
4-[(1S)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[(1R)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3YÎ]PYndin-2-yl}-6-[methyl(propan-2-yl)amino]-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one;
4-[(1R)-1-aminopropyl]-2-{3-[(5S)-5-methyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]tΓiazol·3· yl]phenyl}-6-[methyl(propan-2-yi)amino]-2,3-dihydro-1H-pyrrolo[3t4-c]pyridin-1-one;
4-[(1R)-1-amino-2-methoxyethyl]-6-(Tmethylcyclopropyl)-2-{6-[(5S)-5-methyl-6,7dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1one; or
4-[(1 S)-1-amino-2-methoxyethyl]-6-(1-methylcyclopropyl)-2-{6-[(5S)-5-methyl-6,7dihydro-5H-pyrrolo[2, Vc][1,2,4]triazol-3-yl]pyridin-2-yl}-2,3-dihydro-1H-pyrrolo[3,4-c]pyrfdîn-1one; or a pharmaceutically acceptable sait thereof.
14. A compound having the structure:
15. A compound that is 4-[(1R)-1-aminopropyl]-2-{6-[(5S)~5-methyl-6,7-dihydro-5Hpyrrolo[2,1-c][1,2,4]triazol-3-yl]pyridin-2-yl}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1Hpyrrolo[3,4-c]pyridin-1 -one; or a pharmaceutically acceptable sait thereof.
16. A compound that is 4-[(1R)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl]pyridin-2-yi}-6-[(2R)-2-methylpyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4c]pyridin-1-one; or a pharmaceutically acceptable sait thereof.
17. A compound that is 4-[(1 S)-1-aminoethyl]-2-{6-[(5S)-5-ethyl-6,7-dihydro-5H-pyrrolo[2,1c][1,2,4]triazol-3-yl]pyfidin-2-yl}-6-[(2R)-2-methy]pyrrolidin-1-yl]-2,3-dihydro-1H-pyrrolo[3,4c]pyridin-1-one; or a pharmaceutically acceptable sait thereof.
18. A pharmaceutical composition comprising a compound of any of claims 1 to 17, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient,
19. A compound of any of claims 1 to 17, or a pharmaceutically acceptable sait thereof, for use in a method for the treatment of abnormal cell growth in a mammal.
150
20. Use of a compound of any of claims 1 to 17, or a pharmaceutically acceptable sait thereof, in the manufacture of a pharmaceutical composition for the treatment of abnormal cell growth in a mammal.
21. The compound for use of claim 19 or the use of claim 20, wherein the abnormal cell growth 5 is cancer.
22. A compound of any of claims 1 to 17, or a pharmaceutically acceptable sait thereof, for use in a method for the treatment of abnormal cell growth in a mammal in combination with an additional anticancer therapeutic agent.
23. Use of a compound of any of claims 1 to 17, or a pharmaceutically acceptable sait thereof, 10 in the manufacture of a pharmaceutical composition for the treatment of abnormal cell growth in a mammal in combination with an additional anticancer therapeutic agent.
24. The compound for use of claim 22 or the use of claim 23, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, 15 liver cancer, pancreatic cancer, stomach cancer, and thyroid cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/018,689 | 2020-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA21055A true OA21055A (en) | 2023-10-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112313219B (en) | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
AU2021200951B2 (en) | Benzolactam compounds as protein kinase inhibitors | |
EP3497103B1 (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
EP3880676B1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
JP6545199B2 (en) | 3-Amino-1,5,6,7-tetrahydro-4H-indol-4-ones | |
JP6242885B2 (en) | 5-azaindazole compounds and methods of use | |
AU2021265578B2 (en) | Azalactam compounds as HPK1 inhibitors | |
JP2014521711A (en) | Pyrazolo [3,4-c] pyridine compounds and methods of use | |
WO2021224818A1 (en) | Isoindolone compounds as hpk1 inhibitors | |
OA21055A (en) | Azalactam compounds as HPK1 inhibitors. | |
RU2801140C2 (en) | Azalactam compounds as hpk1 inhibitors | |
RU2790006C2 (en) | 2-aminopyridine or 2-aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | |
OA20310A (en) | 2,3-dihydro-1H-pyrrolo[3,4-C] pyridin-1one derivatives as HPK1 inhibitors for the treatment of cancer. | |
EA044841B1 (en) | 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | |
JP2023054768A (en) | Azalactam compound as hpk1 inhibitor | |
EA042105B1 (en) | 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS |